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ABSTRACT
Peptides  are  becoming  increasingly  important  as  drugs  but  their  clinical  use  is  often
severely hampered by their physicochemical and pharmacokinetic properties such as their
rapid elimination. Therefore, in order to improve the clinical use of peptides, there is a need
to develop peptide delivery systems capable of providing controlled peptide delivery.
In this work, two novel materials, mesoporous silicon (PSi) and photocrosslinked
poly(ester anhydride)s, were developed and characterized for use in controlled peptide
delivery. Previously, these materials have not been greatly exploited in this area. PSi is a
biodegradable and biocompatible, inorganic porous material that has recently attracted
interest in drug delivery. Photocrosslinked poly(ester anhydride)s are a new class of
surface-eroding biodegradable polymers, and their properties can be altered by modifying
the oligomer chemistry. In this study, PSi microparticles and photocrosslinked poly(ester
anhydride) implants were evaluated in vitro and in vivo for  subcutaneous  (s.c.)  peptide
delivery. The model peptide was peptide YY3-36 (PYY3-36, Mw 4050 g/mol), a promising
candidate for the treatment of obesity. Pharmacokinetic parameters of PYY3-36 were
determined based on plasma concentrations of PYY3-36 measured by enzyme-linked
immunosorbent assay.
In vitro peptide release method was first developed for PSi microparticles by comparing
three methods; of these the centrifuge method proved to be most suitable since it  requires
small sample amounts and allows good suspendability of microparticles. PYY3-36 was
adsorbed into PSi microparticles (12-16% w/w), and its release (mice, s.c.) was sustained in
comparison to solution. The surface chemistry of PSi modified peptide release, and several
mechanisms, such as diffusion, may play a role in controlling peptide release.
The drug release mechanism of photocrosslinked poly(ester anhydride) implants was
first examined by using small and higly soluble propranolol HCl as the model drug and by
performing in vitro, in vivo (rats, s.c.) and micro-computed tomography experiments. Drug
release was controlled by polymer surface erosion which also controlled the sustained
PYY3-36 release from photocrosslinked poly(ester anhydride) implants in vivo (rats, s.c.).
Increased hydrophobicity of the poly(ester anhydride) oligomers retarded water
penetration into the polymer matrix and decreased rates of polymer erosion and peptide
release in agreement with the principles of surface erosion-controlled release. Finally,
preliminary measurements of cytotoxicity and cytokine concentrations in plasma indicated
that the photocrosslinked poly(ester anhydride)s appear to be non-toxic.
In conclusion, PSi and photocrosslinked poly(ester anhydride)s are promising materials
for controlled peptide delivery. The advantages of PSi and photocrosslinked poly(ester
anhydride)s include tailorable peptide release rates based on their modifiable material
properties and mild conditions can be used for peptide incorporation that reduces the risk
of peptide inactivation.
National Library of Medical Classification: QT 36.5, QT 37, QU 68, QV 38, QV 785, WK 185, WN 206
Medical Subject Headings: Drug Carriers; Drug Delivery Systems; Delayed-Action Preparations;
Nanostructures; Nanomedicine; Microspheres; Silicon; Porosity; Polymers; Polyesters; Drug Implants;
Peptides/administration & dosage; Peptide YY; Pharmacokinetics; X-Ray Microtomography
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TIIVISTELMÄ:
Peptidien merkitys lääkkeinä on lisääntynyt ja lisääntyy edelleen tulevaisuudessa. Useiden
peptidien kliinistä käyttöä kuitenkin rajoittavat niiden fysikokemialliset ja
farmakokineettiset ominaisuudet, kuten nopea eliminaatio elimistössä. Tämän vuoksi on
kehitettävä antojärjestelmiä, joista peptidi vapautuu aktiivisena halutulla nopeudella.
Tässä työssä kehitettiin peptidien säädeltyyn annosteluun kahta uutta materiaalia,
mesohuokoista piitä ja valosilloitettuja poly(esterianhydridejä), joita on aiemmin tutkittu
hyvin vähän peptidien antoon. Mesohuokoinen pii (PSi) on biohajoava ja –yhteensopiva
epäorgaaninen huokoinen materiaali, jota on viime aikoina ryhdytty tutkimaan
farmaseuttisissa sovelluksissa. Valosilloitetut poly(esterianhydridit) ovat uudentyyppisiä
pintaerodoituvia biohajoavia polymeerejä, joiden ominaisuuksia voidaan muunnella
oligomeerien kemiallista rakennetta muokkaamalla. Tässä työssä peptidin vapautumista
PSi-mikropartikkeleista ja valosilloitettuja poly(esterianhydridi)-implantaatejsta tutkittiin in
vitro ja in vivo-kokein. Mallipeptidinä oli peptidi YY3-36 (PYY3-36, mp. 4050 g/mol), joka on
lupaava lääkekandidaatti liikalihavuuden hoitoon. PYY3-36:n farmakokineettiset
parametrit määritettiin mittaamalla PYY3-36:n pitoisuudet koe-eläinten plasmassa
formulaatioiden annon jälkeen entsyymivälitteisellä immunosorbenttimäärityksellä.
PSi-mikropartikkeleille kehitettiin in vitro-dissoluutiomenetelmä arvioimaan peptidin
vapautumista mikropartikkelista vertailemalla kolmea eri menetelmää. Näistä
menetelmistä sentrifuugimenetelmä osoittautui soveltuvimmaksi, koska se mahdollisti
mikropartikkelien hyvän sekoittumisen dissoluutionesteeseen ja vaati vähän
mikropartikkelinäytettä. PYY3-36:a adsorboitiin PSi-mikropartikkeleihin (12-16 %m/m),
jotka pidensivät PYY3-36:n viipymistä verenkierrossa hiirillä ihonalaisen annon jälkeen
verrattuna PYY3-36-liuokseen. PSi:n pintakemia vaikutti peptidin vapautumiseen ja useat
mekanismit, kuten diffuusio, säätelivät peptidin vapautumista.
Valosilloitettujen poly(esterianhydridi)-implantaattien lääkevapautumismekanismia
tutkittiin aluksi käyttäen vesiliukoista pienimolekyylistä propranololi HCl:a malliaineena.
Polymeerin pintaeroosio kontrolloi pääasiassa propranololi HCl:n ja PYY3-36:n
vapautumista poly(esteri anhydridi)-implantaateista. PYY3-36:a sisältävät implantaatit
pidensivät PYY3-36:n viipymistä verenkierrossa rotilla ihonalaisen annon jälkeen
verrattuna PYY3-36-liuokseen. Poly(esterianhydridi)-oligomeerin hydrofobisuuden
lisääminen hidasti veden tunkeutumista polymeerimatriisiin, mikä hidasti polymeerin
eroosiota ja siten peptidin vapautumista pintaeroosioteorian mukaisesti. Alustavien in vitro
(sytotoksisuus) ja in vivo (plaman sytokiinipitoisuus)–kokeiden perusteella valosilloitetut
poly(esterianhydridit) eivät näyttäisi olevan toksisia materiaaleja.
PSi ja valosilloitetut poly(esterianhydridit) ovat lupaavia materiaaleja peptidien
säädeltyyn annosteluun. Peptidien vapautumisnopeutta näistä materiaaleista voidaan
muunnella, joustavasti muokkaamalla materiaalien ominaisuuksia, ja peptidit säilyvät
aktiivisena hellävaraisten valmistusprosessien aikana.
Luokitus: QT 36.5, QT 37, QU 68, QV 38, QV 785, WK 185, WN 206
Yleinen Suomalainen asiasanasto: farmasian teknologia; lääkeaineet - - annostelu; nanotekniikka;
nanorakenteet; farmakokinetiikka; polymeerit; pii; huokoisuus; polyesteri; implantit; peptidit;
tietokonetomografia
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1 Introduction
Previously, drugs have been small-molecular compounds manufactured by chemical
synthesis or extracted from natural sources. These have been the techniques used since the
emergence of the modern drug industry over a century ago. However, the recent
developments in modern biotechnology and human biology have introduced new
therapeutic targets, and new drug candidates for those targets, such as peptides, proteins,
antibodies, small interfering RNAs (siRNA) or DNA. These have many crucial roles in the
physiological function of human body and therefore they are also attractive as drug
candidates in many therapeutic fields (Lien and Lowman 2003).
Peptides consist of amino acids linked by amide bonds and they are commonly defined
to be less than 50 amino acids in their size (Sato et al. 2006; McGregor 2008; Vergote et al.
2009) but some sources classify polypeptides up to 100 amino acids as peptides (Latham
1999; Lien and Lowman 2003). Insulin (Mw 5.8 kDa, 51 amino acids) can be considered as
the first peptide introduced to the clinical use in 1922 (Karamitsos 2011). Since then, over 70
different peptides have been marketed and more than 150 and 400 peptides are in late-
phase clinical and advanced pre-clinical studies, respectively (Bellmann-Sickert and Beck-
Sickinger 2010; Vlieghe et al. 2010). The financial value of the peptide drugs is believed to
be over 10 billion euros annually even by conservative estimates, and its growth rate
exceeds that of the small-molecular compounds (Marx 2005; Ayoub and Scheidegger 2006;
Vlieghe et al. 2010)
In comparison with small-molecular drugs, peptides, proteins and antibodies can
provide greater efficacy, selectivity and specificity to their targets (Vlieghe et al. 2010). In a
comparison with proteins and antibodies, peptides have a smaller size that allows them to
penetrate tissues relatively more easily. Peptides have also a better safety profile as they are
generally less immunogenic than proteins and antibodies while their degradation products
are amino acids that rarely cause systemic toxicity unlike the metabolites of small-
molecular  drugs.  However,  the  clinical  use  of  peptides  is  hampered by their  rapid in vivo
elimination i.e. their elimination half-lives can range from a few minutes to some hours and
they also suffer from poor permeability through biological membranes due to their size and
hydrophilic properties (Werle and Bernkop-Schnürch 2006; Vlieghe et al. 2010).
Different methods have been introduced in order to overcome the physicochemical and
pharmacokinetic challenges of peptides that prevent their efficient use as therapeutics.
These  include  chemical  means  to  decrease  elimination  of  peptides  such  as  addition  of
poly(ethylene glycol) (PEG) chains to the peptides and replacement of unstable natural
amino acids with more stable non-natural counterparts. In addition, different delivery
systems have been developed to improve the clinical use of peptides. In general, the
advantages of delivery systems include: 1) prolonged duration of action, 2) reduced side
effects, 3) decreased dose and 4) less frequent and possibly less invasive drug
administration improving patient compliance (Langer 1998). The first controlled drug
delivery systems were developed in 1960s (Folkman and Long 1964), and thereafter many
different carrier systems have been investigated (Hoffman 2008). Different drug delivery
systems can be classified in different ways, e.g. by their material, size and drug release
mechanism. Biodegradable polymers, such as polyesters and polyanhydrides, are one of the
most commonly used materials in drug delivery systems but recently also carriers based on
various inorganic materials, such as silicon, carbon and gold, have been introduced (Huang
et al. 2011). The size of the drug delivery systems varies from implants with sizes of
millimeters down to nanoparticles with sizes even smaller than 10 nm. The three main
mechanisms controlling the rate of drug release have been classified as diffusion, chemical
reaction  (e.g. matrix  erosion)  and  solvent  activation  (e.g. swelling of the matrix) (Langer
21990). The challenges of development of peptide delivery systems include finding ways to
circumvent the susceptibility of peptides to degrade either during their incorporation into
the delivery system or during peptide release for example due to degradation products of
polymeric delivery systems (Frokjaer and Otzen 2005).
The aim of this study was to characterize and develop two novel materials, namely
mesoporous  silicon  (PSi)  and  photocrosslinked  poly(ester  anhydride)s  to  be  used  in
controlled peptide delivery. In the case of PSi, different in vitro release methods were first
compared in order to develop an in vitro release method suitable for hydrophilic and
hydrophobic PSi microparticles. Next, peptide delivery via PSi microparticles with different
surface chemistries was examined in vitro and in vivo. In  the  case  of  photocrosslinked
poly(ester anhydride)s, the drug release mechanism was first evaluated by using a
hydrophilic, small molecule as a model compound. Subsequently, photocrosslinked
poly(ester anhydride)s were evaluated for peptide delivery in vivo and in vitro.  In  the
literature review, it is first provided a brief background on the current state and challenges
of peptide delivery and this is followed by a review of the main mechanisms controlling the
drug release. Finally, the properties of porous silicon and surface eroding polymers as
materials for drug delivery systems are described.
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2.1 THERAPEUTIC PEPTIDE DELIVERY
There is some variation in the literature in terms of definitions of what constitutes large
molecules and often borderlines between peptides, proteins, biologics or macromolecules
can be vague. In this review, peptides will be defined to be less than 50 amino acids in their
size (Sato et al. 2006; McGregor 2008) with the exception that insulin (51 amino acids) has
been included into peptides. There are three main sources of peptides: 1) bioactive peptides
isolated from natural sources, 2) peptides discovered from chemical libraries, or 3) peptides
derived from genetic or recombinant libraries (Latham 1999; Sato et al. 2006). Despite the
rapid developments of synthetic library techniques, most peptides currently in clinical use
are unmodified, natural peptides. These have better in vivo stability than synthetic peptides,
and good affinity and specificity to their targets through natural selection (Sato et al. 2006;
Watt 2006).
Peptides can be used to treat various indications, and the most important therapeutic
areas include endocrine functions, infectious diseases, oncology, disorders of central
nervous system and gastroenterology (Stevenson 2009; Bellmann-Sickert and Beck-
Sickinger 2010; Malavolta and Cabral 2011). In addition to their use as drugs, peptides have
also other biomedical applications, such as their incorporation in vaccines (Naz and Dabir
2007), diagnostics (Weiner and Thakur 2005; Lee et al. 2010) or to enhance cellular
penetration of drug delivery systems (Gupta et al. 2005).
2.1.1 Absorption
The poor transport of peptides across biological membranes, due to their large molecular
size and hydrophilicity, limits substantially peptide delivery. Therefore, intravenous (i.v.)
and subcutaneous (s.c.) injections are commonly used to administer peptides. However,
even after administration by s.c. injection, the bioavailability can be decreased due to
variability in local blood flow and peptide degradation at the injection site (Tang et al.
2004). Furthermore, for large peptides (~5 kDa) part of the dose (~20%) can be transported
to lymphatic capillaries instead of blood capillaries after s.c. injection while for small
peptides (~1 kDa), lymphatic absorption is minimal (Supersaxo et al. 1990; Charman et al.
2001; Lin 2009).
In non-invasive peptide delivery, epithelia cells represent a physical absorption barrier
and peptides have to be transported through epithelia via three different routes: 1)
transcellularly through the cells,  2) paracellularly through tight junctions between cells,  or
3) by active transport or receptor mediated mechanism (Fig. 2.1) (Burton et al. 1996;
Boguslavsky et al. 2003). The paracellular route has been suggested to be the most common
absorption route for peptides (Patton 1996; Veuillez et al. 2001; Lin 2009; Ozsoy et al. 2009).
Some general rules of the membrane permeability of peptides have been recognized and
mostly they are similar to those of small-molecular drugs. An increased number of
hydrogen bond donors and acceptors, hydrophilicity and large molecular size (>500-1000
Da) reduce the permeability of peptides (Burton et al. 1996; Ramaswami et al. 1996; Lin
2009; Ozsoy et al. 2009). The high polarity of peptides limits transcellular permeation due to
resistance against transport across lipidic cell membrane while large molecular weight
prevents paracellular transport via intercellular tight junctions (Pauletti et al. 1997; He et al.
1998; Lin 2009). For example, the dimensions of the paracellular route of intestinal epithelia
are between 10 and 50 Å, and this limits transportation through this route to peptides with
a radius of 11-15 Å, corresponding to a molecular weight of ca. 3.5 kDa (Madara and
Dharmsathaphorn 1985; Rubas et al. 1996). The peptide shape also affects membrane
4permeability so that linear peptides have higher permeability through biological
membranes  than more rigid cyclic  peptides  (Boguslavsky et  al.  2003;  Kwon and Kodadek
2007).
The permeation barrier for a peptide varies between administration sites being relatively
weakest in the lung alveoli and strongest in skin. In the alveoli of the lungs, the epithelia
can be only 0.2 μm thick and when combined with the large surface area and high
vascularization, it permits high pulmonary bioavailability and rapid absorption of peptides
(Patton 1996). In contrast, 10-20 μm thick stratum corneum of the skin, formed from
keratinocytes and the lipids between these layers, effectively blocks the permeation of polar
and large peptides (Benson et al. 2003; Benson and Namjoshi 2008; Prausnitz and Langer
2008). In addition, this kind of variation of permeability exists also within routes. For
example, within the oral cavity, permeability varies, being higher in non-keratinized
sublingual and buccal areas than in keratinized gum and palatal area (Veuillez et al. 2001).
With the pulmonary route as an exception, it is generally thought that molecules larger
than 500-1000 Da will need absorption enhancers in order to be effectively absorbed
(Pauletti et al. 1997; Veuillez et al. 2001; Ozsoy et al. 2009).
Enzymatic barriers to absorption for peptides consist of enzymes that degrade peptides
presystematically and they can be located at various sites, including intestinal lumen,
mucosa, or at the epithelia or inside the epithelia cells (Fig. 2.1). Gastrointestinal (GI)-tract is
enzymatically the most active body compartment as its physiological task is to digest
dietary proteins and peptides into amino acids or small peptide fragments, which makes it
a very hostile site for peptides (Pauletti et al. 1997; Tang et al. 2004). The enzymatic activity
present in the GI-tract can be divided into three groups by the sub-location of enzymes 1) in
the intestinal lumen, 2) at the brush border membrane of intestinal epithelia, and 3) in
cytosol of epithelia cells (Bernkop-Schnürch and Schmitz 2007). In the intestinal lumen, a
peptide first encounters pepsin in stomach followed by pancreatic enzymes of small
intestine, such as trypsin and chymotrypsin, or carboxypeptidase A and B, that are
degrading peptides in synergistic manner (Bernkop-Schnürch and Schmitz 2007; Lin 2009).
At the brush border membrane, there are membrane-bound glycoproteins acting as endo-
and exopeptidases but there are conflicting views on the importance of the brush border in
the peptide degradation. On one hand it has been claimed that the enzyme activity of brush
border  is  significantly  lower  than  that  of  luminal  and  cytosolic  enzymes  (Kim  et  al.  1976;
Bernkop-Schnürch and Schmitz 2007) while on the other hand it is suggested that at least a
contact with brush border is required to have significant peptide degradation in lumen
(Pauletti et al. 1997; Gentilucci et al. 2010). The final enzymatic barrier is formed by
cytosolic enzymes degrading peptides absorbed via transcellular pathway (Bernkop-
Schnürch and Schmitz 2007).
In the nasal, intraoral, pulmonary and transdermal administration routes the enzymatic
activity is lower than in GI-tract and additionally hepatic first-pass metabolism can be
avoided (Moeller and Jorgensen 2008). In the pulmonary route, the effect of the enzymatic
barrier depends on the size of the peptides. Natural, unmodified peptides that are less than
3 kDa in size are rapidly degraded by peptidases while larger peptides, such as calcitonin,
are more stable because of the presence of antiproteases in the lungs (Patton et al. 2004).
The buccal route has been postulated to express less enzymatic activity than the nasal route
(Veuillez et al. 2001) but at both administration sites several endo- and exopeptidases exist
decreasing absorption of peptides due to their degradation (Sarkar 1992; Veuillez et al.
2001; Costantino et al. 2007). Another difference between the nasal and buccal routes is the
location of the enzymes; in the nasal cavity, the enzymes are membrane-bound whereas in
oral cavity they are located in cytosol (Veuillez et al. 2001; Costantino et al. 2007). In the
skin,  enzymatic  activity  is  mostly  found  in  the  epidermis  and  dermis  and  the  stratum
corneum acts only as a permeation barrier (Shah and Borchardt 1991; Ogiso et al. 2000;
Bachhav and Kalia 2009).
5In addition, unstirred water and mucus layers reduce the absorption of the peptides by
creating diffusion barrier particularly in GI-tract (Sood and Panchagnula 2001). The
presence of electronic charges can affect the penetration of peptide through the negatively
charged mucosa by preferring the penetration of positively charged molecules (Veuillez et
al. 2001). In the nasal cavity and upper airways, mucicilliary clearance removes unabsorbed
peptide  molecules  from  the  absorption  site.  Finally,  acidic  gastric  fluids  and  alkaline
intestinal fluids can denature peptide within the GI-tract (Sood and Panchagnula 2001).
Figure 2.1. Simplification of peptide absorption routes and barriers to non-invasive peptide
delivery. Modified from Sood and Panchagnula, 2001.
2.1.2 Elimination
Rapid elimination due to poor in vivo stability of peptides is the most significant
pharmacokinetic barrier limiting the clinical use of peptides. The renal filtration of peptides
is  also  efficient  but  its  role  is  often  less  significant  (Tang  et  al.  2004;  Werle  and  Bernkop-
Schnürch  2006).  The  short  elimination  half-lives,  from  a  few  minutes  to  a  few  hours,  of
many peptides can be explained by their physiological role as hormones (Tang et al. 2004).
Rapid degradation allows the strict regulation of endogenous concentrations of peptides,
and consequently prompt adjustment of their functions.
The broad spectrum of proteolytic enzyme activities is main reason for the rapid
elimination of peptides and these enzymes are distributed ubiquitously throughout the
body, most importantly in blood, liver and kidneys (Tang et al.  2004; Werle and Bernkop-
Schnürch 2006; Lin 2009). Furthermore, since peptides are often hydrophilic compounds,
they  are  degraded  by  the  soluble  enzymes  present  in  blood  or  enzymes  bound  at  the
membrane, rather than enzymes in the cytoplasm (Werle and Bernkop-Schnürch 2006). The
proteolytic  enzymes  responsible  for  cleaving  peptides  can  be  divided  into  two  main
categories, namely exo- and endopeptidases (Werle and Bernkop-Schnürch 2006; Lin 2009).
Exopeptidases remove one or two amino acids either from the N- (aminopeptidase) or from
the C-terminals of the peptide chain (carboxypeptidase), whereas endopeptidases cleave
the peptide bonds within the peptide chain (Werle and Bernkop-Schnürch 2006; Lin 2009).
Each peptidase has its own cleavage specificity for certain peptides and the localization of
enzymes between tissues varies (Tang et al. 2004). For example, brush border enzymes are
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peptides, such as angiotensin I and II, bradykinin (Carone and Peterson 1980) or peptide
YY3-36 (Addison et al. 2011). In contrast, larger peptides, such as insulin, are endocytosed
at the luminal membrane of the kidney and subsequently degraded in lysozymes (Carone
et al. 1982). Another specific feature for peptide elimination is receptor-mediated
elimination via cellular uptake at the target sites of peptides (Tang et al. 2004). Receptors
can be saturated at therapeutic concentrations, and thus, this elimination route can
represent a source of non-linear pharmacokinetics.
Peptides are smaller than 10 kDa in size, and thus they are freely filtered by the glomerus
in the kidneys. However, the significance of renal clearance via glomerural filtration is
negligible in the elimination of many peptides unless the enzymatic degradation pathway
is blocked (Lin 2009). This can be illustrated by the fact that the complete removal of the
peptide via kidneys would require approximately 60 minutes for even the peptide strictly
confined within blood circulation. However, many peptides are cleared in less than 60
minutes (Lin 2009). This conclusion is further supported by the studies showing that renal
impairment does not affect insulin pharmacokinetics (Holmes et al. 2005) and that urine
excretion of N-acetyl-seryl-aspartyl-lysyl-proline peptide increased significantly after the
enzyme inhibition (Azizi et al. 1999).
Different chemical modifications of peptides have been introduced in order to prolong
the elimination half-lives of peptides i.e. by making the modified peptide less susceptible to
enzymatic degradation or renal excretion. The main methods of modification are alteration
in the peptide structure, or the conjugation of peptide with protein, polysialic acid or PEG
(Werle and Bernkop-Schnürch 2006; Nestor Jr. 2009; Gentilucci et al. 2010). For example, the
acetylation of N-terminal or amidation of C-terminal, improved the plasma stability of
MART-I27-35 so that the activity of the modified peptide was 5- to 6-fold higher than the
activity of the unmodified counterpart after 20 h incubation in plasma (Brinckerhoff et al.
1999). Another example of structure modification is the replacement of labile, natural L-
amino acids with more stable unnatural D-amino acids since few human enzymes are able
to hydrolyze D-amino acids (Powell et al. 1993; Gentilucci et al. 2010). The conjugation of
the peptide with a large molecule can increase peptide circulation time through two
mechanisms; making the peptide more stable towards enzymes and increasing the
molecular size to reduce the extent of renal filtration (Caliceti and Veronese 2003; Werle
and Bernkop-Schnürch 2006; Nestor Jr. 2009). The latter approach requires the use of a PEG
chain over 38 kDa or alternatively a protein the size of serum albumin. Examples of these
approaches reducing elimination and retaining the biological activity of the peptide include
the conjugation of GLP-1 via linker to serum albumin (Li et al. 2010) or PEGylation of
salmon calcitonin (Ryan et al. 2009) (Table 2.1).
7Table 2.1. Recent  examples  of in vivo studies of peptide delivery systems for different
administration routes.
Technology Peptide (Mw) Result Reference
Intravenous
Albumin-binding peptide
linked with a protease-
sensitive linker to therapeutic
peptide
Glucagon-like
peptide-1 (7-37)
(3.4 kDa)
Extended hypoglycemic effect and
significantly prolonged elimination half-
life
(Li et al.
2010)
Conjugating peptide with a
comb-shaped poly(PEG)
methyl ether methacrylate
Salmon
calcitonin (3.5
kDa)
7- to 15-fold increase in elimination
half-life after i.v. administration but
slight decrease in pharmacological
potency
(Ryan et al.
2009)
Subcutaneous
mPEG-PLGA-mPEG based
thermosensitive in situ
forming gel
Salmon
calcitonin (3.5
kDa)
Controlled release and pharmacological
activity for 20-40 days
(Tang and
Singh 2010)
Spray dried, non-covalent Zn-
peptide adduct
BMS-686117
(1.5 kDa)
Terminal half-life prolonged from 2 to 8
h, and Cmax –values decreased 6- to 8-
fold compared to solution
administration
(Qian et al.
2009)
Peroral
Liposomes modified with
chitosan and aprotin to have
mucoadhesion and enzyme
inhibition, respectively
Eel calcitonin
(3.4 kDa)
11- and 15-fold higher pharmacological
effect with chitosan and chitosan-
aprotin modified liposomes,
respectively, than with solution
(Werle and
Takeuchi
2009)
Absorption enhancement by
loosening tight junctions with
alkylsaccharide (Intravail)
Octreotide
acetate (1.1
kDa)
4-fold increase in bioavailability
compared with s.c. injection of solution
(Maggio and
Grasso
2011)
Conjugation of dextran
nanoparticles with vitamin
B12 to exploit receptor
mediated uptake
Insulin (5.8
kDa)
1.1- to 2.6-fold higher hypoglycemic
effect with vitamin B12 conjugated
dextran nanoparticles than with plain
particles
(Chalasani
et al. 2007)
Liposomes modified with
lectins to exploit active
transport mechanism and
mucoadhesion
Salmon
calcitonin (3.5
kDa)
20-fold increase in pharmacological
effect with modified liposomes
compared to non-modified liposomes
(Makhlof et
al. 2011)
PEGylation of peptide with 2
kDa PEG chain
Salmon
calcitonin (3.5
kDa)
Increased intestinal enzymatic stability
and 3.0- to 5.8-fold higher
pharmacological effect than
unPEGylated calcitonin
(Youn et al.
2006)
Intraoral
Absorption enhancement with
lecithin and propanediol
containing spray
Insulin (5.8
kDa)
Significant decrease of blood glucose
levels and studies with FITC-insulin
showed trans- and paracellular
absorption, and relative bioavailability
29% in a comparison with s.c. injection
(Xu et al.
2002)
Thiolated-chitosan acting as
mucoadhesive and absorption
enhancer in buccal tablets
Pituitary
adenylate
cyclase-activating
polypeptide (3.7
kDa)
Absolute bioavailability 1% and
formulation remained attached to
buccal mucosa for the duration of the
experiment (6 h)
(Langoth et
al. 2006)
(Table continues on the next page)
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Technology Peptide (Mw) Result Reference
Intranasal
Ethylcellulose powder with N-
acetyl–L-cysteine as mucolytic
agent reducing nasal fluid
viscosity
Salmon
calcitonin (3.5
kDa)
2- to 3-fold increased bioavailability
with mucolytic agent
(Matsuyama
et al. 2006)
Synergistic use of
mucoadhesive starch
microspheres with various
absorption enhancers
Insulin (5.8
kDa)
1.4- to 5-fold increase in the
absorption in a comparison with plain
solution depending on enhancer
combination
(Illum et al.
2001)
Cosolvent formulation with n-
tridecyl--D-maltoside as
permeation enhancer in brain
delivery
Hexarelin (0.9
kDa)
1.6-fold higher peptide concentration
in brains in a comparison with i.v.
administration despite lower plasma
concentrations after intranasal
administration
(Yu and Kim
2009)
Pulmonary
HP--cyclodextrin and linear
or branched PEG chains spray
dried to microparticles
Salmon
calcitonin (3.5
kDa)
1.5- and 2.3-fold increase of
bioavailability with branched and
linear PEG, respectively, in
comparison to nebulized solution
(Tewes et al.
2011)
Palmityl-acylation of peptide
to increase adsorption on
porous PLGA microparticles
and albumin binding in blood
circulation
Exendin-4 (4.2
kDa)
Native and palmityl-acylated peptide
administered in microparticles
induced hypoglycemia for 36 h and
over 5 days, respectively
(Kim et al.
2011)
Delivery with liposomes to
increase retention time in
lungs
Insulin (5.8
kDa)
Liposome-encapsulated insulin
enhanced significantly hypoglycemic
effect when compared with insulin
administered outside of liposomes
(Huang and
Wang 2006)
Transdermal
Two-layered dissolving
microneedles prepared from
water-soluble biopolymers
Desmopressin
(1.1 kDa)
Absolute bioavailability was over 90%
and maximum plasma concentration
was reached in 30 min
(Fukushima
et al. 2010)
Insulin encapsulated
nanovesicles delivered with
iontophoresis through
microneedle-induced
microchannels
Insulin (5.8
kDa)
Comparable hypoglycemic effect to
s.c. insulin by using 80-fold higher
dose
(Chen et al.
2009)
Removal surface layers of skin
with microdermabrasion
technique
Insulin (5.8
kDa)
Hypoglycemic effect similar to 160-
fold lower s.c. insulin dose after
removal of epidermis, no
hypoglycemic effect after removal of
stratum corneum
(Andrews et
al. 2011)
2.1.3 Peptide delivery systems
Traditionally, peptides have been administered by i.v. or s.c. injection and typically with a
short duration of action, but non-invasive routes have attracted considerable interest in
order to have pain-free administration. Regardless of the administration route, controlled
delivery systems are needed if one wishes to achieve sustained release and a prolonged
pharmacological  effect.  Various  delivery  systems  such  as  polymeric  implants,  micro-  and
nanoparticles and liposomes have been developed for peptide administration via different
routes (Table 2.1) (Sanders 1990; Dass and Choong 2006; Al-Tahami and Singh 2007).
9Different ways to overcome barriers (i.e. chemical, enzymatic and physical) to efficient
peptide delivery have been tried by adopting different techniques including 1) reduction of
enzymatic degradation by using enzyme inhibitors or peptide conjugation (e.g.
PEGylation), 2) facilitation of permeation through epithelia by using chemical or physical
penetration enhancers, 3) addition of ligands to peptides or delivery systems to exploit
receptor-mediated endocytosis or 4) utilization of delivery systems to provide physical
protection from enzymes, controlled release and mucoadhesion (Table 2.1) (Veuillez et al.
2001; Hussain et al. 2004; Tang et al. 2004; Morishita and Peppas 2006; Antosova et al. 2009;
Lin 2009). Often several different techniques and mechanisms can be employed
simultaneously, such as by encapsulating a peptide in nanoparticles with mucoadhesive
properties and linking a ligand to nanoparticles enabling receptor mediated-endocytosis as
shown for example by Chalasani et al. 2007.
Enzyme inhibitors (e.g. aprotin, bacitracin) can be used to prevent enzymatic cleavage of
peptides which is a notable problem in peroral administration but their efficacy has varied
(Veuillez et al. 2001; Lin 2009). Particularly in the GI-tract, the high number of enzymes can
pose challenges to the efficacy of inhibitors and the long-term use of inhibitors may
potentially affect the digestion of dietary peptides and proteins. An alternative way to
increase enzymatic stability is the use of peptide conjugations such as PEGylation as
discussed in chapter 2.1.2. Chemical penetration enhancers are used to the loosen tight
junctions of epithelia or increase the fluidity of stratum corneum lipids, and thus to
improve transcellular transportation of peptides (Hussain et al. 2004; Williams and Barry
2004; Lin 2009). Various chemicals have been tried as penetration enhancers such as
surfactants, fatty acids, cyclodextrins, N-acetylated -amino acids but there are general
concerns about penetration enhancers i.e. their inherent toxicity, duration of action and
whether they allow leakage of endogenous substances or the influx of toxic compounds
(Aungst 2000; Williams and Barry 2004). In transdermal delivery, not only chemical
penetration enhancers (Williams and Barry 2004), but also physical penetration enhancing
have  been  attempted,  such  as  1)  application  of  physical  energy  to  push  peptides  into  the
skin (e.g. ionto- and sonophoresis), 2) physical penetration, for example with microneedles,
through stratum corneum, 3) ablation of stratum corneum, for example by thermal poration
and radiofrequency thermal ablation techniques (Benson and Namjoshi 2008; Kalluri and
Banga 2011). Receptor-mediated delivery has  been used,  particularly  in  the  peroral  route,
by incorporating of ligands into the peptides or their delivery systems. Examples of ligands
include vitamin B12 (Chalasani et al. 2007; Petrus et al. 2009) or transferrin (Xia and Shen
2001; Lim and Shen 2005) that utilize the natural uptake mechanism of dietary vitamin B12
and iron, respectively. In addition, lectins, that are glycoproteins, can trigger the active
transport of nanocarriers, such as peptide delivery systems (Lehr 2000; Makhlof et al. 2011).
Finally, different delivery systems, such as micro- and nanoparticles, and liposomes, have
been used in order to reduce peptide degradation and to achieve sustained release
(Antosova et al. 2009). Furthermore, if the carrier has mucoadhesive properties, such as
chitosan, this can improve the retention of the carrier on the epithelia and increase the local
peptide  concentrations  and  this  way  enhance  the  possibility  of  absorption  (Veuillez  et  al.
2001). Table 2.1 shows recent examples of different technologies used to improve the
efficacy of peptide delivery in different administration routes.
In  terms  of  clinical  use,  the  nasal  route  is  probably  the  most  popular  non-invasive
administration route. Salmon calcitonin, desmopressin, buserelin acetate, nafarelin acetate
and oxytocin are on the market as plain solution in nasal sprays with bioavailabilities of 3-
10% (Moeller and Jorgensen 2008; Antosova et al. 2009). Desmopressin is only marketed
peptide to be given by per oral administration. The bioavailability of desmopressin tablet
formulation (dose 200 μg) is only 0.1% but nonetheless the pharmacodynamic effect is
similar to that obtained with i.v. administration (dose 2 μg) (Rembratt et al. 2004; Moeller
and Jorgensen 2008). For insulin, buccal Oral-lyn spray containing absorption enhancers
with efficacy comparable to s.c. injections is being developed and is in phase III clinical
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trials (Guevara-Aguirre et al. 2004; Generex 2011; Palermo et al. 2011). The pulmonary
delivery of insulin was expected to be the first commercial non-invasive delivery method
for insulin, and it was indeed launched in 2006 by Pfizer under the tradename Exubera
(Klingler et al. 2009). However, the product was a commercial failure and withdrawn from
the market in 2007. It was not accepted by either physicians and patients since the
therapeutic benefits over s.c. insulin were not demonstrated and the device was bulky
(Kling 2008; Klingler et al. 2009; Heinemann 2011). Furthermore, FDA warned Exubera
patients with smoking background about the significant risk of lung cancer, which raised
concerns about the safety of long-term pulmonary administration of peptides and proteins
(Antosova et al. 2009; FDA 2008). The failure of Exubera also lead other companies, such as
Novo Nordisk and Eli Lilly, to terminate their own development programmes for
pulmonary delivery of insulin (Kling 2008). However, the MannKind company still
continues its development of Technosphere technology for inhalable insulin (Moeller and
Jorgensen 2008; Heinemann 2011).
2.1.4 Stability of peptides in dosage forms
The  long-term  storage  stability  of  peptides  in  aqueous  solutions  is  often  poor,  and
therefore, solid-state formulations are preferred if one wishes to attain sufficient storage
shelf-life (Houchin and Topp 2008; Chang and Pikal 2009). However, formulation
processing and residual moisture in the final formulation can induce peptide degradation
even in  the  solid  state,  and thus  different  stabilizing excipients  and process  optimizations
are needed. The pharmaceutical stability of peptides can be divided into chemical and
physical stabilities (Frokjaer and Otzen 2005; Jorgensen et al. 2009). Chemical degradation is
relevant for all peptides since it involves the primary structure while physical degradation
concerns only peptides with a secondary or higher structure which are altered by physical
degradation (Bilati et al. 2005). Physical degradation of peptides and proteins can be
divided into four classes: 1) denaturation, 2) aggregation, 3) precipitation or particle
formation, and 4) surface adsorption (Manning et al. 2010). The main chemical degradation
reactions include deamidation, hydrolysis, oxidation and disulfide formation. In addition,
one should note that the chemical and physical degradation processes can be interrelated,
for example deamidation can make a peptide more prone to aggregation (Chang and Pikal
2009; Manning et al. 2010).
Different methods have been attempted to stabilize peptides in the liquid and solid states
and during processing. However, the dominating degradation mechanism between
peptides varies, and therefore the development of stabilization methods for peptides
require more of a trial and error approach and a deeper knowledge of degradation
mechanism than with small-molecular drugs (Bilati et al. 2005; Manning et al. 2010). The
typical stabilizing excipients include sugars, surfactants, buffers, ions and cyclodextrins
that are added to the formulation to increase conformational stability, prevent access of
peptides to interfaces or increase the colloidal stability of peptide solution. In addition,
chemical modification such as methionine oxidation of human calcitonin can reduce the
aggregation  of  peptide  (Mulinacci  et  al.  2011).  However,  PEGylation  of  insulin  did  not
inhibit insulin aggregation (Torosantucci et al. 2011). As compared with peptide solutions,
the formulation stability of peptides can be increased by drying techniques from which
freeze-drying  is  probably  the  most  common  method.  In  freeze-drying,  as  in  any  other
formulation method, peptides are exposed to various stresses such as freezing, drying or to
different interfaces (e.g. water-ice, water-air or water-organic solvent) (Bilati et al. 2005;
Jorgensen et al. 2009; Manning et al. 2010). In addition, excess heat can induce peptide
degradation but for example temperatures as high as +80C during the extrusion have been
shown to be tolerated by the small, eight amino acids long, vapreotide (Rothen-Weinhold et
al. 1999a, 1999b).
Peptides may be degraded even in the solid state, for example in polymeric matrices,
such as poly(lactic-co-glycolic acid) (PLGA) and poly(lactic acid) (PLA), examined for
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controlled peptide release (Lucke et al. 2002b; Houchin and Topp 2008). In the controlled
release formulations, one must also realize that if drug release is designed to last for
months, then peptide degradation may also occur at the administration site (Murty et al.
2005). Typical peptide degradation mechanisms in polymer matrices include acylation and
hydrolytic reactions (e.g. peptide chain cleavage and deamidation) (Houchin and Topp
2008). By using a hexapeptide as a model peptide, Houchin et al. (2006) found that
hydrolytic reactions are preferred in acidic and high moisture conditions while acylation is
more favored in neutral and low moisture conditions. Acylation is a the reaction between
ester bonds of the polymer and the primary amines of the N-terminus of peptide (Na et al.
2003) and it can be inhibited by using PEG as a copolymer (Lucke et al. 2002a) or by
incorporating divalent  salts  into  the  polymer matrix  (Sophocleous et  al.  2009;  Zhang et  al.
2009). Basic salts have been proposed to inhibit deamidation (Zhu et al. 2000) but they can
induce base-catalyzed peptide degradation, and therefore proton sponges or basic amines
have been proposed instead of basic salts despite the fact that they can increase the rate of
PLGA hydrolysis (Houchin et al. 2007).
2.2. DRUG RELEASE MECHANISMS OF CONTROLLED RELEASE SYSTEMS
The term drug release mechanism can be defined in slightly different ways, either
describing the way in which drug molecules are transported or released (i.e. true release
mechanism), or the process determining the release rate (i.e. rate-controlling release
mechanism) (Fredenberg et al. 2011b). In this review, the latter definition, rate-controlling
release mechanism, is used since it allows a more distinct classification of release
mechanisms. Furthermore, when designing drug delivery systems, knowledge about the
rate-controlling release mechanism is important as it provides an understanding of how the
drug release rate can be modified (Fredenberg et al. 2011b). However, in order to determine
the rate-controlling process, it is crucial to be aware of the true release mechanisms. One
must also note that the release mechanisms can be altered during the drug release or there
can be more than one mechanism affecting simultaneously to the detected overall drug
release. Furthermore, properties of drug and carrier often can affect drug release as
summarized in Table 2.2. Finally, with this great variety of drug delivery systems, it is
impossible to list all potential phenomena controlling the drug release. Rate-controlling
drug release mechanisms can include processes such as water absorption on the system or
crack formation, instead of a classical drug release mechanism such as diffusion or erosion
(Siepmann and Siepmann 2008).
2.2.1 Diffusion
Diffusion is one of the most common drug release mechanisms and it can occur for example
through a polymer membrane, and through non-porous or porous matrices (Fig. 2.2)
(Langer 1990; Fredenberg et al. 2011b). In addition to being the rate-controlling drug release
mechanism, diffusion can be involved in many cases where other release mechanisms are
dominant and rate-controlling processes. Pure diffusion-controlled release shows drug
release kinetics which obey Fickian diffusion kinetics, that is, drug release rate decreases as
a function of time (Siepmann and Siepmann 2008). This can be described by Fick’s first law:
  


(Eq. 2.1)
in  which,  J  is  the  flux  of  the  drug  and  D  is  the  diffusion  coefficient  of  drug,  and  dC/dx
describes concentration gradient (Martin 1993). Fickian diffusion does not result in zero-
order drug release but instead, drug release follows square-root-of-time kinetics. However,
pseudo-zero order linear release kinetics can be achieved also in diffusion-controlled
systems when there are also some other release mechanisms simultaneously influencing on
the drug release. For example, matrix degradation as a function of time can loosen the
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matrix  structure,  and  consequently  to  increase  the  diffusion  coefficient  of  drug
compensating for the declining concentration gradient and the increasing length of the
diffusion path (Wada et al. 1995; Bezemer et al. 2000; Jansen et al. 2010). However, the
significance  of  the  matrix  degradation can diminish if  the  matrix  becomes swollen (e.g. in
hydrogels)  and  if  the  diffusion  coefficient  of  the  drug  is  high  in  the  intact,  undegraded
matrix (Bezemer et al. 2000).
The physicochemical properties of the drug, such as size, shape, charge and
hydrophilicity-hydrophobicity, have a clear influence on the diffusion-controlled release.
The diffusion coefficient of the drug is affected by its size according to the Stokes-Einstein
equation:
 =
	


(Eq. 2.2)
in which R is molar gas constant, T is absolute temperature,  is the viscosity of the
solvent, r is  the  radius  of  the  spherical  molecule  and  Na is  Avogadro’s  number  (Martin
1993). As shown in Eq. 2.2, as the size of the drug increases its diffusion coefficient
decreases. In addition to the diffusion coefficient, the size of the drug can also influence its
diffusion-controlled release due to the intrinsic properties of the delivery systems. As an
example, propranolol HCl (295 g/mol) is released mainly by diffusion from biodegradable
SiO2 matrices but the release of bovine serum albumin (68 000 g/mol) did not occur until
erosion of SiO2 matrix  since  pores  of  SiO2 matrix  were  not  large  enough  for  diffusion  of
bovine serum albumin (Viitala et al. 2007). Similar results have been shown for protein
release from hydrogels, indicating that differences in diffusion can be explained by the ratio
of the hydrogel mesh size and the hydrodynamic radii of proteins (Van Tomme et al. 2005;
Censi et al. 2009).
Not only the size of the drug, but also the shape of the large molecules (e.g. proteins) can
affect the diffusion coefficients so that more asymmetrical molecules have lower diffusion
coefficients (Florence and Attwood 2006). Furthermore, negative or positive charges of the
drug molecule can decrease diffusion significantly in the presence of oppositely charged
groups within the drug delivery system (Van Tomme et al. 2005; Klose et al. 2008).
Hydrophilicity  and hydrophobicity  of  the  drug and carrier  matrix  can also  have an effect
on the release mechanism. For example, the hydrophilic compound, 5-fluorouracil, was
partitioned in the hydrophilic PEG domains of PLGA-PEG-PLGA hydrogel and could be
released by a diffusion-controlled mechanism (Qiao et al. 2005). In contrast, the
hydrophobic drug, indomethacin, partitioned into the hydrophobic PLGA domains, and
therefore, after initial diffusion-controlled release, its release was controlled by hydrogel
erosion.
For  example,  even  though  drug  can  diffuse  through  a  non-porous  polymer  matrix,  the
diffusion may be too slow for drug delivery applications (Polakovi et al. 1999; Fredenberg
et al. 2009, 2011a). Therefore, diffusion-controlled drug release from matrix often occurs
through pores or channels (Fig. 2.2). Before the drug is released by diffusion through pores
or  channels,  it  must  be  dissolved by the  penetrated water,  unless  the  drug is  dissolved in
polymer. Hence, the degree of water penetration into the delivery system can affect
diffusion-controlled drug release. In the case of insufficient water penetration, poor drug
dissolution can limit the drug release. Thus, the drug release is controlled by water
diffusion into the matrix, not by the drug diffusion out of matrix (Kreye et al. 2011a, 2011b,
2011c). In addition, the increase of an initial drug loading degree increases the mobility of
the drug, particularly in the case of lipophilic or hydrophobic matrices (Guse et al. 2006;
Rosenberg et al. 2007; Kreye et al. 2011c). The high drug loading degree creates connected
regions of drug in the matrix which enhance water penetration into the matrix and
consequently drug release is increased. Interestingly, Polakovic et al. found that lidocaine
release was diffusion-controlled only at low drug loading degrees, when the drug was
molecularly dispersed, whereas at high drug loading degrees (>30% w/w) the dissolution of
drug crystals controlled the release (Polakovi et al. 1999).
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When the size of the non-degradable delivery system increases, the length of the
diffusion path increases which decreases drug release as a function of time. However, in the
case  of  biodegradable  delivery  systems,  the  effect  of  matrix  size  on  drug  release  is  more
complicated. For example, enhanced autocatalytic degradation inside the larger nonporous
PLGA microparticles has increased the mobility of the drug, and thus compensated for the
effect  of  the  larger  matrix  size  on  drug  release  (Siepmann  et  al.  2005;  Klose  et  al.  2008).
Similarly, in dextran-based hydrogels, the increased device size could be compensated for
by the increased diffusion coefficient of the drug due to the swelling of the hydrogel (Cadée
et al. 2002).
Figure 2.2. Diffusion-controlled drug release through polymer film and through non-porous and
porous matrices.
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Table 2.2. Effect of drug and carrier properties on drug release in different rate-controlling drug
release mechanisms.
Property Effect Reference
Diffusion-controlled
Size of the drug Diffusion coefficient decreases as the size
of the drug increases
(Van Tomme et al. 2005;
Viitala et al. 2007; Censi
et al. 2009)
Charge of the drug Electrostatic interactions between
oppositely charged functional groups of
carrier and drug retard drug diffusion
(Van Tomme et al. 2005;
Klose et al. 2008)
Hydrophobicity of the drug Interactions with hydrophobic domains of
carrier retard diffusion
(Qiao et al. 2005)
Water penetration into the
carrier
Poor water permeation limits drug
dissolution, and consequently diffusion
(Kreye et al. 2011a,
2011b, 2011c)
High drug loading degree Enhances diffusion by increasing water
uptake
(Guse et al. 2006;
Rosenberg et al. 2007;
Kreye et al. 2011b)
Pores and cracks of the carrier
matrix
Enhances diffusion (Guse et al. 2006;
Fredenberg et al. 2009)
Surface erosion-controlled
Erosion rate of the carrier Ideally determines release rate (Tamada and Langer
1993; Göpferich 1996)
Physicochemical properties of
drug
Small and hydrophilic molecules can diffuse
out of matrix before matrix erosion
(Mathiowitz and Langer
1987; Shieh et al. 1994)
Drug loading degree High drug loading degree can change
release mechanism from surface erosion-
controlled to diffusion-controlled
(Mathiowitz and Langer
1987; Shieh et al. 1994)
Degradation-controlled
Base or acid property of the
drug
Effects on autocatalytic degradation of
matrix
(Alexis et al. 2004)
Osmosis-controlled
Ratio of length and diameter of
release orifice or channel
Orifices or channels need to be small and
long enough to avoid diffusion-controlled
release
(Ryu et al. 2007; Tobias
et al. 2010)
Amount of excipients with
osmotic activity
Increase of amount of excipients increases
drug release rate
(Gu et al. 2006, 2007)
Total volume of excipients and
drug
If percolation threshold is exceeded,
release not controlled by osmosis
(Shaker and Younes
2010)
Brittleness of the monolithic
polymer matrix
Brittle matrices show faster drug release (Gu et al. 2007)
Ion-exchange-controlled
Valence of counter-ions Divalent ions induce faster release than
monovalent ions
(Liu et al. 2001; Li et al.
2008)
Counter-ion concentration and
affinity
High ion concentration and affinity to
functional groups of carrier increase the
release
(Li et al. 2008; Dadsetan
et al. 2010)
pH of the release medium Ionization of drug and matrix (Tarvainen et al. 1999;
Zhang et al. 2006a)
Stimuli responsive
External or internal stimulus,
e.g. pH, temperature,
ultrasound or glucose
Stimulus triggers a change in properties of
delivery system which leads to drug release
(Bajpai et al. 2008;
Ganta et al. 2008)
15
2.2.2 Surface erosion
In  surface  erosion,  the  degradation of  chemical  bonds of  polymer is  faster  than the  water
diffusion into the polymer matrix, and therefore erosion is limited on the external surface of
the matrix. As the matrix erodes, the drug incorporated into the matrix is released
simultaneously, i.e. surface  erosion  controls  the  drug  release  regardless  of  the
physicochemical properties of the drug (Fig. 2.3) (Tamada and Langer 1993; Göpferich
1996). Therefore, the advantage of this mechanism is the feasibility for modifying the
release  rate  by  tailoring  the  erosion  properties  of  the  delivery  system.  Typically,  surface
erosion-controlled mechanism is preferred in controlled drug delivery since ideally it
allows linear, zero-order release kinetics whereas drug release from bulk-eroding matrices
obeys non-linear kinetics.
The challenge of this mechanism is to adjust the properties of the delivery system so that
the diffusion of the drug does not exceed the erosion rate, otherwise the release mechanism
changes from surface erosion-controlled to diffusion-controlled. For example, pore
formation can favor diffusion-controlled release instead of surface erosion-controlled
release (Okumu et al. 1997; Breitenbach 2000). High hydrophilicity or high drug loading
degree tend to alter the release mechanism from surface erosion- to diffusion-controlled as
demonstrated with polyanhydrides (Mathiowitz and Langer 1987; Shieh et al. 1994). In
contrast,  high  hydrophobicity  and  a  low  loading  degree  of  drug  favor  surface  erosion-
controlled release from polyanhydrides due to the increased affinity for the drug to the
polymer matrix (Park et al. 1997).
2.2.3 Degradation
Degradation  is  defined  as  the  cleavage  of  the  chemical  bonds  (Göpferich  1996)  and  drug
release  can  be  controlled  by  degradation  from  drug  delivery  systems  including  bulk-
eroding polymers and hydrogels. (Fig. 2.3). However, degradation-controlled release is
often connected to diffusion-controlled release and thus is not typically the sole release
mechanism  during  the  entire  duration  of  the  drug  release  process.  For  example,  drug
release from bulk-eroding delivery systems displays typically three phases:  1) burst phase
due  to  rapid  drug  diffusion  from  the  matrix  surface,  2)  diffusional  release  phase,  and  3)
final  fast  release  phase  after  the  collapse  of  the  matrix  due  to  degradation  and  erosion
(Gallagher and Corrigan 2000; Tarvainen et al. 2002; Alexis et al. 2004). In crosslinked
hydrogels, degradation of the crosslinks enlarges the mesh size, and thus increases
particularly  the  release  rate  of  macromolecules,  changing the  drug release  from diffusion-
or swelling-controlled to degradation-controlled release (Lu and Anseth 2000; Zhang and
Chu 2001; Cadée et al.  2002).  Similarly, since the loosening of the polymer network due to
degradation enhances both the water uptake and polymer swelling, the drug release rate is
consequently increased (Wang et al. 2006a; Zhang et al. 2007). Thus, it might be difficult to
distinguish between different release mechanisms and to identify mechanism that is
actually controlling the rate of release.
Figure 2.3. Surface erosion- and degradation-controlled drug release
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2.2.4 Osmosis
Osmotic delivery systems can be divided into two main categories: either an osmotic pump
with a semi-permeable film or monolithic polymer matrix with microcompartments of drug
and excipient  (Fig.  2.4).  The osmotic  pump systems are  in  the  clinical  use  in  oral  delivery
and they are based on a delivery system encapsulated with polymer film which is
permeable to water but impermeable to dissolved drugs or excipients inside the delivery
system (Conley et al. 2006). Small orifices are drilled into the semi-permeable film in order
to  let  the  drug  pass  through  them.  The  drug  is  in  a  solution  in  the  osmotic  pump,  so  the
length of the release channel and the diameter of orifice will dictate the drug release
mechanism (Ryu et al.  2007; Tobias et al.  2010).  If  release channels are too wide and short,
the release is based on diffusion instead of being osmotically controlled zero-order release.
In the monolithic system, the drug release starts with water penetration into polymer
matrix  in  order  to  create  saturated  solutions  of  drug  and  excipients  in  the
microcompartments (Gu et al. 2007; Shaker and Younes 2010). Subsequently, these will
attract more water because there is a chemical potential gradient until the
microcompartment  ruptures  and  drug  is  released.  In  the  monolithic  systems,  the  release
rate can be controlled by the amount of excipients with osmotic activity (e.g. trehalose), so
that an increased amount of excipient increases the release rate without affecting the release
mechanism  (Gu  et  al.  2006,  2007).  The  susceptibility  of  the  polymer  to  rupture  as  the
microcompartment swells affects also the release rate, and more brittle polymers exhibit
faster release rates (Gu et al. 2007). Monolithic systems lose their osmotically controlled
release property if the volume of the drug and the excipient particles in the devices exceed
the percolation threshold (30-35% v/v), since in that case diffusion, through interconnected
particles dominates the release (Shaker and Younes 2010).
The advantages of the osmotically controlled release systems include zero-order release,
release  rates  independent  on  physicochemical  properties  of  the  drug,  and  combined  and
sequential  release  of  different  drugs  from  the  same  delivery  system  (Amsden  and  Cheng
1995; Ryu et al. 2007; Chapanian and Amsden 2010).
Figure 2.4. Osmosis-controlled release from osmotic pump or monolithic system.
2.2.5 Swelling
Matrix  swelling  is  an  important  release  mechanism,  particularly  in  peroral  delivery  with
hydrophilic (e.g. hydroxypropyl methylcellulose) matrix tablets (Siepmann and Peppas
2001; Maderuelo et al. 2011). In matrix swelling, water first penetrates into the delivery
system inducing hydration of the glassy (dry) polymer, followed by the relaxation of the
polymer chains (Fig. 2.5) (Gupta et al. 2002). This is seen macroscopically as swelling and
microscopically  as  an  increase  in  the  mesh  size  leading  to  higher  drug  mobility  through
swollen polymer layer (Gupta et al. 2002; Messaritaki et al. 2005). Drug release kinetics from
swelling-controlled system show typically declining drug release rates as a function of time
due  to  the  increasing  length  of  diffusion  path  and  a  decreasing  diffusion  gradient
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(Maderuelo et al. 2011). However, quasi-linear release profile might be seen if an untypical
large time-dependent increase in the surface area and diffusion coefficient of the drug can
compensate longer diffusion paths and decreased diffusion gradients (Kim and Lee 1992).
Nevertheless, it requires suitable drug loading degree since the increase of drug loading
degree in hydrogel over the percolation threshold may change the release mechanism from
being swelling to diffusion-controlled (Kim and Lee 1992). In addition, it is possible that
swelling controls the drug release only during a certain phase of the drug release, such as
the initial stage of the drug release when water is penetrating into the delivery system (Wu
et al. 2003; Messaritaki et al. 2005). Then, after the initial swelling-controlled release, the
drug release can be controlled for example by degradation of hydrogel or drug diffusion
through the polymer matrix.
2.2.6 Ion-exchange
Ion-exchange-controlled drug release is based on the process in which counter-ions replace
the drug bound on the charged functional groups of the carrier (Fig. 2.5) (Guo et al. 2009).
The rate of this exchange, and consequently the rate and extent of the drug release, depends
upon the  concentration of  counter-ions  and their  affinity  for  the  charged groups (Li  et  al.
2008; Dadsetan et al. 2010). Furthermore, an increased number of ions, also higher ionic
concentration gradient driving counter-ions to the delivery system increases the release rate
(Liu  et  al.  2001).  However,  this  is  mainly  relevant  under in vitro conditions since the ion
concentration is relatively constant in the body. Furthermore, the valency of ions affects the
release rate, and as an example, in the presence of divalent calcium ions, the release rate is
higher and more complete than in the presence of monovalent sodium ions (Liu et al. 2001;
Li et al. 2008). The better efficacy of divalent ions is due to their higher affinity for charged
groups and their possibility to interact with two functional groups instead of one group.
Interestingly, the ionic strength of drug adsorption solution affects the drug release from
ion-exchange  membranes  (Tarvainen  et  al.  1999).  The  drug  release  was  slower  from
membranes  loaded  at  a  higher  solution  ionic  strength  due  to  decreased  binding  sites
available for drug. Finally, the pH of the release medium can have an influence on the drug
release  from  ion-exchange  membranes  since  pH  affects  the  degree  of  ionization  of  both
functional groups of the delivery system and the drug, and therefore also interactions
between them (Tarvainen et al. 1999; Zhang et al. 2006a).
Figure 2.5. Swelling- and ion-exchange-controlled drug release mechanisms.
2.2.7 Stimuli-responsive
In  stimuli-responsive  drug  delivery,  the  drug  release  is  attributable  to  the  reversible
changes of the delivery system, such as swelling, shape change or conformational change,
triggered by stimulus, such as pH, temperature, redox-reactions, physiological compounds
(e.g. glucose) and ultrasound (Fig. 2.6) (Schmaljohann 2006; Bajpai et al. 2008; Ganta et al.
2008).  Some of these stimuli are naturally encountered by the delivery system, such as the
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acidic pH conditions inside of tumours or lysosomes while other stimuli need to be applied
externally, e.g. ultrasound.
An  example  of  an  external  stimulus  is  pH  which  varies  within  the  body  and  cells.  For
example  pH of  tumour or  sites  of  inflammation decreases  from normal  pH 7.5  to  pH 6.5,
while  inside  the  cell,  the  pH  of  lysomes  is  less  than  5  (Wike-Hooley  et  al.  1984;  Gerweck
and  Seetharaman  1996).  In  pH-responsive  micelles,  drug  release  can  be  controlled  by
linking the drug to the carrier by pH-sensitive hydrazone linkers that will be cleaved at pH
5-6  (Bae  et  al.  2005).  Another  example  of  internal  stimulus  is  the  plasma  glucose  level.  In
glucose-responsive insulin release, glucose or its byproducts trigger insulin release from a
delivery  system  (Roy  et  al.  2010).  An  example  of  an  external  stimulus  is  magnetic  field,
which has been investigated to create hyperthermia in order to trigger temperature-
responsive drug release from tumour-targeted magnetic nanoparticles (Ganta et al. 2008).
Poly(N-isopropylacrylamide) (PNIPAAm) is a well known temperature-responsive
polymer,  since  it  exhibits  a  sharp change from hydrophilicity  to  hydrophobicity  at  +32°C,
and this change can be used to trigger the drug release (Schmaljohann 2006).
Figure 2.6. pH- and temperature-responsive release presented as an examples of stimuli-
responsive drug release.
2.3. POROUS SILICON AND SURFACE-ERODING POLYMERS FOR
CONTROLLED DRUG DELIVERY
2.3.1 Porous silicon
Porous silicon (PSi) was described for the first time over 50 years ago (Uhlir Jr 1956) but the
current interest in this material originates from the 1990’s when its photoluminescence and
biodegradability were reported by Canham et al. (Canham 1990, 1995). PSi is fabricated by
electrochemical anodization of Si in hydrofluoric acid based solutions and its properties
such as porosity, pore size and pore shape can be modified by the fabrication settings (e.g.
current density) (Anglin et al. 2008; Salonen and Lehto 2008; Salonen et al. 2008a). The as-
anodized surface of PSi is hydrogen-terminated and its stability is poor. Therefore, different
chemical modifications such as oxidation, hydrosilylation and thermal carbonization have
been developed in order to stabilize the surface and to modify the surface properties such
as hydrophobicity or surface charge.
Recently, the possibilities of PSi for controlled parenteral delivery have attracted much
interest as summarized in Table 2.3. Furthermore, considerable research has focused on oral
delivery  and  its  use  as  a  way  to  improve  the  dissolution  of  poorly  soluble  drugs  by
undertaking amorphization of drug molecules inside the pores due to confinement
(Salonen et al. 2005) but this particular research area will not be discussed in this review. In
addition, PSi has been examined for use in ophthalmic applications (Low et al. 2009;
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Andrew et al. 2010), photothermal therapy (Hong et al. 2011) and as a porous coating of
implantable drug delivery devices (Gultepe et al. 2010).
The most common method to load drug into PSi particles is simple immersion of PSi into
the drug solution (Salonen et  al.  2008a).  Despite  its  simplicity,  several  factors  such as  pH,
drug  concentration  and  particularly  the  chemical  reactivity  between  the  drug  and  PSi
surface can influence the drug loading (Salonen et al. 2008a; Pastor et al. 2011). The
advantage of the immersion loading method is the possibility to avoid harsh chemical
conditions and to perform the procedure at room temperature, which is beneficial for many
sensitive drugs, e.g. peptides and proteins (Salonen et al. 2008a). Other drug loading
methods include impregnation in which a controlled volume of drug solution is transferred
into the pores by capillary action (Foraker et al. 2003), or covalent attachment of drugs to
the pore wall via Si-C bonds (Fig. 2.7) (Wu et al. 2008, 2010). The molecular interactions
between drugs and the surface of PSi are not well understood, although it is postulated that
they  are  dependent  on  chemical  structure  of  drug  and  PSi  surface  chemistry.  Jarvis  et  al.
(2011)  examined  adsorption  of  dyes  onto  the  surface  of  oxidized  PSi  and  found  that
methylene blue was adsorbed via electrostatic interactions while the adsorption mechanism
of ethyl violet and orange G was chemisorption (Fig. 2.7). Furthermore, electrostatic
interaction has been proprosed to be the adsorption mechanism of positively charged
doxorubicin onto the oxidized PSi surface (Fig. 2.7) (Park et al. 2009). Protein adsorption
onto unoxidized PSi surface was claimed to be due to hydrophobic interactions resulting in
structural changes and the loss of bioactivity (Jarvis et al. 2010). The adsorption mechanism
onto thermally oxidized PSi was electrostatic interaction for positively charged proteins,
with the proteins retaining their biological activity, but there was structural rearrangement
for negatively charged proteins, which could have caused irreversible loss of native protein
structure (Jarvis et al. 2010).
Figure 2.7. Summary of different techniques studied in order to load drug into and to control
drug release from PSi-based drug delivery systems.
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Multi-stage  delivery  systems  which  are  composed  of  PSi  particles  (size  1.6-3  μm)  with
pore sizes of ~30 nm, have been recently developed by Ferrari et al. (Table 2.3) (Godin et al.
2011; Serda et al. 2011). The particles are loaded with different nanovectors such as drug- or
siRNA loaded liposomes (Tanaka et al. 2010b; Mann et al. 2011), iron oxide nanoparticles
(Serda et al. 2010) or quantum dots (Tasciotti et al. 2008) for drug delivery and imaging
purposes (Fig. 2.7). The geometry of the PSi particles is devised to be hemispherical in order
that they will have optimal behavior in the systemic circulation but to minimize their
accumulation in the liver (Decuzzi et al. 2010). In vivo studies have demonstrated the
efficacy of the multi-stage delivery system by significantly enhancing the drug delivery to
the bone marrow (Mann et al. 2011) and by inducing antitumoral effect by siRNA in
ovarian cancer disease model (Tanaka et al. 2010b).
PSi  delivery  systems  with  drug  release  controlled  by  PSi  degradation  instead  of  drug
diffusion out of pores have been recently developed (Table 2.3, Fig. 2.7). These systems are
based on the covalent linking of drugs (doxorubicin and daunorubicin) by Si-C bonds (Wu
et al. 2008, 2010) or on the utilization of the reducing capacity of PSi to cap pores by Pt
reduced from cisplatin (Park et al. 2011). Some recent studies have revealed the possibility
to control the drug release by means of external stimuli, such as temperature (Vasani et al.
2011), pH (Xue et al. 2011) or magnetic fields (Gu et al. 2010) but these studies are still quite
preliminary regarding the drug delivery applications (Table 2.3, Fig. 2.7).
Table 2.3. Examples of controlled and targeted drug delivery systems based on PSi.
Delivery system Result Reference
Multistage delivery systems
E-selectin-targeted quasi-hemispherical PSi
particles (1.6 μm) loaded with paclitaxel
liposomes (25-35 nm) into pores (30 nm) in
order to treat bone marrow diseases
In vivo studies showed that 20% of injected
dose was delivered to bone marrow with
targeting, and 200-fold increase in liposomal
delivery to bone marrow compared to plain
liposomes
(Mann et
al. 2011)
Hemispherical PSi particles (1.6 μm) with
26 nm pores loaded with liposomes
containing siRNA against EphA2 gene.
Antitumor effects lasted for 3 weeks after
single i.v. administration in ovarian cancer
mouse model, and was comparable to twice
a week liposomal siRNA delivery
(Tanaka et
al. 2010b)
Degradation-controlled release
Drug is covalently attached to undecylenic
acid treated PSi pore surface via Si-C-
bonds. Drug release is based on PSi
degradation, and hydrolysis of Si-C-bonds
Sustained in vitro release of doxorubicin and
daunorubicin for 5 and 30 days, respectively,
and drug release correlated with PSi
degradation
(Wu et al.
2008,
2010)
Dodecene and undecylenic acid modified PSi
loaded with Pt-containing cisplatin. PSi
reduces cisplatin to deposit Pt on the pore
orifice and trap unreduced cisplatin
PSi degradation allows cisplatin to bypass
capping and to be released in vitro in
sustained manner, PSi delivery enhanced
cytotoxicity compared to free drug
(Park et al.
2011)
External stimulus sensitive system
PSi nanorods (200-400 nm x 100-200 nm)
with pH-sensitive cyclodextrin-based
nanovalves on the pore orifices. Nanovalves
closed at pH 7.4, and opened at pH <6
pH-controlled in vitro release of model drug,
and cell culture studies indicated endocytosis
of nanorods and drug release in acidic
lysosomes
(Xue et al.
2011)
PSi films grafted with a thermoresponsive
poly(N-isopropylacrylamide)
Temperature controlled in vitro drug release,
above +35C release rate of camptothecin
was 2-fold higher than below +35C
(Vasani et
al. 2011)
Microparticles loaded with doxorubicin and
superparamagnetic iron oxide nanoparticles
for localized drug delivery with magnetic
guidance and fluorescent tracking
In vitro drug release for 9 days, magnetic
guidance required for in vitro cytotoxic effect
of doxorubicin, without magnetic guidance
too low drug concentration for cytotoxic
effect
(Gu et al.
2010)
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PSi has been shown to be biocompatible and biodegradable (Canham 1995; Salonen et al.
2008a) (Table 2.4). In the body, it is degraded into monomeric silicic acid (Si(OH)4) which is
a bioavailable form of silicon and rapidly excreted via kidneys (Popplewell et al. 1998;
Salonen and Lehto 2008). Oxidized PSi nanoparticles were cleared from the body mostly
within 1 week and completely cleared in 4 weeks (Park et al. 2009). In vitro cytotoxicity
studies, for example with Caco-2 and RAW 264.7 macrophage cells, have shown that
different properties i.e. the particle size, surface chemistry and dose of PSi micro- and
nanoparticles can influence their effect on cell viability (Santos et al. 2010; Bimbo et al.
2011). The in vivo studies performed so far have not shown significant signs of toxicity
(Table 2.4), and thus, it can be concluded that PSi appears to be safe material for drug
delivery applications.
Table 2.4. Examples of in vivo toxicity and biocompatibility studies of PSi.
PSi type Experimental setup Result Reference
Oxidized spherical
nanoparticles (126 nm)
Single i.v. dose (20 mg/kg) to mice,
particle degradation and
histopathological analysis of liver,
spleen and kidney studied for 4
weeks
Particles cleared from
the body in 4 weeks, no
significant toxicity in
histopathological studies
(Park et al.
2009)
Negatively or positively
charged quasi-
hemispherical particles
(1.6 μm)
Single (~0.2, 2, 11 mg/kg) and
subchronic (2 mg/kg/week for 4
weeks) i.v. administration for mice,
hepatic and renal biomarkers, and
plasma cytokines measured
In overall, no obvious
changes in biomarker or
cytokine concentrations
in plasma
(Tanaka et
al. 2010a)
Hydrophobic
microparticles (38-53
μm)
Single s.c. dose (74 mg/kg) to mice
and plasma cytokines measured up
to 6 h
In overall, no obvious
changes in plasma
cytokine concentrations
(Kilpeläinen
et al. 2009)
Unmodified, dodecene-
and oxidized particles
(15-30 μm)
Intravitreal dosing (12 mg/eye) to
rabbits, histological and other
evaluation of ocular biocompatibility
Results showed good
biocompatibility for
ocular delivery
(Cheng et
al. 2008)
Oxidized, aminosilanised
membranes, thickness
145 μm
Membrane implanted under the rat
conjunctiva, membrane dissolution
and tissue histology analyzed
Thin fibrous capsule
formed around
membrane which was
dissolved in 9 weeks and
little host reaction
(Low et al.
2009)
2.3.2 Surface-eroding polymers
Polymer erosion is defined as the loss of material due to monomers and oligomers leaving
the polymer, and it can be divided into surface and bulk erosion (Tamada and Langer 1993;
Göpferich 1996). In ideal surface erosion, material is lost solely from the external surface of
the polymer and the erosion rate is proportional to the surface area of the matrix. The drug
release rate from an ideal surface-eroding polymer is identical to the polymer erosion rate
since polymer erosion is the sole factor controlling the drug release, and no drug diffusion
out of the polymer should occur. In contrast, in bulk erosion, material is lost throughout the
entire volume of the polymer and drug release is more difficult to control. Whether the
polymer undergoes surface or bulk erosion, is defined by the diffusivity of water inside the
matrix (D), the degradation rate of polymer bonds (	), and the device geometry (L)
(Burkersroda et al. 2002). Increases in the 	/D ratio and in L, can convert the erosion
mechanism from bulk to surface erosion.
Surface-eroding polymers offer several advantages for peptide delivery including: 1) the
possibility to control the peptide release solely by the polymer erosion rate, 2) acidic
polymer degradation products do not accumulate in the polymer matrix, as in the case of
bulk-eroding polymers, and thus the degradation products do not affect the activity of the
unreleased peptide, 3) protection of unreleased peptide from the surrounding medium and
22
subsequently from enzymatic and hydrolytic degradation before its release, and 4) once
peptide  release  is  completed,  no  remnants  of  polymer  should  exist  (Heller  et  al.  2002b;
Wang et al. 2002). The chemical structures of polymers reported to undergo surface erosion
is presented in Figure 2.8.
Figure 2.8. Chemical structures of most common surface-eroding polymers in drug delivery
applications.
2.3.2.1 Polyanhydrides
Polyanhydrides are among the most widely investigated surface-eroding polymers and one
of them, the copolymer of 1,3-bis(p-carboxyphenoxy)propane and sebacic acid (p(CPP-SA))
has been approved by FDA for clinical use (Katti et al. 2002; Buonerba et al. 2011).
Polyanhydrides  were  proposed  for  use  in  controlled  drug  delivery  initially  in  1983  when
cholic acid release was shown to be surface erosion-controlled from poly[bis(p-
carboxyphenoxy)methane] (Rosen et al. 1983). Today, polyanhydride wafers incorporated
with carmustine are used in the local treatment of brain tumors under the tradename of
Gliadel (Buonerba et al. 2011). In addition, polyanhydrides have been investigated as local
drug  delivery  carriers  for  treatment  of  osteomyelitis  in  humans  (Chiu  Li  et  al.  2002),  and
restenosis (Orloff et al. 1995), local anesthesia (Masters et al. 1993) and glaucoma (Jampel et
al. 1990) in animal models. Polyanhydrides contain both anhydride bonds that are highly
susceptible to hydrolytic degradation and hydrophobic elements to limit water penetration,
and thus surface erosion is possible (Kumar et al. 2002; Jain et al. 2005). Modifications in the
type of monomers and their ratios alter the polymer hydrophobicity, and consequently the
erosion time of polyanhydrides can be varied from days to years (Leong et al. 1985; Uhrich
et al. 1996; Katti et al. 2002). Enzymatic degradation has no or only minimal importance for
the erosion of polyanhydrides (Domb and Nudelman 1995; Göpferich and Tessmar 2002).
Polyanhydrides can be sub-divided according to their chemical structure into different
classes, such as aliphatic polyanhydrides, aromatic polyanhydrides and their copolymers
(Fig. 2.8) (Göpferich and Tessmar 2002). Aliphatic polyanhydrides (e.g. poly(sebacic acid),
p(SA))  are  formed  from  diacids  linked  by  anhydride  bonds  and  they  are  generally  fast
eroding while, in contrast, aromatic polyanhydrides are slowly eroding, limiting their use
in biomedical applications. Copolymers of aromatic and aliphatic polyanhydrides have
been developed to optimize the erosion rate of the polyanhydrides. One of the most widely
investigated and best characterized copolymer consists of 1,3-bis(p-carboxyphenoxy)
propane and sebacic acid (p(CPP-SA) which is used also in the commercial Gliadel wafers
(Göpferich and Tessmar 2002; Wang et al. 2002). In order to improve the mechanical
properties and to increase the hydrophobicity even more, copolymers with fatty acids (e.g.
copolymer of SA and erucic acid, p(FAD-SA)) have been developed with similar erosion
behavior  to  that  obtained  with  p(CPP-SA)  (Domb  and  Maniar  1993).  Finally,  crosslinked
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polyanhydrides have been developed to further increase the mechanical stability of
polyanhydrides, for example, in order to make them suitable for orthopedic applications
(Muggli et al. 1999).
Different factors affect polymer erosion of polyanhydrides despite their surface-eroding
property as summarized in Table 2.5. In general, it can be stated that by modifying polymer
hydrophobicity by the means of polymer chemistry, the erosion rate can be tailored
(Göpferich and Tessmar 2002). For example, aliphatic polyanhydrides composed of
monomers with long carbon chain (7-10 carbons) are poorly water-soluble (<0.01 – 2.4
mg/ml) and therefore they erode more slowly (20% w/w in 48 h) than more water-soluble
(1.6 – 50 mg/ml) monomers with short carbon chains (4-6 carbons, 70% w/w in 48 h) (Domb
and Nudelman 1995). In the aromatic polyanhydrides, if one changes the alkane of
poly[bis(p-carboxyphenoxy)alkane] from methyl to hexyl the erosion rate can be modified
by three orders of magnitude (Leong et al. 1985). In copolymers of aliphatic and aromatic
polyanhydrides, such as p(CPP-SA), the increase of the aromatic:aliphatic ratio decreases
the erosion rate of the polymer due to increased hydrophobicity (Leong et al. 1985;
Göpferich and Langer 1993).
The molecular weight of the polymer does not affect the erosion behavior of
polyanhydrides apart from the induction period of erosion, since the molecular weight is
decreased below 10 kDa rapidly after the exposure to water (Domb and Nudelman 1995;
Dang et al. 1996). Instead, polymer crystallinity and amorphicity affect the erosion rate of
polyanhydrides, since amorphous regions of the p(SA) will erode more quickly than
crystalline regions (Göpferich and Langer 1993; Shakesheff et al. 1994). In addition, the
porosity of the polymer matrix can influence on the erosion rate of polyanhydrides i.e.
dense  microspheres  of  p(CPP-SA)  were  eroded  more  slowly  than  more  porous
microspheres (Mathiowitz et al. 1990). The increase of pH of surrounding medium
increases the erosion rate since the hydrolysis of anhydride bonds is base-catalyzed and
acidic degradation products more easily diffuse out of the matrix due to their higher
solubility in the ionized form (Leong et al. 1985; Jain et al. 2005). It must be noted that a
high concentration of degradation products in the surrounding medium retards erosion of
polyanhydrides (Wu et al. 1994). The effect of drug loading on the erosion depends on the
physicochemical properties of the incorporated drug. Hydrophilic drugs can accelerate the
erosion  as  they  will  diffuse  out  of  matrix  which  increases  the  surface  area  susceptible  for
degradation (Mathiowitz and Langer 1987; Park et al. 1996; Sandor et al. 2002), while
hydrophobic drugs can retard the polymer erosion by limiting water penetration (Park et
al. 1996).
In  order  to  exhibit  ideal  surface  erosion,  the  polymer  matrix  should  retain  its  constant
surface area since this affects water uptake. Nano- and microparticles will erode much
faster than macroscopic devices from the same polymers since water can more easily
penetrate throughout the entire particle (Mathiowitz and Langer 1987; Mathiowitz et al.
1992; Tabata and Langer 1993; Lee and Chu 2008). With respect to polyanhydride
nanoparticles, the surface erosion can hardly be observed since it has been postulated that
polyanhydride devices need to be larger than 100 μm in order to be surface-eroding
(Burkersroda et al. 2002). In the case of macroscopic devices, the erosion is fastest for
smaller devices (Tamada and Langer 1993; Akbari et al. 1998). Furthermore, the mass of
p(CPP-SA) can decrease markedly due to release of SA monomers during the first week of
erosion  but  the  dimensions  will  decline  more  slowly  since  a  porous  skeleton  of  CPP  is
formed after the release of SA (Göpferich and Langer 1993).
Surface erosion of polyanhydrides occurs similarly both in vitro and in vivo (Katti et al.
2002). For example, after intracranial application of p(CPP-SA) (20:80) wafers to rats, the
polymer erosion was slower in the initial stage but the overall erosion profile was similar to
that measured in vitro (Wu et al. 1994). The in vivo erosion occurred in a layerwise manner
so that the porosity of the wafer increased as the erosion front proceeded towards interior
of the wafer (Dang et al. 1996), as had been detected earlier in vitro (Göpferich and Langer
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1993). The in vivo elimination of CPP and SA monomers has been studied in rats (Domb et
al. 1994). After 7 days, 40 % of SA was exhaled as CO2 being produced via beta oxidation
pathway of fatty acids. Only 4% of CPP was eliminated via urine and faeces in 7 days
(Domb et al. 1994). This difference can be explained by the 100-fold higher water solubility
of SA than that of CPP.
Table 2.5. Effects of various factors on in vitro erosion of polyanhydrides.
Property Effect Reference
Polymer chemical
structure
Increased hydrophobicity due to increased
number aromatic structures or longer alkenyl
chains
(Leong et al. 1985; Tamada
and Langer 1993; Göpferich
and Tessmar 2002)
Molecular weight of
polymer
Affects only the induction period of erosion, not
the overall erosion kinetics
(Domb and Nudelman 1995;
Dang et al. 1996)
Concentration and
solubility of
degradation products
Increased water solubility due to either shorter
alkenyl chain or higher pH of surrounding
medium enhances the erosion. High
concentration of degradation products in
surrounding medium decreases erosion rate
(Leong et al. 1985; Wu et al.
1994; Domb and Nudelman
1995; Jain et al. 2005)
Ratio of polymer
crystallinity and
amorphicity
Amorphous regions erode faster than
crystalline regions
(Göpferich and Langer 1993;
Shakesheff et al. 1994)
pH of the surrounding
medium
Increased pH increases the erosion rate due to
base-catalyzed hydrolysis of anhydride bonds
and diffusion of degradation products out of the
matrix
(Leong et al. 1985; Jain et al.
2005)
Porosity Higher porosity increases the erosion rate (Mathiowitz et al. 1990)
Incorporated drug Hydrophilic drugs and their high loading
degrees can increase the erosion rate as the
surface area is increased due to prematurely
released drug. Hydrophobic drugs decrease the
erosion by limiting water penetration.
(Mathiowitz and Langer 1987;
Park et al. 1996; Sandor et al.
2002)
Device size and
geometry
Erosion is accelerated with a decrease in device
size
(Mathiowitz and Langer 1987;
Mathiowitz et al. 1992; Tabata
et al. 1993; Tamada and
Langer 1993; Akbari et al.
1998; Lee and Chu 2008)
The different factors affecting in vitro drug release from polyanhydrides are
summarized in Table 2.6, but only few publications investigating the mechanisms of in vivo
drug release have been published. In general, polyanhydrides are considered to release
drug by a surface erosion-controlled mechanism (Rosen et al. 1983; Leong et al. 1985;
Mathiowitz and Langer 1987). However, physicochemical properties of the drug, such as
aqueous solubility and miscibility with polymer have been demonstrated to affect the drug
release. When the drug loading degree is increased and the drug has a sufficiently high
aqueous solubility, polyanhydrides can no longer control the drug release. Consequently,
the  drug  release  mechanism  from  polyanhydrides  is  changed  from  surface  erosion-
controlled to diffusion-controlled since diffusion channels are formed inside the matrix
(Mathiowitz and Langer 1987; Shieh et al. 1994; Park et al. 1996, 1997, 1998; Göpferich 1997;
Kipper et al. 2002; Berkland et al. 2004). Hydrophobic drugs have higher affinity towards
polymer matrix, and thus their release is typically surface erosion-controlled. Therefore,
hydrophilic model compounds should be used when the drug release mechanism of
surface-eroding polymers are being examined (Göpferich and Tessmar 2002). The aqueous
solubility of the drug also affects the duration of the release. For example, cefazolin sodium
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(aqueous solubility 350 mg/ml, Mw 454 g/mol) was released in 14 days from p(FAD-SA)
(50:50) while only 15% of paclitaxel (0.042 mg/ml, Mw 854 g/mol) was released in 77 days
(Park et al. 1998). Furthermore, the drug-polymer miscibility influences the release kinetics,
i.e. poor miscibility of drug in the polymer can precipitate drug in the matrix and thus lead
to burst release (Shen et al. 2002). However, drug precipitation also influences polymer
degradation, and thus the release may be still surface erosion-controlled. Furthermore, the
drug release rate will be decreased if there is an increase in polymer hydrophobicity
(Kipper et al. 2002). In the cases of protein and peptide of delivery, an increase in polymer
hydrophobicity has reduced the moisture and water content of the polymer matrix, and
therefore the aggregation tendency of peptides and proteins has been reduced and their
stability increased (Ron et al. 1993).
In general, in vitro and in vivo toxicity studies of polyanhydrides have indicated that the
material is well-tolerated (Katti et al. 2002; Jain et al. 2005). P(CPP), p(CPP-SA) and p(FAD-
SA) have been shown to be non-toxic materials after corneal, subcutaneous, intramuscular
and intracranial implantation (Leong et al. 1986; Brem et al. 1989, 1992; Tamargo et al. 1989;
Laurencin et al. 1990; Domb 1992). No signs of increased inflammation, histopathological
findings or other clinical signs of abnormalities have been detected around the implants as
compared to the controls. In addition, even after administration of high doses of p(CPP-SA)
(rat, s.c.), no systemic effects were found (Laurencin et al. 1990).
Table 2.6. Effects of various factors on in vitro drug release from polyanhydrides.
Property Effect Reference
Hydrophilicity/
hydrophobicity of the
drug
Hydrophilic drugs are released faster than
hydrophobic drugs that prefer to remain in the
polymer matrix
(Mathiowitz and Langer 1987;
Shieh et al. 1994; Park et al.
1996, 1997, 1998; Göpferich
1997; Kipper et al. 2002;
Berkland et al. 2004)
Drug particle size As the size of dispersed drug particles
decreases, or drug is dissolved in polymer,
release is more surface erosion-controlled
(Mathiowitz and Langer 1987;
Shieh et al. 1994)
Drug loading degree With the high loading degree (>10-27 %) of
hydrophilic drug, no surface erosion-controlled
release occurs
(Mathiowitz and Langer 1987;
Shieh et al. 1994)
Miscibility of drug and
polymer and drug
distribution in matrix
A burst release is detected if the drug has poor
miscibility with the polymer or it is not evenly
distributed
(Kipper et al. 2002; Shen et al.
2002)
Hydrophobicity of
polymer
Increased polymer hydrophobicity decreases
drug release rate particularly in the case of
hydrophilic drugs
(Leong et al. 1985; Shieh et
al. 1994; Kipper et al. 2002;
Shen et al. 2002)
Device size The smaller or thinner the device, the faster is
the drug release if the release is surface
erosion-controlled
(Mathiowitz and Langer 1987;
Ron et al. 1993; Berkland et
al. 2004)
2.3.2.2 Poly(ortho ester)s
Poly(ortho ester)s (POE) have three geminal ether bonds in their structure (Fig. 2.8) and
they been developed since 1970’s (Ulery et al. 2011). They are classified in four distinct
families designated as POE I, II, III and IV (Heller et al. 2000, 2002b) from which POE IV is
the most advanced for providing surface erosion-controlled drug release. POE I, II and III
families are no longer in active development due to problems encountered in their
synthesis and hydrolysis.
The POE I and II families have been investigated for delivery of naltrexone,
contraceptives, anti-cancer drugs and insulin in solid or semisolid disks or rods (Einmahl et
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al. 2001b). The applicability of POE I family was restricted due to autocatalytic hydrolysis
and low glass transition temperatures (Heller et al. 2002b). Thermal and mechanical
properties of POE II could be adjusted to range from being hard and glassy to semisolids by
using diols but POE II was very hydrophobic under physiological conditions, and acidic
excipients were needed to accelerate its erosion. The advantage of injectable POE III is that
the  drug  can  be  incorporated  into  a  semi-solid  polymer  by  simple  mixing  at  room
temperature without the need for solvents (Einmahl et al. 2001b; Heller et al. 2002b). For
example,  POE  III  has  been  evaluated  for  ocular  delivery  in  which  it  was  shown  to  be
biocompatible (Zignani et al. 2000a, 2000b; Einmahl et al. 2001a). However, the drug release
mechanism from POE III is dependent on the polymer molecular weight, physicochemical
properties of the drug and excipients, and thus surface erosion-controlled release is rarely
achieved (Merkli et al. 1994, 1995; Einmahl et al. 1999).
POE IV family is an advanced version of the POE II family in that lactic or glycolic acid
segments are incorporated into the polymer backbone (Heller et al. 2000, 2002b). These
segments act as the latent acid catalyst, and thus they remove the need to add acidic
excipients  as  in  the  case  of  POE  II.  Furthermore,  the  rate  of  POE  IV  erosion  can  be
controlled by modifying the amount of acid segments or by the nature of the diol groups
used in the polymer synthesis (Ng et al. 1997; Schwach-Abdellaoui et al. 1999; Heller et al.
2000). POE IV is eroded mainly through surface erosion as demonstrated by the linear mass
loss and the simultaneous release of degradation products (Schwach-Abdellaoui et al.
1999). However, some water can penetrate into the POE IV matrix during the erosion
(Schwach-Abdellaoui et al. 1999; Capancioni et al. 2003). Due to the high hydrophobicity of
POE IV, its erosion shows a lag time which is inversely proportional to the amount of acidic
segments in the polymer backbone. However, the lag time can be eliminated by the
addition of PEG chains (Rothen-Weinhold et al. 2001; Heller et al. 2002a).
The drug release from macroscopic POE IV devices is controlled by the surface erosion
and the release rate is proportional to the erosion rate (Ng et al. 2000; Rothen-Weinhold et
al. 2001; Schwach-Abdellaoui et al. 2001; van de Weert et al. 2002). As an example, drug
release rate (in mg/h) from POE IV films has been shown to be directly proportional to the
drug loading degrees (Ng et al. 2000). Even with high drug loading degrees (15% w/w), no
burst release was detected from POE IV extruded strands (Rothen-Weinhold et al. 2001).
However, the drug release from POE IV microspheres was proposed to be a combination of
diffusion- and surface erosion-controlled mechanisms (Bai et al. 2001), and the
physicochemical properties of drug may affect its release rate from POE IV. The basic and
poorly water soluble drug, tetracycline, stabilized the POE IV matrix due to the inhibition
of acid-catalyzed degradation mechanism of POE IV (Schwach-Abdellaoui et al. 2001). As a
result, the tetracycline release rate decreased in parallel with an increase in drug loading
degree.  In  contrast,  incorporation  of  proteins  with  high  pI  values,  and  thus  with  high
number of amine residues, accelerated POE IV degradation due to amine catalyzed
degradation of ester bonds but this effect could be prevented by using buffering salts (van
de Weert et al. 2002). Biocompatibility studies after intraocular, colonic and subcutaneous
administration of POE IV have indicated good biocompatibility in experimental animals
(Ng et al. 2000; Einmahl et al. 2003; Heller and Barr 2004). Clinical trials with POE IV for the
treatment of periodontitis in humans revealed also good tolerance to the polymer.
(Schwach-Abdellaoui et al. 2002).
Most active research on POEs was conducted in the 1990’s and early 2000’s, and since
then the research enthusiasm has declined. More recently, acid-catalyzed degradation
feature of POE IV has been utilized in designing microspheres that release their DNA
content in response to a low phagosomal pH (Wang et al. 2004; Nguyen et al. 2008). In
addition, poly(ortho ester amide) hydrogels have been synthesized for temperature- and
pH-sensitive surface erosion-controlled drug release (Tang et al. 2009).
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2.3.2.3 Polycarbonates
Polycarbonates  have two geminal  ether  bonds and one carbonyl  bond (Fig.  2.8).  They can
be classified according to the chemical group, typically trimethyl, ethylene, propylene or
tetramethylene, that is attached to one of the ether bond oxygens (Ulery et al. 2011). The
most widely investigated polycarbonate with surface erosion property is poly(trimethyl
carbonate) (PTMC). A common feature of polycarbonates is their susceptibility for
enzymatic degradation which was found already almost 30 years ago (Kawaguchi et al.
1983) but most work on their applications in drug delivery has been conducted only in
recent years.
PTMC is eroded by enzymes and superoxide anion radicals, and also macrophages can
be involved in mediating the erosion (Zhu et al. 1991; Pêgo et al. 2003; Zhang et al. 2006c;
Bat et al. 2009). In vivo erosion of PTMC films has been reported to last from 3 weeks (rat,
s.c.) (Pêgo et al. 2003) up to approximately 12 weeks (rabbit, bone) (Zhang et al. 2006b),
whereas erosion of PTMC elastomers required over one year (rat, s.c.) (Chapanian et al.
2009). Hydrolytic degradation of PTMC is very minimal, and therefore in vitro erosion
studies  performed without  enzymes or  oxides  do not  correlate  with in vivo studies which
have revealed surface erosion. The role of enzymes and macrophages in vivo was confirmed
by the fact that little erosion occurred in enzyme-free and avascular vitreous (Jansen et al.
2011). Furthermore, Bat et al. demonstrated the surface erosion of PTMC in cell culture
medium in the presence of direct contact with macrophages whereas no erosion was
detected in the absence of direct contact (Bat et al. 2009). Based on in vitro experiments,
cholesterol esterase and superoxide anion radicals secreted from the macrophages have
been claimed to contribute to the macrophage-mediated polymer erosion since these agents
eroded the PTMC surface similar to that encountered in vivo (Bat et al. 2009; Chapanian et
al. 2009). Oxidation has been claimed to play a dominant role in the erosion in the case of
low molecular weight (7300 g/mol) PTMC elastomers (Chapanian et al. 2009) whereas the
erosion rates of high molecular weight (291 000 g/mol) elastomers were similar in enzyme
and oxide solutions (Bat et al. 2011).
Surface properties, preparation methods and copolymers affect the degradation and
erosion of PTMC-based systems. Increased surface hydrophilicity due to lower molecular
weight of PTMC reduces the access of enzymes to the polymer surface (Zhang et al. 2006c)
since, for example, the structure of lipase enzyme is hyperactive at hydrophobic surfaces
(Bastida et al. 1998). In addition, the dense, crosslinked PTMC network limits the access of
enzymes to the carbonate bonds but crosslinking has a less significant effect on the role of
superoxide anions (Bat et al. 2011). Macrophage adhesion, and consequently macrophage-
mediated erosion of PTMC are also affected by surface properties (Bat et al. 2011).
Therefore, the erosion rate of PTMC can be tailored by modifying its surface properties, e.g.
by changing the molecular weight of the PTMC (Zhang et al. 2006b), incorporating
copolymer (e.g. PCL) in different ratios (Bat et al. 2008, 2010a, 2010b; Chapanian et al. 2009)
or modifying the crosslinking density by altering the crosslinking method (Bat et al. 2008,
2011).
Similarly to PTMC, poly(ethylene carbonate) (PEC) poly(propylene carbonate) (PPC) are
eroded non-hydrolytically by surface erosion. The surface erosion of PEC occurs in the
presence of superoxide radical anions secreted by inflammatory cells adhering to its
surface, and in vivo erosion (s.c. rats or rabbits) takes 3-4 weeks (Stoll et al. 2001; Dadsetan
et al. 2003). However, in contrast to PTMC, PEC has not been reported to be degraded
enzymatically (Stoll et al. 2001). Furthermore, the polymer molecular weight influences the
in vivo erosion  of  PEC  similarly  to  the  situation  with  PTMC.  This  leads  to  suppressed
erosion of PECs with molecular weights less than 100 000 g/mol, which is probably due to
the increased surface hydrophilicity inhibiting intimate cell adhesion (Acemoglu et al. 1997;
Stoll et al. 2001). PPC has been eroded by a surface erosion mechanism in vivo (mouse s.c.),
and in vitro experiments suggest that enzymatic degradation is the main mechanism even
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though the role of superoxide anions cannot be excluded (Hwang et al. 2006; Kim et al.
2008).
With the respect to the drug delivery applications, polycarbonates have not yet been
widely investigated. In vitro releases of gentamycin sulfate (Mw 576 g/mol) and vancomycin
hydrochloride (Mw 1486 g/mol) from PTMC films in lipase solutions were surface erosion-
controlled for the first 3 days (50-60% of the drug released) and thereafter diffusion-
controlled (Kluin et al. 2009; Neut et al. 2009). The molecular weight of PTMC was also an
influencing factor i.e. more drug was released from high molecular weight PTMC than from
low  molecular  weight  PTMC,  which  is  in  agreement  with  the  faster  erosion  of  the  high-
molecular  weight  PTMC.  If  the  drug  release  from  PTMC  is  studied in vitro without
enzymes, the drug release is typically diffusion-controlled (Dinarvand et al. 2005; Zhang et
al. 2006b; Kluin et al. 2009; Neut et al. 2009). Neverthless, in vitro release of vitamin B12 was
shown to be degradation-controlled from certain photocrosslinked PTMC formulations
resulting in zero-order drug release profile (Jansen et al. 2010). In vivo drug release from
PTMC has not been investigated so far. In vitro drug  release  from  PEC  coatings  of  drug
eluting stents was fast (total release in < 12 h) in the presence of superoxide anions but
minimal (< 20% in 20 days) in the absence of superoxide radicals. In vivo, the release of
ocreotide  and  human  interleukin-3  from  PEC  was  controlled  by  surface  erosion  after  s.c.
administration in rats (Stoll et al. 2001). Furthermore, PEC has been investigated as an
injectable in situ forming parenteral delivery system (Liu et al. 2010) and it has also shown
promising features as a long-circulating nanocarrier (Bege et al. 2011).
In general, the biocompatibility of PTMC, PEC and PPC materials has been
demonstrated to be good. PTMC materials have induced from mild to moderate tissue
reaction after s.c. implantation into the rat (Pêgo et al. 2003; Bat et al. 2010b) and in rabbit
eye (Jansen et al. 2011). In other experiments, no cytotoxicity has been detected (Bat et al.
2008; Jansen et al. 2010). Similarly, PEC and PPC polymers and their degradation products
have shown good biocompatibility in different animal models (Stoll et al. 2001; Dadsetan et
al. 2003; Kim et al. 2008)
2.3.2.4 Aliphatic polyesters
Non-modified biodegradable aliphatic polyesters, such as PLA, PLGA and poly(-
caprolactone) (PCL), display the properties of bulk erosion based on hydrolytic degradation
(Nair and Laurencin 2007). However, chemically modified polyesters, particularly PCL and
PCL-based copolymers, may undergo surface erosion due to enzymatic degradation instead
of bulk erosion based on hydrolytic degradation (Woodruff and Hutmacher 2010).
Enzymes are large molecules (25-50 kDa) and thus they cannot penetrate into the bulk of
the polymer, and chain cleavage due to enzymatic degradation is limited to that occurring
on the polymer surface causing surface erosion (Landry et al. 1996).
Different chemical modifications and copolymers have been synthesized to prepare
surface-erodible PCL. For example, Li et al. have published a series of reports investigating
PCL and PLA or -butyrolactone copolymers showing in vitro surface erosion due to
pseudomonas and porcine pancreatine lipase-, and protenaise K –catalyzed degradation (Li
et al. 2004; Zhao et al. 2007; Lenglet et al. 2009; Liu et al. 2009). PCL is preferably degraded
by enzymes and also some degree (< 20% of copolymer) of PLA blocks could be degraded
by lipase (Zhao et al. 2007). Other PCL-based copolymers e.g. PCL-polycarbonates have
been reported to erode in vitro by  surface  erosion  in  buffer  containing  porcine  pancreatic
lipase (Peng et al. 2010) and PCL-PEG-PLA (Wang et al. 2006b). Furthermore, the PCL-PLA
copolymer has been proposed to be degraded enzymatically in the subconjunctival pocket
of rabbits, since PCL-PLA microfilms exhibited a liner decrease in thickness after ocular
administration (Peng et al. 2011). In addition to copolymers, other chemical modifications
can induce enzyme-sensitive degradation. For example, oxazoline-linked PCL undergoes
surface erosion in vitro by pseudomonas lipase-catalyzed degradation and in vivo after s.c.
implantation in rats (Tarvainen et al. 2003; Pulkkinen et al. 2007, 2009). Even  though
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enzymatic degradation is clearly the most common mechanism for surface erosion of PCL,
photocrosslinked, star-shaped PCL-PLA elastomers have been demonstrated to be surface-
erodible depending on the crosslinking density (Amsden et al. 2006). PCL-PLA networks
formed from smaller macromonomers were more tightly crosslinked and this caused
limited water absorption, and therefore surface erosion was detected in vitro and in vivo
(rat, s.c.). In contrast, elastomers with a more loose network underwent bulk erosion.
Amorphocity and hydrophobicity have been shown to be beneficial in promoting the
attack of enzymes on the polymers (Wang et al. 2006b; Liu et al. 2009; Peng et al. 2010).
Wang et al. (2006b) conducted a SEM- and DSC-analysis, and determined that a pit-like
surface of PCL-PEG-PLA was formed after pancreatin attacked the amorphous regions of
the surface. The effect of polymer hydrophobicity on erosion based on enzymatic
degradation was demonstrated with PCL-polycarbonate copolymers modified with PEG.
Hydrophilic PEG chains on the surface prevented the access of pancreatin lipase to the
polymer surface, and the erosion rate of the polymer was decreased (Peng et al. 2010).
PCL is the most common example of surface-eroding aliphatic polyesters but also other
aliphatic polyester have shown surface erosion. Cui et al. reported interesting results with
surface-eroding electrospun PLA fibers (Cui et al. 2006, 2008a, 2008b). Electrospinning
made the PLA fiber surface more hydrophobic, due to the effects of surface enrichment of
hydrophobic groups (e.g. methyl group) and the increased surface roughness (Cui et al.
2006, 2008b). Consequently, water penetration into the PLA fiber decreased and the surface
erosion was detected. However, this behavior was not translated into surface erosion-
controlled in vitro drug release since paracetamol release from PLA fibers showed high
burst release followed by a period of slow release not correlating with matrix erosion (Cui
et al. 2006, 2008b). Other PLA- or PLGA-based approaches for surface-eroding polymers
include  the  branched  polyester  with  short  PLGA  chains  and  high  amine  substitution
(Unger et al. 2008), and PLGA macromers linked with varying carbon chain lengths (Xu et
al. 2006).
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3 Aims of the Study
The general objective of this study was to develop and characterize two novel materials,
namely mesoporous silicon (PSi) and photocrosslinked poly(ester anhydride)s to be used in
controlled peptide delivery. The specific aims of the study were as follows:
1. To develop a method to investigate in vitro peptide release from both hydrophilic
and hydrophobic PSi microparticles by comparing different in vitro release methods.
2. To evaluate PSi for controlled peptide delivery and to analyze the effect of surface
chemistry of PSi microparticles on in vitro and in vivo peptide release. The gut
hormone peptide YY3-36, a promising candidate for the treatment of obesity, was
used as a model peptide.
3. To develop photocrosslinked poly(ester anhydride)s based on functionalized poly(-
caprolactone) oligomers for surface erosion-controlled peptide delivery. First,
propranolol HCl was used as a model compound to examine whether surface
erosion truly controls the drug release from poly(ester anhydride)s. Propranolol HCl
was  chosen  due  to  its  small  size  (Mw 296 g/mol) and high aqueous solubility (50
mg/ml) which could allow its rapid diffusion out of the polymer matrix. Further
analysis  of  the  effects  of  hydrophobicity  of  poly(ester  anhydride)  oligomers  and
drug loading degree on polymer erosion and drug release mechanisms were
performed non-destructively by using micro-computed tomography (micro-CT).
4. To investigate photocrosslinked poly(ester anhydride)s for controlled peptide
delivery, and to examine the effect of hydrophobicity of poly(ester anhydride)
oligomers for in vivo peptide release by using peptide YY3-36 as a model peptide. In
addition, preliminary safety of photocrosslinked poly(ester anhydride)s was
evaluated in vitro and in vivo.
5. To compare properties of PSi microparticles and photocrosslinked poly(ester
anhydride) implants for controlled peptide delivery.
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4 In Vitro Dissolution Methods for Hydrophilic and
Hydrophobic Porous Silicon Microparticles1
Abstract:
Porous silicon (PSi) is an innovative inorganic material that has been recently developed for
various drug delivery systems. For example, hydrophilic and hydrophobic PSi
microparticles have been utilized to improve the dissolution rate of poorly soluble drugs
and to sustain peptide delivery. Previously, the well-plate method has been demonstrated
to be a suitable in vitro dissolution method for hydrophilic PSi particles but it was not
applicable to poorly wetting hydrophobic thermally hydrocarbonized PSi (THCPSi)
particles.  In  this  work,  three  different in vitro dissolution techniques, namely centrifuge,
USP Apparatus 1 (basket) and well-plate methods were compared by using hydrophilic
thermally carbonized PSi (TCPSi) microparticles loaded with poorly soluble ibuprofen or
freely soluble antipyrine. All the methods showed a fast and complete or nearly complete
release of both model compounds from the TCPSi microparticles indicating that all
methods described in vitro dissolution equally. Based on these results, the centrifuge
method was chosen to study the release of a peptide (ghrelin antagonist) from the THCPSi
microparticles since it requires small sample amounts and achieves good particle
suspendability. Sustained peptide release from the THCPSi microparticles was observed,
which  is  in  agreement  with  an  earlier in vivo study. In conclusion, the centrifuge method
was demonstrated to be a suitable tool for the evaluation of drug release from hydrophobic
THCPSi particles, and the sustained peptide release from THCPSi microparticles was
detected.
1 Adapted with permission of MDPI Publishing from: Mönkäre J, Riikonen J, Rauma E, Salonen J, Lehto VP, Järvinen K.
In vitro dissolution methods for hydrophilic and hydrophobic porous silicon microparticles. Pharmaceutics 3: 315-325,
2011.
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4.1 INTRODUCTION
Porous silicon (PSi) is an inorganic mesoporous material that has been developed in recent
years for particulate drug delivery systems and it is fabricated from silicon wafers by
electrochemical etching of silicon in hydrofluoric acid (Anglin et al. 2008; Salonen et al.
2008a). The native PSi surface is chemically unstable and is therefore typically stabilized by
different  surface  treatments  which  not  only  increase  the  surface  stability  but  also  modify
the hydrophobicity or hydrophilicity of the surface (Salonen et al. 2008a). The drug is most
often loaded into the pores of the PSi particles by an immersion technique and the
advantages of the loading process are that it allows mild conditions which do not cause
drug degradation, and it can achieve high loading degrees that can be as high as 40-50%
w/w (Salonen et al. 2005; Heikkilä et al. 2007; Kaukonen et al. 2007; Riikonen et al. 2009). In
oral  drug  delivery  research,  PSi  microparticles  have  enhanced  the in vitro dissolution  of
poorly soluble compounds (Salonen et al. 2005; Heikkilä et al. 2007; Kaukonen et al. 2007) as
well as drug permeation through Caco-2 monolayers (Foraker et al. 2003; Kaukonen et al.
2007). Recently, it was shown that thermally hydrocarbonized PSi (THCPSi) microparticles
could sustain in vivo delivery  of  peptides  involved  in  the  regulation  of  food  intake
(Kilpeläinen et al. 2009, 2011).
Unlike the situation for tablets or capsules, there is no gold standard for assessing release
from particulate drug delivery systems, instead, many different in vitro drug release tests
have been developed and the field is still evolving. The commonly used methods for testing
of drug release from particulate drug delivery systems can be divided into three classes: 1)
sample and separate, 2) dialysis, and 3) continuous flow methods (Washington 1990;
D’Souza and Deluca 2006). Earlier, well-plates with cell culture inserts have been
commonly  used  to  study  drug  release  from  hydrophilic  thermally  oxidized  (TOPSi)  or
thermally carbonized (TCPSi) PSi microparticles (Salonen et al. 2005; Heikkilä et al. 2007;
Kaukonen et al. 2007). However, the well-plate method is not suitable for hydrophobic
THCPSi  microparticles  as  the  wettability  of  these  particles  is  poor  and therefore,  they are
not homogenously dispersed in the dissolution medium but float on the surface (Limnell et
al. 2007).
The objective of this work was to compare three in vitro dissolution methods, namely
centrifuge, USP Apparatus 1 (basket) and well-plate method, for testing of drug release
from hydrophilic porous silicon microparticles. Based on these results, an in vitro
dissolution method was developed for evaluating peptide (ghrelin antagonist, GhA) release
from hydrophobic porous silicon microparticles.
4.2 EXPERIMENTAL SECTION
4.2.1 Materials
Silicon wafers Si (100) of p+-type with resistivity values of 0.01–0.02 
cm (Cemat silicon,
Poland)  were  used in  the  preparation of  PSi.  Ibuprofen was acquired from Orion Pharma
(Espoo, Finland), antipyrine, was purchased from Sigma-Aldrich (St. Louis, Missouri, USA)
and ghrelin antagonist ([D-Lys-3]-GHRP-6, H-His-D-Trp-D-Lys-Trp-D-Phe-Lys-NH2) was
purchased from Peptides International Inc. (Louisville, Kentucky, USA). Deionized water
was processed by the Milli-Q system (Gradient AS-10, Millipore). Solvents used in HPLC
analysis were HPLC grade and reagents used in making the phosphate-buffered saline
(PBS, pH 7.4) were reagent grade. Ethanol (99.5%) used in electrolyte and loading solution
was purchased from Altia (Finland) and methanol and HF (37% - 39%) from Merck KGaA
(Germany).
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4.2.2 Preparation and characterization of TCPSi and THCPSi microparticles
The PSi was prepared by anodizing the wafers in an HF (38%)–ethanol mixture (HF:EtOH,
1:1) with a current density of 50 mA/cm2. The process was performed in the dark and free-
standing films were obtained by abruptly increasing the current. Free-standing porous
silicon films were ball-milled after anodization, followed by sieving to obtain a particle size
< 38μm. Thermal carbonization and thermal hydrocarbonization were used to stabilize the
PSi surface after the oxidized surface had been replaced by the hydrogen-terminated
surface. The surface modification followed the procedure described by Salonen et al. (2002,
2004) and Limnell et al. (2007). The surfaces of thermally carbonized PSi (TCPSi) and
thermally hydrocarbonized PSi (THCPSi) are hydrophilic and hydrophobic, respectively,
and they are chemically more stable than the untreated as-anodized surface (Salonen et al.
2002, 2004).
The drug loading was performed in ethanol or in water for ibuprofen and antipyrine,
respectively. The particles were soaked either in 300 mg/ml ibuprofen solution for one hour
or in 1.1 g/ml antipyrine solution for 1.5 h. Subsequently, loaded microparticles were
vacuum filtrated from the solution and finally, the loaded microparticles were dried in an
oven at 65 °C for 1 h. Two batches of TCPSi particles were loaded with ibuprofen. One
batch was used in the centrifuge and well-plate method and with the other being examined
in the USP Apparatus 1 (basket) method. The pore volumes of the batches (2.1 and 1.7
cm3/g) were different, leading to some discrepancies also in the loading degrees.
GhA was dissolved in methanol and mesoporous THCPSi microparticles were soaked in
the peptide solution for 1.5 h at room temperature. The loading solution was subjected to
ultrasound 3 times during loading to ensure homogenous loading. The particles were
filtered from the solution and dried for 4 h at room temperature.
The loading degree of samples (mdrug/(mparticles +  mdrug) and the amount of crystallized
substance on the external surface of the microparticles (mdrug on surface /(mparticles +  mdrug) were
characterized with thermogravimetry (TG; TGA 7, Perkin Elmer, 10 °C/min, N2 gas purge)
and differential scanning calorimetry (DSC; Pyris Diamond DSC, Perkin Elmer, 10 °C/min,
N2 gas purge) as described earlier (Lehto et al. 2005).
4.2.3 Drug release experiments
4.2.3.1 Centrifuge method
Ibuprofen, antipyrine and GhA loaded microparticles (1 mg) were weighed into the
microcentrifuge tubes and suspended in 1.5 ml of pH 7.4 PBS at +37 °C. In the case of GhA
release, 0.1% w/V bovine serum albumin (BSA) was added to the PBS in order to prevent
peptide adsorption to lab ware. Sink conditions were maintained: the maximum theoretical
concentrations of dissolved ibuprofen, antipyrine and GhA were 20%, < 0.1% and < 1% of
their saturation concentrations, respectively. The microcentrifuge tubes were placed in the
water bath shaker with orbital shaking at a frequency of 120 strokes/min at +37 °C (Grant
OLS200, Cambridge, UK). At pre-determined time intervals, the tubes were centrifuged for
2 minutes (13 000 rpm, 17 000 g, Heraues Biofuge Fresco, Osterode, Germany) and the
supernatant was collected for the analysis of the drug concentration. The microparticles
were re-suspended in the fresh buffer before the tubes were replaced in the shaker.
4.2.3.2 USP Apparatus 1 (basket)
Ibuprofen  release  from  the  TCPSi  microparticles  was  studied  by  the  USP  Apparatus  1
(basket) (Sotax AT6, Sotax AG, Basel, Switzerland) method. Ibuprofen-loaded TCPSi
microparticles (40 mg) were weighed into soft gelatin capsules (size 00). The volume of pH
7.4 PBS was 900 ml (+37 °C) and the rotation speed of the basket was 100 rpm. Sink
conditions were maintained for ibuprofen: the maximum theoretical concentration of
dissolved ibuprofen was < 1% of the saturation concentration. A sample of 5 ml was
withdrawn at pre-determined time intervals and this volume was replaced by fresh buffer.
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The samples were filtered through a 0.45 μm Minisart filter (Sartorius, Goettingen,
Germany) before the analysis of the drug concentration.
4.2.3.3 Well-plate method
The well-plate method was adapted from the earlier study of Salonen et al. 2005. Transwell
cell culture inserts were used as the donor chamber and 6-well culture plates (Corning
Corp., Corning NY, USA) as the acceptor chamber. Two different membrane materials,
polyester and polycarbonate membranes (Transwell, Corning Corp., Corning, NY, USA)
separating the chambers were studied in order to evaluate the effect of the membrane on
dissolution. Both membranes had an identical membrane area (4.7 cm2) and pore size (0.4
μm). However, the pore densities of the membranes were different, as the pore density of
the polycarbonate membrane (1x108 pores/cm2) was 25 times higher than that of the
polyester membrane (4x106 pores/cm2).  In  order  to  clarify  the  effects  of  the  studied
membranes on the ibuprofen and antipyrine release rates from the microparticles, the
transport of the drugs, applied either as a solution or powder to the donor chamber, across
the membranes was also determined.
Plain drug powder (1 mg) or drug-loaded TCPSi microparticles (2 mg) was weighed to
the donor chamber and 1.5 ml of pH 7.4 PBS was added to the donor chamber on top of the
samples, and 2.75 ml was pipette into the acceptor chamber. In the case of the drug
solution, 1.5 ml of 0.67 mg/ml drug solution in pH 7.4 PBS (i.e. 1 mg of drug) was added to
the donor chamber. Sink conditions were maintained for antipyrine: the maximum
theoretical concentration of dissolved antipyrine in donor chamber was < 0.1% of the
saturation concentration. Non-sink conditions were utilized for ibuprofen: the maximum
theoretical concentrations of dissolved ibuprofen in donor chamber were 37% and 48% of
the saturation concentration for microparticles and powder, respectively. Cell culture plates
were placed in a temperature-controlled (+37 °C) orbital shaker with constant shaking at
130 rpm (Titramax 1000 and Heidolph Inkubator 1000, Heidolph Instruments, Germany).
At pre-determined time intervals, donor chambers were moved onto the top of the next
acceptor chamber with fresh pH 7.4 PBS buffer, and the sample was collected from the
previous acceptor chamber.
4.2.4 Drug analysis
In the tests with the centrifuge and well plate methods, ibuprofen (	 = 220 nm) and
antipyrine (	 = 240 nm) concentrations in the samples were analyzed with a UV-
spectrophotometer (Thermo Spectronic Genesys 10, Madison WI, USA). In the tests with
the USP Apparatus 1 (basket), ibuprofen concentrations were analyzed in a Gilson High
Performance Liquid Chromatograph (HPLC). The system consisted of UV detector
(UV/VIS-151), pump (321), autoinjector (234), interface (506C) and integrator (Unipoint 3.0).
The mobile phase was a mixture of acetonitrile (70 %v/v), water (30 %v/v) and
trifluoroacetic acid (0.1 %v/v). The analytical column was a reverse-phase Supelcosil® C-8
column (150 × 4.6 mm id, particle size 5 μm, Supelco, Bellefonte, PA, USA). The injection
volume was 20 μl, flow rate 1 ml/min, and ibuprofen was detected at 214 nm. GhA was
analyzed with a similar HPLC system as used for ibuprofen but the interface unit was
Hercule Lite for Borwin 1.5 and the integrator was a Borwin 1.5. The mobile phase was a
mixture of acetonitrile (73 %v/v), water (27 %v/v) and trifluoroacetic acid (0.1 %v/v). The
analytical column was a reverse-phase Supelcosil® LC-18-DB column (150 × 4.6 mm id,
particle size 5 μm, Supelco, Bellefonte, PA, USA). The injection volume was 100 μl, flow
rate 1 ml/min, and ibuprofen was detected at 220 nm.
4.2.5 Statistical analysis
The non-parametric Kruskal-Wallis test (SPSS 14.0 for Windows) was used to test the
statistical significance of differences between methods. The post hoc test (Siegel and
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Castellan 1988) was employed to test the significance of the differences of the means. The
level of significance was taken as p < 0.05.
4.3 RESULTS AND DISCUSSION
4.3.1 Comparison of the in vitro dissolution methods
USP Apparatus 1 (basket), centrifuge and well plate methods were compared by using
hydrophilic TCPSi microparticles loaded with a poorly soluble ibuprofen and freely soluble
antipyrine (Table 4.1). In the present study, the solubility of ibuprofen at pH 7.4 PBS (+37
°C) was determined to be 1.68 mg/ml whereas antipyrine is freely soluble in water (>1000
mg/ml) (Salonen et al. 2005). High drug loading degrees were achieved for antipyrine
loaded microparticles (56% w/w) and two batches of ibuprofen loaded microparticles (47%
w/w  for  centrifuge  and  well-plate  methods,  31%  w/w  for  USP  Apparatus  1).  In  addition,
virtually no crystallized (<2% w/w) drug was observed on the external surfaces of the
studied  microparticles.  The  differences  in  the  loading  degrees  of  ibuprofen  are  due  to
different pore volumes of the particles, as a correlation between pore volumes and drug
loading degrees has been recently demonstrated (Riikonen et al. 2009).
Table 4.1. In vitro dissolution  methods  used  for  different  batches  of  PSi  microparticles  and
characterization  results  of  average  pore  diameter  before  drug  load  (D),  pore  volume  before
drug  load  (V),  drug  loading  degree  (%  w/w)  and  amount  of  adsorbed  drug  on  the  external
surface of the microparticles.
Sample Methods D (nm) V (cm3/g) Drug% w/w Surface% w/w
TCPSi + antipyrine Centrifuge, well-plate 21 2.1 56 2
TCPSi + ibuprofen Centrifuge, well-plate 21 2.1 47 0
TCPSi + ibuprofen USP Apparatus 1 23 1.7 31 0
THCPSi + GhA Centrifuge 8.9 0.93 7.8 N/A
All the methods showed a fast and complete or nearly complete release of both model
compounds from the TCPSi microparticles indicating that these methods were describing in
vitro drug release equally. Both ibuprofen (Fig. 4.1) and antipyrine (Fig. 4.2) were released
within 15 minutes in the centrifuge and USP Apparatus 1 (basket) methods under sink
conditions. In the well plate method, the contributions of the actual drug release from the
microparticles and the resistance of the membrane to the drug transport rate were
evaluated by applying the drugs either as a powder or a solution into the donor chamber.
Figures 4.3 (ibuprofen) and 4.4 (antipyrine) illustrate that the amounts of drug in the
acceptor chamber as a function of time display similar shapes irrespective of whether the
drug was applied as a solution, a powder or loaded into the TCPSi microparticles. These
results indicate that the diffusion of the drugs through the studied membranes was the
factor limiting the measured drug release from the microparticles (Figs. 4.1 and 4.2). The
barrier role of the membranes is further illustrated by the fact that the difference in the
porosity between polycarbonate (12.5%) and polyester (0.5%) membranes clearly affected
the rate  of  drug transport  (Figs.  4.3  and 4.4).  Thus,  the  drug release  was rapid also  in  the
well-plate method, and these conclusions were observed under both sink (antipyrine) and
non-sink (ibuprofen) conditions.
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Figure 4.1. Ibuprofen  release  (%)  from  TCPSi  microparticles  at  pH  7.4  PBS  (+37  °C)  with
centrifuge (),  USP  Apparatus  1  (basket)  ()  and  well-plate  methods  (polyester  () and
polycarbonate () membranes).  Mean ± SD values are shown (n = 3),  Statistical  differences:
*p < 0.05USP Apparatus 1 vs. well-plate (polyester membrane), # p < 0.05centrifuge vs. well-
plate (polyester membrane), ¤ p < 0.05well-plate (polycarbonate membrane) vs. well-plate
(polyester membrane).
Figure 4.2. Antipyrine release (%) from TCPSi microparticles at pH 7.4 PBS (+37°C) with
centrifuge () and well-plate methods (polyester () and polycarbonate () membranes). Mean
± SD values are shown (n = 3). Statistical differences: * p < 0.05 centrifuge vs. well-plate
(polyester membrane).
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Figure 4.3. Ibuprofen  release  from  TCPSi  microparticles  (),  or  the  transport  of  ibuprofen
applied either as a powder () or a solution () into the acceptor chamber across the polyester
(solid line) or polycarbonate (dashed line) membranes using the well-plate method. Mean ± SD
values are shown (n = 3).
Figure 4.4. Antipyrine  release  from  TCPSi  microparticles  (),  or  the  transport  of  antipyrine
applied either as a powder () or a solution () into the acceptor chamber across the polyester
(solid line) or polycarbonate (dashed line) membranes using the well-plate method. Mean ± SD
values are shown (n = 3).
4.3.2 Ghrelin antagonist release from THCPSi microparticles
The in vitro release method needs to be able to incorporate factors such as the
suspendability of hydrophobic THCPSi microparticles and the stability of the released
peptide. Based on the results described above (Figs. 4.1-4.4), the centrifuge method was the
technique of choice for evaluating GhA release from hydrophobic THCPSi microparticles.
The drug release from PSi microparticles is based on diffusion of drug from pores as PSi is
wetted (Kilpeläinen et al. 2011). Therefore, it is postulated that the method comparison
performed  with  hydrophilic  PSi  particles  is  also  valid  for  hydrophobic  PSi  as  long  as  the
method allows the sufficient wetting of particles. Both USP Apparatus 1 (basket) and
centrifuge methods allow an efficient dispersion and wetting of microparticles in the
release medium. However, the centrifuge method is more cost-effective as it requires
significantly less sample than the USP Apparatus 1 (basket) method. Further, in the
centrifuge method, the whole sample volume can be changed at the sampling times, which
is  beneficial  if  the  drug  is  rapidly  degrading  or  poorly  soluble  in  the  release  medium
(maintenance of sink conditions).
GhA loaded THCPSi microparticles (loading degree 7.8% w/w) displayed three phases:
1) burst phase, 2) diffusional release phase and 3) plateau phase (Fig. 4.5). The initial burst
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release of GhA (29%) occurred within the first 15 minutes. The burst release can be
explained by the peptide located on the external surface of the particles and near to the
pore orifices as well as release of the multilayers of peptides on the pores not in direct
contact with the hydrophobic surface (Ng et al. 2008; Riikonen et al. 2009). After the burst
release, the release was sustained for 2-3 h, and the release reached a plateau when 54% of
loaded GhA was released. Even the extraction of the microparticles with ACN/H2O mixture
at the end of the experiment, did not achieve any additional release (Fig. 4.5). This rather
stable plateau between 3 and 8 h suggests that the interactions between GhA and THCPSi
slowed down the GhA release and impaired its complete release. This kind of incomplete in
vitro drug release from particulate drug delivery systems has been reported also earlier
(Giteau et al. 2008). The incomplete release might be also explained by adsorption of BSA,
present in the in vitro release medium to prevent peptide adsorption onto lab ware. In our
studies, BSA was shown to adsorb onto the non-porous THCPSi surface (7.5% w/w) by
thermogravimetric analyses (Salonen et al. 2008b). Furthermore, earlier publications have
reported human serum albumin adsorption onto a PSi surface (Karlsson et al. 2003, 2005).
Therefore, it is postulated that the BSA adsorption could hinder the release of GhA from the
THCPSi pores, resulting in incomplete in vitro release.
Previously, in vivo delivery via THCPSi microparticles has prolonged the effect of the
GhA compared with its administration in solution (Kilpeläinen et al. 2009). Here, this
finding was confirmed in vitro by using the centrifuge method that allows good particle
suspendability and the use of small sample amounts. The sustained peptide release from
THCPSi microparticles if compared with the fast release of small-molecular drugs from
TCPSi microparticles can be attributed to differences in the physicochemical properties of
the loaded molecules and PSi materials. For example, the molecular weight of GhA (Mw 930
g/mol) is substantially higher than that of ibuprofen (Mw 206 g/mol) and antipyrine (Mw 188
g/mol), and THCPSi is more hydrophobic than TCPSi.
Figure 4.5. Ghrelin antagonist release from THCPSi microparticles as assessed by the centrifuge
method. Mean ± SD values are shown (n = 3).
4.4 CONCLUSIONS
Three different in vitro dissolution methods (centrifuge, USP Apparatus 1, well-plate) were
compared for testing drug release from hydrophilic TCPSi microparticles; all methods
produced comparable results. The centrifuge method was the method chosen to evaluate
release of a peptide, i.e. a ghrelin antagonist, from the hydrophobic THCPSi particles since
this method required only small sample amounts and achieved good particle
suspendability. Sustained peptide release from the THCPSi microparticles was observed in
vitro by the centrifuge method, which is in agreement with an earlier in vivo study.
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5 Mesoporous silicon (PSi) for sustained peptide delivery:
effect of PSi microparticle surface chemistry on Peptide
YY3-36 release2
Abstract:
Purpose: To achieve sustained peptide delivery via mesoporous silicon (PSi) microparticles
and to evaluate the effects of different surface chemistries on peptide YY3-36 (PYY3-36)
delivery.
Methods: PYY3-36 was loaded into thermally oxidized (TOPSi), thermally hydrocarbonized
(THCPSi) and undecylenic acid treated THCPSi (UnTHCPSi) microparticles with
comparable porous properties. In vitro, PYY3-36 release was investigated by centrifuge. In
vivo, PYY3-36 plasma concentrations were analyzed after delivery in microparticles or
solution.
Results: Achieved loading degrees were high (12.2 – 16.0% w/w). PYY3-36 release was
sustained from all microparticles; order of PYY3-36 release was TOPSi>THCPSi>UnTHCPSi
both in vitro and in vivo. In mice, PSi microparticles achieved sustained PYY3-36 release
over 4 days, whereas PYY3-36 solution was eliminated in 12 h. In vitro, only 27.7, 14.5 and
6.2% of loaded PYY3-36 was released from TOPSi, THCPSi and UnTHCPSi, respectively.
Absolute PYY3-36 bioavailabilities were 98, 13, 9 and 38% when delivered subcutaneously
in  TOPSi,  THCPSi,  UnTHCPSi  and  solution,  respectively.  The  results  clearly  demonstrate
improved bioavailability of PYY3-36 via TOPSi and the importance of surface chemistry of
PSi on peptide release.
Conclusions: PSi represents a promising sustained and tailorable release system for PYY3-36.
2 Adapted with permission of Springer from: Kovalainen M, Mönkäre J, Mäkilä E, Salonen J, Lehto V-P, Herzig K-H,
Järvinen K. Mesoporous Silicon (PSi) for Sustained Peptide Delivery: Effect of PSi Microparticle Surface Chemistry on
Peptide YY3-36 Release. Pharmaceutical Research 29: 837-846, 2012.
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5.1 INTRODUCTION
Recently, porous silicon (PSi) has attracted considerable interest in drug delivery research
due to its beneficial properties, such as biodegradability and biocompatibility, as a drug
carrier material (Salonen et al. 2008a; Bimbo et al. 2010; Tanaka et al. 2010a). PSi
microparticles contain nanosized pores which tremendously increase the effective surface
area of the particles. In drug delivery applications, the drug molecules are attached onto the
large internal surface area of PSi, which further allows the adsorption and delivery of high
drug payloads within the nanopores. Previously, the PSi pore structure and surface
chemistry have been shown to affect the nature of drug adsorption, dissolution and release
in vitro (Karlsson et al. 2003; Salonen et al. 2005; Limnell et al. 2007; Prestidge et al. 2007,
2008). PSi has been investigated for its ability to be used in oral delivery of small, traditional
drug molecules with the aim being to improve the absorption of poorly soluble drugs, such
as indomethacin (Salonen et al. 2005; Wang et al. 2010a). In addition, PSi has potential for
cancer chemotherapy applications, for example oxidation triggered delivery of doxorubicin
has been investigated in vitro (Wu et al. 2008). Also proteins or peptides, such as
human/bovine serum albumin (HSA/BSA), papain and insulin, have been loaded on PSi
surfaces with different surface modifications and investigated in vitro, including
intracellular protein delivery (Foraker et al. 2003; Karlsson et al. 2003; Prestidge et al. 2007,
2008; De Rosa et al. 2011). Our recent in vivo studies with several different physiological
parameters indicated that THCPSi microparticles could sustain the in vivo effects of
peptides (Kilpeläinen et al. 2009, 2011). Favorably, peptide loading onto PSi does not
require stressful procedures, which could damage the molecules leading to their
bioinactivation, which has been a problem with various particulate systems (Witschi and
Doelker 1998; Frokjaer and Otzen 2005; Ye et al. 2010).
Native PSi is unstable and is therefore typically stabilized and depending on the type of
application, the PSi surface can be further modified. Partial oxidation of PSi (thermally
oxidized PSi, TOPSi) surface under mild temperatures produces a hydrophilic surface with
moderate stability, whereas thermal hydrocarbonization of PSi creates more stable,
hydrophobic surface covered with hydrocarbons (THCPSi) (Salonen et al. 2004, 2008a). A
novel surface chemistry procedure, thermal functionalization of THCPSi with undecylenic
acid (UnTHCPSi) produces a moderately hydrophilic surface with hydroxyl groups, which
can be easily further modified. As far as we are aware, the pharmacokinetic parameters of
peptides after the administration in PSi and the effects of different surface chemistries of
PSi on those parameters have not been reported earlier.
Peptide YY (PYY) is an endogenous peptide belonging to the same peptide family as
neuropeptide Y (NPY) and pancreatic polypeptide (PP). PYY consists of 36 amino acids and
is a gut peptide secreted by enteroendocrine L-cells of the gastrointestinal tract in response
to a caloric load (Karhunen et al. 2008). It was isolated originally from porcine intestinal
and it is able to cross the blood brain barrier through a non-saturable mechanism (Tatemoto
and Mutt 1980; Nonaka et al. 2003). The effects of PYY3-36 on food intake have been
investigated in several animal species and also in humans (Koegler et al. 2005; Beglinger et
al. 2008). In rodents, it has been shown that PYY administration can reduce both food intake
and body weight (Chelikani et al. 2006). In obese and normal-weight human subjects PYY3-
36 has a reducing effect on food intake (Batterham et al. 2002, 2003; Abbott et al. 2005). In
addition to appetite regulation, PYY3-36 also seems to have a role in fuel substrate
partitioning and energy homeostasis (van den Hoek et al. 2007). Due to these actions; the
PYY system has been suggested to be a potential target for the treatment of obesity
(Chandarana and Batterham 2008; Karra et al. 2009).
In attempts to investigate its physiological functions, PYY3-36 has been delivered
chronically via osmotic minipumps or infusions using different experimental arrangements
in laboratory animals (Chandarana and Batterham 2008; Karra and Batterham 2010)
However, because of the promising characteristics of PYY in the treatment of obesity, also
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other suitable delivery systems have been investigated. For example, reversibly PEGylated
PYY3-36 has been shown to evoke a prolonged inhibition of food intake in mice (Shechter et
al. 2005). In humans, intranasal delivery of PYY3-36 has been tested in obese adults (Gantz
et al. 2007). However, the administration frequency was three times per day. Higher doses
caused nausea in  the  test  subjects  and no statistically  significant  weight  loss  was detected
with lower doses. A longer lasting clinical trial has also been conducted by Nastech
Pharmaceutical Company Inc. (Nastech Pharmaceutical Company, Inc. 2009) using
intranasal PYY3-36 with a similar administration frequency as in the previous study.
Recently, PYY3-36 has been combined with GLP-1 and the combination was administered
orally  with  a  delivery  agent  SNAC,  but  elevated  plasma  concentrations  could  only  be
detected for 2 h (Beglinger et al. 2008). Since all of these tested delivery systems require
repeated administration, a sustained release system would be preferable. Furthermore, a
sustained release system could help to overcome the side effects evoked by high doses as
well as eliminating the need for frequent administration. Due to the interesting
physiological features of PYY3-36 and previous promising results achieved using PSi in
peptide delivery (Kilpeläinen et al. 2009, 2011), this peptide was chosen as a model peptide
for pharmacokinetic evaluation of PSi formulations. In the present study, the effects of three
different surface chemistries of PSi microparticles on peptide delivery properties were
investigated both in vitro and in vivo by using PYY3-36.
5.2 MATERIALS AND METHODS
5.2.1 Reagents
The silicon wafers were purchased from Cemat Silicon S.A. (Warsaw, Poland). Ethanol
(EtOH, 99.5%) was bought from Altia (Helsinki, Finland). Hydrofluoric acid (HF) (37% –
39%) was acquired from Merck KGaA (Darmstadt, Germany). The nitrogen (99.999%) and
the acetylene (99.6%) gases were bought from AGA (Espoo, Finland). Sodium chloride
solution (9  mg/ml)  for  injections  was obtained from B.  Braun Melsungen AG (Melsungen,
Germany).
Human PYY3-36 (PYY3-36, Mw 4050 g/mol) was prepared by BCN Peptides (Barcelona,
Spain). HPLC reagents were acetonitrile (HPLC grade, JT Baker, Deventer, The
Netherlands), trifluoroacetic acid (Sigma–Aldrich, St. Louis, MO, USA). pH 7.4, 0.15 M
phosphate-buffered saline (PBS, μ0.167) was used as a buffer in the in vitro release
experiments. The buffer contained 8.0 g sodium chloride (JT Baker Deventer, The
Netherlands), 0.2 g potassium chloride (Merck KGaA, Darmstadt, Germany), 1.4 g
disodium hydrogen phosphate (Merck KGaA, Darmstadt, Germany) and 0.2 g potassium
dihydrogen phosphate (Merck KGaA, Darmstadt, Germany) in 1000 ml of deionized water.
In  addition,  bovine serum albumin (BSA,  Sigma–Aldrich,  St.  Louis,  MO,  USA) (0.1% w/v)
was dissolved to the PBS in order to prevent adsorption of PYY3-36 onto the laboratory
materials during the in vitro experiments (Akers and DeFelippes 1999).
5.2.2 Particle preparation
The preparation of free standing porous silicon films was described previously (Limnell et
al. 2007). The free standing films were ball milled and dry sieved to a 38 – 53 μm size
fraction. Aiming to remove any remaining small particles, after the dry sieving the particles
were washed on a 38 μm sieve with ethanol. The microparticles were treated with a 1:1
HF:EtOH  solution  to  replace  the  oxidized  surface  formed  during  the  milling  with  a
hydrogen termination and dried at 65°C for 1 h.
Thermal hydrocarbonization of PSi microparticles (THCPSi) was performed under
continuous N2/acetylene (1:1) flow as described earlier (Salonen et al. 2004). Treatment at
500°C for 10 min was used in order to maintain partial hydrocarbon terminated and hence
a hydrophobic surface.
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Functionalization of THCPSi microparticles was made by thermal treatment of the
particles in undecylenic acid (UnTHCPSi) at 120°C for 16 h adapting the treatment for the
hydrogen terminated PSi introduced by Boukherroub et al. (2002). Due to the stressed and
unsaturated carbon-carbon bonds existing on the hydrophobic surface of THCPSi particles
immediately after the thermal hydrocarbonization, undecylenic acid covalently binds to the
THCPSi surface and a treatment efficiency of about 50% can be achieved compared to the
hydrogen terminated PSi (Fig. 5.1). This clearly changes the characteristics of the particles,
such as their drug loading and release properties, hydrophilicity and zeta potential. In
addition,  the  carboxyl  groups  attached  onto  the  surface  can  be  used  for  further
functionalization of the particles. Thermal oxidation of PSi microparticles (TOPSi) was
performed at 300°C for 2 h in ambient air immediately after milling without any HF
treatment. The treated particles were characterized using FTIR measurements (Spectrum
BX II, Perkin-Elmer: Fig. 5.2).
Figure 5.1. TG measurements of thermally oxidized PSi (TOPSi), hydrocarbonized PSi (THCPSi)
and undecylenic acid treated thermally hydrocarbonized PSi (UnTHCPSi) and PYY3-36 loaded
TOPSi. Reduction in weight correlates with the decomposed surface moieties desorbing from the
samples.
Figure 5.2. FTIR spectra of TOPSi, THCPSi, UnTHCPSi. Spectra have been shifted to clarify the
figure.
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Specific surface area of the microparticles was calculated using BET-theory (Brunauer et
al. 1938). The pore volume, average pore diameter and of the PSi microparticles were
calculated from desorption branch of the nitrogen sorption measurements (Tristar 3000,
Micromeritics) according to BJH-theory (Barrett et al. 1951). The calculated values for
TOPSi revealed an average pore diameter of 10.3 nm, specific surface area of 222 m2/g and
pore volume of 0.76 cm3/g, for THCPSi; average pore diameter of 11.2 nm, specific surface
area of 273 m2/g and pore volume of 0.94 cm3/g and for UnTHCPSi; average pore diameter
of 10.4 nm, specific surface area of 231 m2/g and pore volume of 0.76 cm3/g, which slightly
reduce during the surface treatments (Table 5.1).
Table 5.1. The characteristics of PSi microparticles (38–53 μm) and PYY3-36 release behavior in
vitro and in vivo.
5.2.2 Particle loading
PYY3-36 was dissolved in water and the PSi microparticles were immersed in the peptide
solution (100 mg/ml) for 1.5 h at room temperature. The loading solution was treated with
ultrasound 3 times during the loading to guarantee homogeneity. The particles were
filtered from the solution and dried for 3 h at room temperature and then for an additional
30 min in a vacuum. The loading degree was determined by thermogravimetric (TG)
analysis (20°C/min, 25°C – 800°C N2 gas purge 200 ml/min, TGA 7, PerkinElmer) (Lehto et
al. 2005). The loading degrees are presented in Table 5.1. Two batches of loaded TOPSi
were used in the experiments. Possible interactions between the peptide and the different
PSi surface chemistries were studied with attenuated total reflectance (ATR)-FTIR
spectroscopy as shown in Fig. 5.3.
Figure 5.3. ATR-FTIR spectra of solid peptide PYY3-36 compared with PYY3-36 loaded THCPSi,
UnTHCPSi and TOPSi.
PSi type Pore
diameter
(nm)
Specific
surface
area
(m2/g)
Loading
degree
(% w/w)
Load
(μmol/m2)
Pore
volume
(cm3/g)
In vitro
released
PYY3-
36 (%)
PYY3-36
plasma
concentration
at 1 h (ng/ml)
TOPSi 10.3 222 14.4–15.2 0.16 0.76 27±2.7 102.7±10
THCPSi 11.2 273 12.2 0.11 0.94 14.5±3 6.1±0.8
UnTHCPSi 10.4 231 16.0 0.17 0.76 6.2±0.6 4.1±0.7
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5.2.3 In vitro release
Approximately 2 mg of PYY3-36 loaded TOPSi, THCPSi or UnTHCPSi microparticles
(containing 293, 250 and 347 μg PYY3-36 in TOPSi, THCPSi and UnTHCPSi, respectively)
were suspended in 1.5 ml of pre-warmed 0.15 M PBS buffer containing 0.1% w/v BSA (pH
7.4, μ0.167, +37°C) in microcentrifuge tubes. These tubes were placed in a water bath
shaker (Grant OLS200, Cambridge, UK) with orbital shaking at a frequency of 120
strokes/min at +37°C. At pre-determined time intervals, the tubes were centrifuged for 2
min (13 000 rpm, 17 000g, Heraues Biofuge Fresco, Osterode, Germany), and supernatants
were collected for the HPLC analysis of PYY3-36 concentrations. The microparticles were
re-suspended in fresh pre-warmed (+37°C) PBS buffer containing BSA (0.1% w/v) after the
supernatant collection. The concentration of water soluble PYY3-36 in buffer was <10% of
its maximum solubility (~100 mg/ml in water), and therefore sink conditions were
maintained throughout the experiment.
5.2.4 High performance liquid chromatography analysis of PYY3-36
The samples from PYY3-36 in vitro release experiment were analyzed with a Gilson High
Performance Liquid Chromatograph. The system consisted of an UV detector (UV/VIS-151),
pump (321), autoinjector (234), interface (506 C) and integrator (Unipoint 3.0). The mobile
phase was a mixture of acetonitrile (31.5% v/v), water (68.5% v/v) and trifluoroacetic acid
(0.1% v/v). The analytical column was a reverse-phase Supelco Discovery Biowide® C-18
column (1504.0 mm id, particle size 5 μm, Supelco, Bellefonte, PA, USA) which was
placed in a column heater during the analysis (+40°C). Samples were diluted appropriately
with the mobile solutions before their injection into the HPLC system. The injection volume
was 100 μl, flow rate 1 ml/min and PYY3-36 was detected at 200 nm. The concentrations of
PYY3-36 were determined by measuring peak areas, which were compared to a linear
calibration curve prepared using known standard PYY3-36 concentrations (1–50 μg/ml).
5.2.5 In vivo experiment
The BALB/c x DBA2 hybrid mice, for investigating PYY3-36 plasma concentrations after its
intravenous and subcutaneous delivery in different formulations, were purchased from Lab
Animal Center (Kuopio, Finland) at age of ~8 weeks, weighing 25 – 30 g. They were group
housed in a regulated environment; temperature +221°C, relative air humidity 5515%
and 12/12 h light/dark cycle with lights on at 7 am. Commercial rodent food (Teklad 2016,
Harlan Inc.) and tap water were available ad libitum throughout the experiment. The
research adhered to the Principles of Laboratory Animal Care. The National Animal
Experiment Board of Finland approved the experiments. Procedures were conducted in
accordance with the guidelines set by the Finnish Act on Animal Experimentation (62/2006)
and European Community Council Directives 86/609/EEC.
The different formulations, containing 20 μg of human PYY3-36 in 1) TOPSi 2) THCPSi 3)
UnTHCPSi or 4) 0.9% NaCl-solution were administered subcutaneously in a volume of 200
μl and 5) 20 μg of human PYY3-36 was injected in 0.9% NaCl-solution intravenously
through lateral tail vein in a volume of 100 μl. Blood samples were collected from
saphenous vein at predetermined time points into heparinized microcapillaries
(Drummond Microcaps, Drummond Scientific Co. Broomall, Pa. USA). Plasma was
separated by centrifugation (+ 4°C, 3 min, 12000 rpm, Heraues Biofuge Fresco, Osterode
Germany) and frozen immediately. Plasma samples were later analyzed using total human
PYY3-36 ELISA following the manufacturer’s instructions (Millipore Corp., Billerica, MA,
USA).
5.2.6 Pharmacokinetic analysis
Pharmacokinetic parameters for PYY3-36 were determined from plasma concentration-time
data by using WinNonlin software (WinNonlin Professional, 5.3, Pharsight Corp, USA) and
non-compartmental model for extravascular or bolus intravenous injection in the cases of
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s.c.  or  i.v.  administration,  respectively,  and  with  uniform  weighing.  Cmax and  tmax –values
were obtained directly from the plasma concentration –time data and area under the
concentration time curve-value (AUC0-last) was determined by the linear trapezoidal rule
and AUC0--value as follows: AUC0-lastClast/Ke,  where  Clast is the last measured plasma
concentration and Ke, is the terminal elimination constant. Absolute and relative
bioavailabilities were calculated by using AUC0--values,  Fabsolute%AUCPSi/s.c.
solution/AUCi.v.solution x 100%, Frelative%AUCPSi/AUCs.c.solution x 100%.
5.2.7 Statistical analysis
Statistical differences of PYY3-36 plasma concentrations were analyzed using 2-way Anova
with Bonferroni post test for multiple comparisons. Pharmacokinetic parameters analyzed
using 1-way Anova with Bonferroni post-test (GraphPadPrism 4.03 for Windows,
GraphPad Software Inc., CA, USA). P-value< 0.05 was considered to be statistically
significant.
5.3 RESULTS
In the present work, PSi microparticles with three different surface chemistries, showing
comparable porous properties, were investigated for their abilities to sustain PYY3-36
release in vitro and in vivo. PYY3-36 was successfully loaded into all the three types of
investigated PSi microparticle surfaces and high loading degrees were obtained for the
microparticles i.e. 12.2, 15.2 and 14.4, 16.0% w/w of PYY3-36 in THCPSi, two batches of
TOPSi and UnTHCPSi, respectively. Sustained PYY3-36 delivery was achieved with all the
microparticles, TOPSi, THCPSi and UnTHCPSi but the surface chemistry strongly affected
the PYY3-36 release both in vitro and in vivo. The characteristics of PSi microparticles and
their PYY3-36 releasing behavior in vitro and in vivo are summarized in Table 5.1.
5.3.1 In vitro release
PYY3-36 release from TOPSi, THCPSi and UnTHCPSi microparticles was measured for 14
days in vitro (Fig. 5.4). There was sustained but incomplete PYY3-36 release from all the
investigated surfaces and the surface chemistry affected the fraction of peptide released.
The highest peptide fraction was released from TOPSi (27.72.7% of loaded PYY3-36,
meanSEM) followed by THCPSi (14.53.0%) and UnTHCPSi (6.20.6%) microparticles,
indicating weaker in vitro interactions between PYY3-36 and TOPSi than between PYY3-36
and THCPSi  or  UnTHCPSi.  This  hypothesis  is  supported by an ATR-FTIR analysis  of  the
peptide loaded PSi. The spectral features of PYY3-36 are superposed on the characteristic
spectra of the different PSi surface chemistries after the peptide loading, as presented in
Fig. 5.3. The most notable features are appearance of the broad amide I and II bands
centered at 1650 cm-1 and 1550 cm-1. Compared with the solid PYY3-36, used as a reference,
the adsorption into PSi does not cause major alterations to the FTIR spectra of the peptide.
The PYY3-36 loaded TOPSi shows practically no detectable changes in the characteristic
amide band regions, for example, the amide I band at 1650 cm-1 does not indicate
appreciable shift compared with the reference spectra. Similarly, the amide II band appears
unchanged. However, The PYY3-36 loaded THCPSi and UnTHCPSi spectra show small
changes in both, the amide I and II band regions. In both cases, there appears to be a
general shift of 4–5 cm-1 towards higher wavenumber. These small shifts are considered to
be  related  to  local  changes  in  a  particular  conformation  (Arrondo  and  Goñi  1999).  As  the
main difference between the PSi surface chemistries is their hydrophilicity, the shift in the
amide bands presumably indicates that peptide has a slightly different orientation after the
adsorption to the pore wall surface of THCPSi or UnTHCPSi microparticles.
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Figure 5.4. In vitro PYY3-36 release from PSi microparticles with three different surface
chemistries (PBS, pH 7.4, +37°C) (Mean ± SEM, n = 4).
5.3.2 Pharmacokinetics of PYY3-36 after subcutaneous delivery via PSi microparticles in
mice
A dose of 20 μg of PYY3-36 was administered using the differently surface treated PSi
microparticles (TOPSi n5, THCPSi n6 and UnTHCPSi n6, s.c.). Subcutaneous (n4)
and intravenous (n6) PYY3-36 (dose 20 μg) solutions were studied as controls. First, there
was sustained PYY3-36 release from all the microparticles (Fig. 5.5). When PYY3-36 was
injected in a subcutaneous or intravenous solution, the peptide had been eliminated within
12 h from the plasma (Fig. 5.5). On the contrary, after administration of the PYY3-36 loaded
microparticles, PYY3-36 could be detected in plasma up to 96 h after the injections (Fig. 5.5).
After administration of the PSi formulations, there are many simultaneous pharmacokinetic
processes; PYY3-36 release from the PSi, absorption to the blood circulation and
elimination. When terminal half-lives (t1/2) were calculated for circulating PYY3-36, the
results were 71 (meanSEM), 212 and 201 h after subcutaneous administration of
TOPSi, UnTHCPSi and THCPSi, respectively, whereas the half-life of the PYY3-36 solution
was a mere ~25 min (Table 5.2). This is evidence for so-called flip-flop pharmacokinetics for
PYY3-36 delivery via PSi microparticles since the peptide release from the microparticles
controls the detected PYY3-36 plasma concentrations (Boxenbaum 1998).
Figure 5.5. Sustained PYY3-36 release after delivery in PSi microparticles is affected by surface
chemistry of the microparticles (THCPSi and UnTHCPSi n = 6, TOPSi n = 5, PYY3-36 solution s.c.
n = 4, mean ± SEM). *TOPSi vs. THCPSi/UnTHCPSi p < 0.001 0–1 h; p < 0.005 TOPSi vs.
THCPSi/UnTHCPSi at 4h.
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Table 5.2. Pharmacokinetic  values  of  PYY3-36  (dose  20  μg)  after  subcutaneous  (s.c.)  and
intravenous (i.v.) administration in mice. PYY3-36 was delivered in solutions (i.v., s.c.) and in
mesoporous silicon (PSi) microparticles (s.c.) with different surface chemistries; thermally
oxidized (TOPSi), thermally hydrocarbonized (THCPSi) and thermally functionalized THCPSi with
undecylenic acid (UnTHCPSi). (Mean ± SEM, n = 4–6)
PYY sol i.v. PYY sol s.c. TOPSi s.c. THCPSi s.c. UnTHCPSi s.c.
Cmax (ng/ml) 2327±725 137±35
c 103±8a,b 22±6a,b,c 13±2 a,c
tmax (min) 3±1 26±11 51±9
d 11±2d 19±8d
t½ (h) 0.4 ±0.02 0.4±0.02
c,d 7±1a,d 20±1a,c 21±2a,c
AUC0-last (h ng/ml) 471±75 181±31
a 457±73a 59±5a 44±5a
AUC0- (h ng/ml) 471±75 181±31
a 462±73a 61±6a 45±5a
F (%) 38 ±7a 98 ± 16a 13 ±2a 9± 1a
Frelative, s.c.(%) 256±41
a 34±3a 25±2a
a p<0.001 TOPSi vs. THCPSi/UnTHCPSi/s.c. solution, b p<0.01 TOPSi vs THCPSi, c p<0.001 s.c. solution vs
THCPSi/UnTHCPSi, d p < 0.05 TOPSi vs THCPSi/UnTHCPSi/s.c. solution.
Secondly, the particle surface chemistry strongly affected the release rate of PYY3-36 and
hence modified the pharmacokinetics (Table 5.2). The highest PYY3-36 peak concentration
(Cmax) was obtained for TOPSi being 1038 ng/ml, when the corresponding values for
THCPSi and UnTHCPSi were 226 ng/ml and 132 ng/ml, respectively. However, the
time  when  the  Cmax was  reached  (tmax) with TOPSi (519 min) was significantly delayed
when  compared  with  tmax values of THCPSi and UnTHCPSi (112 min and 198 min,
respectively), but not from that of the s.c. solution (2611 min). PYY3-36 plasma
concentrations  were  significantly  higher  until  4  h  after  the  administration  with  TOPSi
microparticles compared with THCPSi and UnTHCPSi.
Thirdly, the extent of released fraction of PYY3-36 exhibited the same rank order
TOPSiTHCPSiUnTHCPSi in vitro and in vivo, but the absorbed fractions were higher in
vivo than the released fractions in vitro (Figs. 5.4 and 5.5). The absolute bioavailability of
PYY3-36 after administration in TOPSi was 9816% indicating complete peptide release
and absorption from the particles, while the absolute bioavailabilities after PYY3-36
delivery in THCPSi and UnTHCPSi were 132 and 91%, respectively (Table 5.2).
Interestingly, the bioavailability of s.c. PYY3-36 solution was only 387%. The relative
bioavailabilities, when compared with s.c. solution, of PYY3-36 after administrations in
TOPSi, THCPSi and UnTHCPSi were 25641%, 343% and 252%, respectively (Table
5.2).
5.4 DISCUSSION
The experimental protocol and the results are summarized in Fig. 5.6. In general, the drug
molecules are adsorbed non-covalently onto PSi and released from the surface and the
pores by simple diffusion as PSi wetted by the solvent or when PSi dissolves (Leoni et al.
2002; Park et al. 2009; Kilpeläinen et al. 2011). The structure of the pore wall surface and the
functional groups of the drug affect the adsorption interactions (Salonen et al. 2005; Limnell
et al. 2007). Here, the investigated THCPSi, UnTHCPSi and TOPSi microparticles had
comparable porous properties, i.e. specific surface area, pore diameter and pore volume,
and PYY3-36 loading degree (12–16% w/w) as presented in Table 5.1. Therefore, the effect
of porous properties of the investigated PSi microparticles on PYY3-36 release can be
excluded and the results are explained by the surface chemistry of PSi. Previously, effect of
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PSi surface chemistry on in vitro release of a protein (papain) from PSi powders was
demonstrated (Prestidge et al. 2007). In the present study, three PSi surfaces were
characterized for in vitro and in vivo peptide (PYY3-36) delivery; TOPSi surface is the most
hydrophilic, whereas UnTHCPSi is moderately hydrophilic and THCPSi is hydrophobic.
Figure 5.6. PYY3-36 was loaded into the nanopores of porous silicon microparticles with three
different surface chemistries. The formulations were investigated both in vitro and in vivo. The
surface characteristics clearly influence the PYY3-36 delivery. TOPSi improves the relative
bioavailability and UnTHCPSi shows the most sustained release.
The  ATR-FTIR  analysis  of  the  loaded  TOPSi,  THCPSi  and  UnTHCPSi  do  not  indicate
strong interactions between the PSi surface and the loaded PYY3-36. Instead, the negligible
differences observed with TOPSi may indicate that combined with the better wettability of
the  material,  the  peptide  is  readily  desorbed  from  the  surface,  while  with  more
hydrophobic THCPSi and UnTHCPSi PYY3-36 may be oriented towards the surface of the
PSi according to its hydrophobic segments. The carboxylic acid terminated UnTHCPSi
surface additionally indicates slightly stronger conformational changes than THCPSi, as the
-helix structure and random conformation related peaks at 1654 cm-1 and 1641 cm-1
become  more  pronounced  (Hegefeld  et  al.  2011).  The  presence  of  possible  hydrogen
bonding  between  the  surface  carboxyl  groups  and  the  peptide  amine  groups  cannot  be
excluded,  as  both  the  amide  I  band  and  the  adjacent  carbonyl  peak  at  1715  cm-1 overlap
considerably.
Surface chemistry of PSi clearly affected in vitro (Fig. 5.4) and in vivo release of PYY3-36
(Table 5.2). Both in vitro and in vivo results  indicate  that  TOPSi  released  PYY3-36  most
efficiently but the absorbed fraction of PYY3-36 was higher in vivo than the released fraction
in vitro. These results demonstrate the importance of both surface chemistry and release
medium  in  the  release  of  PYY3-36  from  PSi.  The  interactions  between  PYY3-36  and  PSi
surface control the peptide release, which is further affected by compounds present in the
release medium that may influence diffusion-controlled peptide release or dissolution rate
of PSi. As mentioned earlier, in addition to the diffusion, the drug release can take place as
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the PSi degrades as was shown by doxorubicin release from oxidized PSi nanoparticles
during their dissolution (Park et al. 2009). Of the PSi microparticles investigated here, the
degradation rate of TOPSi is the fastest while THCPSi is the most stabile. The faster
degradation of TOPSi could partially explain the differences seen in the bioavailabilities
values (9816, 91 and 132%, respectively). To illustrate the complexity between the PSi
in vitro and in vivo results, it was recently shown that PSi degrades faster in serum, than in
phosphate buffered saline (PBS) (Godin et al. 2010), supporting our observations of
significantly faster in vivo degradation of THCPSi (unpublished data). Therefore, the PSi
degradation might not affect significantly the peptide release in vitro in  the  time frame of
the experiment (14 days), but it may play a role in vivo. In addition, more hydrophobic
particle surface of THCPSi and UnTHCPSi decreases their wetting which might slow down
the peptide release.
Recently, interactions of three proteins, HSA, lysozyme and papain with TOPSi
microparticles were investigated in vitro and TOPSi  was shown to  be  able  to  preserve the
native structure of the proteins and therefore the investigated proteins were suggested to
maintain their biological activity (Jarvis et al. 2010). In addition, a recent study regarding
the adsorption of lysozyme on silica nanoparticles indicated that even the conformation of a
peptide may change due to the adsorption, these changes are reversed during desorption
(Felsovalyi et al. 2011). The method used in the present study, for detecting PYY3-36 from
plasma (ELISA), is based on specific antibody binding to active human PYY. Therefore, the
assay confirms the activity of the delivered peptide. In the present study, PYY3-36 loading
into PSi microparticles protected PYY3-36 from degradation before its release from the
particles, since the peptide could be detected during several days from the blood
circulation. The interesting result is that the TOPSi microparticles significantly improved
the absolute bioavailability of PYY3-36 (9816%) from that of the s.c. solution (387.5%).
These results suggest that a complete absorption of subcutaneous PYY3-36 requires a
tailored controlled release formulation instead of an immediate release formulation, such as
solution.  Also  a  permeation  enhancing  feature  of  PSi  could  also  account  for  improved
bioavailability since PSi has been reported to improve the in vitro permeation of furosemide
(Kaukonen et al. 2007) and insulin through Caco2-monolayers (Foraker et al. 2003).
However, it must be noted that, despite the promising earlier and present results, TOPSi
might not be optimal for all peptides and proteins, because it is more reactive than more
hydrophobic PSi surfaces. In addition, further studies are needed to clarify the mechanism
of subcutaneous PYY3-36 absorption.
5.5 CONCLUSION
This work demonstrates that PSi microparticles are capable to achieve a high a peptide
loading degree and sustained in vivo PYY3-36 delivery over  several  days.  In  addition,  the
peptide releasing properties can be modified with different surface chemistries and
therefore the release can be optimized as needed for the particular peptide. In the case of
PYY3-36, TOPSi microparticles are capable of significantly improving the absolute
bioavailability when compared with subcutaneous administration of PYY3-36 solution.
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6 Biocompatible photocrosslinked poly(ester anhydride)
based on functionalized poly(-caprolactone) prepolymer
shows surface erosion controlled drug release in vitro and
in vivo3
Abstract:
Star-shaped poly(-caprolactone) oligomers functionalized with succinic anhydride were
used as prepolymers to prepare photocrosslinked poly(ester anhydride) to evaluate their in
vivo drug delivery functionality and biocompatibility. Thus, in this work, erosion, drug
release and safety of the photocrosslinked poly(ester anhydride) were examined in vitro
and in vivo. A small water-soluble drug, propranolol HCl (Mw 296 g/mol, solubility 50
mg/ml), was used as the model drug in an evaluation of the erosion controlled release.
Drug-free and drug-loaded (10–60% w/w) poly(ester anhydride) discoids eroded in vitro
(pH 7.4 buffer, + 37 °C) linearly within 24–48 h. A strong correlation between the polymer
erosion and the linear drug release in vitro was observed, indicating that the release had
been controlled by the erosion of the polymer. Similarly, in vivo studies (s.c. implantation of
discoids in rats) indicated that surface erosion-controlled drug release from the discoids
(drug loading 40% w/w). Oligomers did not decrease cell viability in vitro and  the
implanted discoids (s.c., rats) did not evoke any cytokine activity in vivo. In summary,
surface erosion-controlled drug release and the safety of photocrosslinked poly(ester
anhydride) were demonstrated in this study.
3Adapted with permission of Elsevier from: Mönkäre J, Hakala RA, Vlasova MA, Huotari A, Kilpeläinen M, Kiviniemi
A, Meretoja V, Herzig KH, Korhonen H, Seppälä JV, Järvinen K. Biocompatible photocrosslinked poly(ester
anhydride) based on functionalized poly(-caprolactone) prepolymer shows surface erosion controlled drug release in
vitro and in vivo. Journal of Controlled Release 146: 349-355, 2010.
51
6.1 INTRODUCTION
Poly(ester anhydride)s have been developed in order to combine advantageous properties
of the polyesters and polyanhydrides (Storey and Taylor 1997; Jiang and Zhu 2001;
Korhonen and Seppälä 2001; Slivniak and Domb 2002; Pfeifer et al. 2005a; Jaszcz et al. 2008).
Polyesters and polyanhydrides are well-characterized biocompatible materials for drug
delivery and other medical applications. Aliphatic polyesters, such as poly(-caprolactone)s
and polylactides, possess usually good mechanical strength but they often show bulk
erosion,  and  thus,  they  may  not  be  ideal  candidates  for  achieving  controlled,  linear  drug
release (Tamada and Langer 1993; Albertsson and Varma 2003). In contrast to the
polyesters, polyanhydrides are surface eroding polymers which means that they enable
controlled,  linear  drug  release,  but  in  turn,  they  often  are  fragile  which  may  hinder  the
development of controlled drug delivery systems (Göpferich and Tessmar 2002; Domb
2007). In recent years, thermoplastic poly(ester anhydride) delivery systems have been
developed for example for intratumoral injection of paclitaxel (Shikanov et al. 2004, 2008,
2009), and for DNA encapsulation and cellular transfection (Pfeifer et al. 2005b).
Recently, Seppälä et al. have developed thermoplastic and crosslinked poly(ester
anhydride)s which are prepared from different polylactone oligomers (Korhonen et al.
2006; Seppälä et al. 2009). Molecular architecture (linear or star-shaped), molecular size, and
hydrophobicity of the oligomers can be readily modified during the synthesis of the
oligomers (Hakala et al. 2009; Seppälä et al. 2009). For example, by changing the molecular
architecture or adjusting the molecular size, the physical state of the oligomer at room
temperature  can  be  changed  from  a  solid  to  a  viscous  liquid  (Hakala  et  al.  2009).  In
addition, by increasing the hydrophobicity of the polyester prepolymers by functionalizing
the oligomers with alkenylsuccinic anhydrides containing alkenyl chains of various lengths,
the erosion rate of the poly(ester anhydride)s can be modified (Korhonen et al. 2006; Hakala
et al. 2009). Furthermore, some of the crosslinkable versions can be photocrosslinked under
mild conditions with visible light to form network-structured poly(ester anhydride)s.
The advantages of photocrosslinking are that a wide variety of drugs and heat-sensitive
macromolecules can be entrapped as solid powders into the photocrosslinkable polymer
network under mild reaction conditions without the need for heat or solvents (Elisseeff et
al. 1999; Quick et al. 2004; Baroli 2006). In addition, photocrosslinking is a suitable method
for in situ administration as injectable oligomers can be polymerized in a rapid and
controlled manner at physiological temperatures (Anseth et al. 1999; Elisseeff et al. 1999).
Previously, many photocrosslinkable polymers have been studied as drug delivery systems
in which the drug release has been typically diffusion-controlled (Takao et al. 1994; West
and Hubbell 1995; Wu et al. 2003; Haesslein et al. 2006; Gu et al. 2007; Weiner et al. 2008).
Earlier in vitro studies have indicated that crosslinked poly(ester anhydride)s based on
functionalized polyester oligomers could be used for controlled drug delivery or tissue
engineering applications (Helminen et al. 2003; Rich et al. 2009; Seppälä et al. 2009).
However, no study has reported the functionality and biocompatibility of these polymers
as drug delivery systems in vivo. Therefore, the aim of these in vitro and in vivo experiments
was to evaluate the erosion, drug release and preliminary safety of photocrosslinked
poly(ester anhydride) based on the star-shaped poly(-caprolactone) prepolymer
functionalized with succinic anhydride. A small water-soluble drug, propranolol HCl (Mw
296  g/mol,  solubility  50  mg/ml),  was  used  as  a  model  drug  to  confirm  erosion  controlled
release in vitro and in vivo. In general, we are developing photocrosslinked poly(ester
anhydride)s for parenteral and oral drug delivery systems, including in situ forming drug
delivery systems. A wide spectrum of therapeutic agents, ranging from small-molecular
drugs to proteins, can be entrapped as solid powders into the polymer network under mild
reaction conditions with the drug release being controlled by surface erosion of the
polymer.
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6.2 MATERIALS AND METHODS
6.2.1 Materials
Oligomers were polymerized from -caprolactone (Solvay Interox Ltd., Warrington,
England)  in  the  presence  of  stannous  octoate  (SnOct2, Sigma-Aldrich Chemie, Germany)
and pentaerythritol (Sigma-Aldrich Chemie, Germany). The -caprolactone was dried over
molecular sieves. Stannous octoate as an initiator and pentaerythritol as a co-initiator were
used without further treatment in the ring-opening polymerization of the oligomers.
Succinic anhydride (Sigma-Aldrich Chemie, Germany) and methacrylic anhydride (Sigma-
Aldrich Chemie, Germany) were used in the functionalizations, and camphorquinone
(Sigma-Aldrich Chemie, Germany) was used as an initiator for photo-curing. They were
used as received.
Propranolol HCl (Mw 296 g/mol, solubility 50 mg/ml, Societa Italiana Medicinali
Scandicci, Florence, Italy) was used as the model drug in the study. Acetonitrile (JT Barker,
Netherlands), trifluoroacetic acid (Sigma-Aldrich, USA) and triethylamine (Sigma-Aldrich,
Belgium) were HPLC grade. pH 7.4 (0.2 M NaOH-KH2PO4) buffer was used in the erosion
(i.e. polymer weight loss) and drug release studies. NaOH was received from FF-Chemicals
(Yli-Ii, Finland) and KH2PO4 from Merck (Darmstadt, Germany).
6.2.2 Animals
Male Wistar rats (10–12 weeks, 200–300 g) (Kuopio, Finland) were housed in an
environment-controlled room temperature +22 ± 1 °C, relative air humidity 55 ± 15% and
12/12 h light/dark cycle with lights on at 7 am with food (Lactamin R36, Sweden) and tap
water available ad libitum. The Institutional Animal Care and Use Committee of the
Provincial Government approved the experiments. Procedures were conducted in
accordance with the guidelines set by the European Community Council Directives
86/609/EEC.
6.2.3 Preparation of poly(ester anhydride) oligomers
The synthesis and properties of the poly(-caprolactone) based poly(ester anhydride)
oligomers have been described earlier (Helminen et al. 2003; Rich et al. 2009). Briefly, -
caprolactone monomers were polymerized to star-shaped hydroxyl telechelic oligomers by
ring-opening polymerization. In the next step, the hydroxyl termination was changed to
acid termination with succinic anhydride. Finally, in order to obtain crosslinkable
poly(ester anhydride) oligomers with labile anhydride bonds, acid-terminated oligomers
were allowed to react with methacrylic anhydride.
6.2.4 Preparation of poly(ester anhydride) discoids
Poly(ester anhydride) discoids were prepared as follows. The liquid methacrylated
prepolymers, camphorquinone (1% w/w) and propranolol HCl powder (10, 20, 40 and 60%
w/w) were stirred until  homogeneity was achieved and the mixture was then applied to a
mold  in  order  to  produce  discoids  (2  mm  in  thickness,  5  mm  in  diameter  and  50  mg  in
weight). The discoids were photocured in a Teflon mold in a Triad 2000 light curing oven
with visible light (350–550 nm, DeguDent) to produce crosslinked polymers. The exposure
time in  the  irradiation chamber  was 10  min.  The light  intensity  at  the  surface  level  of  the
cured discoids was measured with an HD2102.1 photo-radiometer (Delta Ohm, Italy) to be
on average 220 mW/cm2.
The gel contents of the discoids were measured by extracting the soluble phase in
dichloromethane at room temperature for 24 h. Attenuated total reflectance infrared
spectroscopy (ATR-FTIR, Nicolet Magna-FTIR spectrometer 750 equipped with PIKE
Technologies GladiATR with diamond crystal plate) was used to monitor the double bond
conversion of the methacrylated oligomers. The double bond conversion in the discoids
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was calculated based on the decrease in absorbance near 1637 cm1, a characteristic
absorbance of the methacrylate double bond (Burdick et al. 2001; Helminen et al. 2003).
6.2.5 Preparation of polyester discoids
In order to evaluate the effect of anhydride bonds on the erosion of and drug release from
the poly(ester anhydride) discoids, the corresponding polyester discoids without anhydride
bonds were prepared. In the preparation of polyester discoids, the hydroxyl termination
was not changed to acid termination. Otherwise the synthesis of the polyester discoids was
identical to preparation of poly(ester anhydride) discoids.
6.2.6 In vitro erosion and drug release
The in vitro erosion (n = 3) and drug release (n = 4) from the poly(ester anhydride) discoids
were  studied in  40  ml  of  pH 7.4  buffer  in  the  water  bath shaker  with  orbital  shaking at  a
frequency of 120 strokes/min at + 37 °C (Grant OLS200, Cambridge, UK). Fresh buffer was
changed every 12 h and the pH of the buffer remained constant at pH 7.4 ± 0.2.
The erosion of the samples was studied by removing discoids from the pH 7.4 buffer at
pre-determined time intervals, and drying them in a vacuum for 48 h prior to weighing.
The erosion (%) was calculated by using the Eq. 6.1.
Erosion % = 100  100 ×
 () ()
() ()
(Eq. 6.1)
where md(0) and mpro(0) are the masses of the discoid and propranolol HCl in the discoid,
respectively, at the beginning of the experiment, and, md(t) and mpro(t) are the masses of the
discoid and propranolol HCl in the discoid, respectively, at the sampling time point.
The  drug  release  from  the  discoids  was  studied  by  taking  samples  (5  ml)  at
predetermined time intervals and the sampling volume was replaced by fresh pre-warmed
buffer. The released propranolol HCl in the buffer was analyzed with the HPLC-UV
method described below.
The erosion and drug release from the control polyester discoids without anhydride
bonds were studied in a similar manner except that the fresh pH 7.4 buffer was changed
only every 3–4 days. The pH of the buffer remained at a constant level at pH 7.4 ± 0.2.
6.2.7 In vivo erosion and drug release
The erosion of  drug-free  poly(ester  anhydride)  discoids  (n  =  3)  and the  drug release  from
40% w/w propranolol HCl loaded poly(ester anhydride) discoids (n = 3–4) were evaluated
in 12 weeks old Wistar male rats weighing 300 g. The discoids were purified with
ethanol:water (70:30) solution before implantation. The discoids were implanted
subcutaneously (one discoid in three different dorsal location for each animal) and
removed either 12, 24, 36 or 48 h after implantation. Before implantation or the removal of
the discoid, the rats were anesthetized with a fentanyl citrate/fluanizone/midazolam
combination (0.158 mg/5 mg/2.5 mg/kg, s.c.).
To determine the erosion of the drug-free poly(ester anhydride) discoids, they were
dried in a vacuum for 48 h before weighing. The erosion (%) was calculated by dividing the
weight of the removed discoid by its original weight.
Drug release was analyzed by dissolving in pH 7. 4 buffer (+ 37 °C) the propranolol HCl
loaded  discoids,  which  had  been  removed  from  the  rats,  to  determine  the  amount  of  the
remaining propranolol HCl in the discoids. Released drug fraction at the sampling point
was calculated by Eq. 6.2.
Released drug % =
 () – ()
 ()
(Eq. 6.2)
where mpro(0) is the theoretical amount of propranolol HCl of the discoid, calculated
based on the weight of the discoid, and mpro(t) is the amount of propranolol HCl in the
discoid at the time of its removal. The amount of the propranolol HCl in pH 7.4 buffer was
analyzed with HPLC-UV method as described below.
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6.2.8 HPLC analysis
The concentration of propranolol HCl was analyzed with Gilson High Performance Liquid
Chromatograph (HPLC). The system consisted of an UV detector (UV/VIS-151), pump
(321), autoinjector (234), interface (506C) and integrator (Unipoint 3.0). The mobile phase
was a mixture of acetonitrile (40% v/v), water (60% v/v), trifluoroacetic acid (0.1% v/v) and
triethylamine (0.15% v/v). The pre-column was a reverse-phase Pelliguard® LC-18 column
(20 × 4.6 mm id, particle size 40 μm, Supelco, Bellefonte, PA, USA) and the analytical
column was a reverse-phase Supelcosil® C-18 column (150 × 4.6 mm id, particle size 5 μm,
Supelco, Bellefonte, PA, USA). The injection volume was 20 μl, flow rate 1 ml/min, and
propranolol HCl was detected at 289 nm. The calibration curve of the propranolol HCl was
linear over the range of 0.1–25 μg/ml with a correlation coefficient R2 > 0.998. The area
under the curve was used for the quantification of the drug concentration.
6.2.9 In vitro cytotoxicity of oligomers
Human gingival fibroblasts were plated at a density of 25,000 cells/cm2 in 96-wells and
allowed to adhere for 24 h. A dilution series of the oligomers with different functionalities
(either hydroxyl terminated, carboxyl acid terminated or methacrylated) were prepared in
acetone,  and  pipetted  onto  the  top  of  the  cells  in  6  replicates.  The  final  concentrations  of
acetone and oligomers were 2.5% and 50–400 μg/ml, respectively. The cells were cultured
for an additional 24 h and washed with phosphate buffered saline. The cell activities were
determined using AlamarBlue™ assay (BioSource International) in colorimetric format.
Measured absorbances (Multiskan MS ELISA plate reader, Labsystems, Finland; 560 nm
and 595 nm) were used to calculate the reduction of AlamarBlue reagent in accordance with
the manufacturer's instructions. The activity of acetone-treated cells was set to 100%.
6.2.10 Cytokine release
In order to evaluate the preliminary in vivo toxicity of poly(ester anhydride) discoids, the
cytokine release was measured after the implantation of the drug-free discoid in rats. A
discoid purified in 100% ethanol was implanted subcutaneously dorsally (one discoid per
animal, polymer dose 200 mg/kg) into 10 week old Wistar male rats weighing 200–300 g (n
= 5). Rats were anaesthetized under isoflurane anesthesia (5% for induction, 2–3% for
maintenance) during the implantation. Control group was sham-operated and received
0.9% NaCl (300 μl). Blood samples were collected from the femoral vein 12, 24, 36, 48 and
120 h after the implantation into heparinized capillaries and the plasma was separated by
centrifugation. All the discoids had eroded within 120 h as confirmed by the visual
inspection of the implantation site. The concentrations of nine cytokines (IL-1, IL-1, IL-2,
IL-4, IL-6, IL-10, GM-CSF, TNF- and IFN-) in plasma were measured using Bio-Plex Rat
Cytokine  9-Plex  Panel  with  Bio-Plex  instrument,  based  on  Luminex  xMAP  technology
following the manufacturer's instructions (Bio-Plex®, Bio-Rad Laboratories Inc.).
6.2.11 Statistical analysis
The non-parametric Kruskal–Wallis test (SPSS 14.0 for Windows, SPSS Inc.) was used to test
the statistical significance of differences between groups in in vitro erosion and drug release
studies. The post hoc test (Siegel and Castellan 1988) was employed to test the significance of
the differences of the means. The level of significance was taken as p < 0.05. Pearson's
product moment correlation was calculated by using GraphPadPrism 4.03 for Windows
(GraphPad Software Inc.) software.
Results from in vitro cytotoxicity experiments were analyzed using Kruskal–Wallis test
and Dunn's Multiple Comparison post-test (GraphPadPrism 4.03 for Windows, GraphPad
Software Inc) and the level of significance was taken as p < 0.05. Results from the cytokine
release experiments were analyzed using two-way ANOVA and Bonferroni post test
(GraphPadPrism 4.03  for  Windows,  GraphPad Software  Inc.)  and the  level  of  significance
was taken as p < 0.05.
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6.3 RESULTS AND DISCUSSION
6.3.1 Preparation of poly(ester anhydride) discoids
The synthesis of the photocrosslinked poly(ester anhydride) networks is illustrated in
Scheme 6.1. The preparation of the drug-loaded discoids was performed at room
temperature which requires an appropriate viscosity of photocrosslinkable oligomers. By
using  10  mol%  of  pentaerythritol  as  a  co-initiator,  transparent  viscous  oligomer  liquid
(molecular weight 1160 g/mol) suitable for the photocrosslinking and the mixing of the
drug powder (10–60% w/w) at room temperature was obtained. After the
photocrosslinking, the samples were elastic and the extraction of the samples in
dichloromethane showed gel contents above 95% indicative nearly complete crosslinking of
precursors. In addition, final double bond conversions of the photocrosslinked discoids
were between 92 and 98%.
It is noteworthy that in the present process there was no need to dissolve the drug into
any  solvent  since  the  drug  could  be  simply  mixed  with  the  oligomers  as  a  plain  drug
powder. In typical preparation methods of biodegradable polymeric drug delivery systems,
such as hot melt extrusion and solvent casting methods, one must heat the polymer mass or
dissolve  the  drug  in  an  organic  solvent  in  order  to  mix  the  polymer  and  the  drug  which
may result in loss of compound activity, particularly, in the cases of peptides and proteins
(Leuner and Dressman 2000). Organic solvents can be also problematic due to toxic solvent
residues (Leuner and Dressman 2000). In addition to the mentioned advantages, the present
polymer enabled a high drug loading degree, up to 60% w/w.
Scheme 6.1. Preparation of poly(ester anhydride) networks.
6.3.2 Poly(ester anhydride) erosion and drug release in vitro and in vivo
Surface erosion of photocrosslinked poly(ester anhydride)s occurred both in vitro and in
vivo. Fig. 6.2 clearly shows that the dimensions of drug-free poly(ester anhydride) discoids
shrunk steadily and the discoid core remained intact during the in vitro and in vivo studies.
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Figure 6.2. Core  of  drug-free  poly(ester  anhydride)  discoids  remained  intact  whereas  the
dimensions decreased steadily during the in vitro (A)  and in vivo (rats, s.c.) (B) studies.
Discoids at 0, 12, 24, 36 and 48 h after incubation in 7.4 buffer and implantation in rats. Initial
diameter 5 mm, height 2 mm and weight 50 mg.
In vitro (pH 7.4, 37 °C), after a lag-time of 4–8 h, the studied poly(ester anhydride)
discoids eroded linearly (R2 0.961–0.990) within 24 to 48 h (Fig. 6.3, Table 6.1). Poly(ester
anhydride) discoids with the propranolol HCl loading from 10 to 40% w/w tended to have
a slightly higher erosion rate than drug-free and 60% w/w drug loaded discoids (Fig. 6.3).
The steady-state erosion rate of propranolol HCl loaded discoids varied from 2.61%/h (60%
w/w) to 4.05%/h (20% w/w) (Table 6.1). However, one can conclude that the drug loading
degree did not influence greatly the erosion of the poly(ester anhydride) discoids as the
statistically significant (p < 0.05) differences were detected only between 20 and 60% w/w
loaded discoids at 4 h, between 10 and 40% w/w loaded discoids at 8 h, between 0 and 20%
w/w loaded discoids at 12 h and between 0 and 10% w/w loaded discoids at 24 h. For
comparison, propranolol HCl loaded (10% w/w) discoids from corresponding polyester
discoids without anhydride bonds hardly eroded at all in 48 h (Fig. 6.3). The difference
between the in vitro erosion of photocrosslinked poly(ester anhydride) and polyester
discoids (Fig. 6.3) clearly shows that the erosion of the poly(ester anhydride) is due to the
rapid hydrolysis of the anhydride bonds. During the erosion process, anhydride bonds are
remaining intact inside the poly(ester anhydride) matrix until they are exposed to the water
as the erosion front proceeds.
Figure 6.3. Erosion of drug-free and drug-loaded poly(ester anhydride) (solid line) was linear in
vitro (pH 7.4,  + 37 °C),  while corresponding polyester without anhydride bonds (dashed line)
did not erode. Drug loading degrees:  0%  10%,  20%,  40% and  60% w/w propranolol
HCl. Mean±SEM, n = 3. Statistically significant (p < 0.05) differences were found between 20
and 60% w/w at 4 h, between 10 and 40% w/w at 8 h, between 0 and 20% w/w at 12 h and
between 0 and 10% w/w at 24 h.
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Table 6.1. In vitro erosion of and propranolol HCl release from poly(ester anhydride) discoids.
Drug
loading
degree
(% w/w)
Linear
release
period
(h)
R2-value
of release
Release ratea
%/h
(mean±SEM)
Linear
erosion
period (h)
R2-
value of
erosion
Erosion ratea
%/h
(mean±SEM)
R2
correlationb
0 N/A N/A N/A 0-48 0.987 2.04±0.04 N/A
10 8-28 0.990 3.32±0.13 8-28 0.970 3.77±0.12 0.973
20 8-32 0.990 3.16±0.05 8-30 0.961 4.05±0.13 0.982
40 8-36 0.980 2.68±0.10 8-35 0.990 3.23±0.06 0.995
60 1-36 0.987 2.10±0.18 4-35 0.965 2.61±0.17 0.988
a The release and erosion rates are calculated from the reported linear release (n= 4) and erosion (n=3)
periods, bCorrelation between the drug release rate and the erosion rate (Pearson’s correlation test).
In vivo (s.c., rats), erosion of the drug-free poly(ester anhydride) discoid showed linear
(R2 0.925) erosion between 12 and 48 h (Fig. 6.4). The in vivo erosion profile of the drug-free
discoid closely followed the in vitro erosion profile of the corresponding discoid although
statistically significant differences (p < 0.05) were detected between the in vitro and in vivo
profiles at 12 h and 24 h (Fig. 6.4). The similarity between the in vitro and in vivo erosion of
the poly(ester anhydride) suggests that the in vivo erosion is based on the hydrolytic
degradation of the anhydride bonds. If enzymes or other biological factors were playing a
significant role in the erosion process, then the erosion would be quicker in vivo than in vitro
(Kluin et al. 2009).
Figure 6.4. Erosion of drug-free poly(ester anhydride) discoids in vitro () and in vivo (rat, s.c.)
(). Mean±SEM, n = 3. Statistically significant (p < 0.05) differences were found at 12 h and 24
h.
Surface erosion is defined as the erosion of the polymer from the external surfaces of the
polymer matrix (Tamada and Langer 1993). Therefore, as long as the external area of the
polymer matrix remains constant, a linear drug release can be achieved if the drug release
is erosion controlled. Göpferich and Tessmar (2002) stated that a hydrophilic model
compound should be used if one wishes examine the erosion controlled release from
polyanhydrides. Therefore, in this study, a small water-soluble drug, propranolol HCl (Mw
296 g/mol, solubility 50 mg/ml), was used as the model drug to evaluate whether release
from photocrosslinked poly(ester anhydride)s was erosion controlled.
In vitro (pH 7.4, 37 °C), propranolol HCl (10–40% w/w) release from poly(ester
anhydride) discoid showed a linear (R2 0.980–0.990) drug release with the lag time of 8 h
(Fig. 6.5, Table 6.1). It was noticed already in the erosion studies that there is a lag time
before  the  beginning of  the  linear  erosion phase  (Table  6.1).  Thus,  it  is  suggested that  the
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lag time of the drug release is related to the similar delay in the beginning of the polymer
erosion. When the drug loading degree was 60% w/w, there was no lag time in the release
profile, instead an initial burst release of 10% within the first hour was observed (Fig. 6.5).
The burst release can be explained for example by manufacturing conditions and the
heterogeneity of polymer matrices as discussed by Huang and Brazel (2001). The steady-
state propranolol HCl release rate from poly(ester anhydride) discoids varied from 2.10%/h
(60% w/w) to 3.32%/h (10% w/w) (Table 6.1). The drug release profiles were found to be
statistically (p>0.05) similar when the drug loading degrees were 10–40% w/w. Statistically
significant differences in propranolol HCl release were detected between the 10 and 60%
w/w loaded discoids at 1 and 8 h and between 20 and 60% w/w loaded discoids at 1, 6 and
8 h. Thus, the drug loading degree (10–40% w/w) could be varied extensively without
affecting the drug release rate.
Figure 6.5. Drug  release  from  poly(ester  anhydride)  discoids  (solid  line)  and  corresponding
polyester  discoids  without  anhydride  bonds  (dashed  line) in vitro (pH  7.4,  +  37  °C).  Drug
loading degrees:  10%,  20%,  40% and  60% w/w propranolol  HCl.  Mean±SEM, n = 4.
Statistically significant (p < 0.05) differences were found between the drug loading degrees of
10 and 60% w/w (from 1 to 8 h), and 20 and 60% w/w (at 1, 6 and 8 h).
In order to study if poly(ester anhydride) in vitro erosion and the resulting drug release
kinetics are similar, Pearson's product moment correlation was determined (Table 6.1, Fig.
6.6).  High  R2-values (> 0.973) were found for all the studied drug loaded (10–60% w/w)
poly(ester anhydride) discoids confirming erosion controlled drug release from the
poly(ester anhydride).
Figure 6.6. The clear correlation between the erosion of  and the drug release from poly(ester
anhydride) discoids in vitro (pH 7.4, + 37 °C) was observed. Only mean values are shown for
the sake of clarity. Drug loading degrees:  10% (solid line),  20% (dotted-dashed line), 
40% (dashed line), and  60% w/w (dotted line) propranolol HCl.
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In order to clarify the effect of the anhydride bonds on the release, the drug release from
corresponding polyester discoids without anhydride bonds was studied. Fig. 6.5 clearly
indicates the importance of anhydride bonds in the drug release as very little propranolol
HCl was released from 10% w/w loaded polyester discoids within 48 h. In contrast to the
poly(ester anhydride) discoids, the drug release rates from the polyester discoids increased
with increasing drug loading degrees. Drug release rates were 0.04, 0.10 and 0.38%/h from
10, 40 and 60% w/w propranolol HCl loaded polyester discoids, respectively, in the first 48
h of the drug release.
In vivo (s.c., rats), propranolol HCl release from poly(ester anhydride) discoids (40%
w/w) exhibited a linear drug release (R2 0.953) between 12 and 48 h (Fig. 6.7). However, the
drug release rate of the linear release phase was lower in vivo (1.66%/h) than in vitro
(2.68%/h). The in vivo drug release (Fig. 6.7) is consistent with the in vivo erosion (Fig. 6.4)
both lasting approximately 48 h, indicating surface erosion-controlled drug release.
Figure 6.7. Both in vitro (pH  7.4,  +  37  °C).  () and in vivo (rat, s.c.) () drug release from
poly(ester anhydride) discoids loaded with 40% w/w propranolol HCl followed closely linear
kinetics. Mean±SEM, n = 3–4.
6.3.3 Safety evaluation of poly(ester anhydride) in vitro and in vivo
In vitro cytotoxicity of oligomers with different functionalities (hydroxyl terminated,
carboxyl acid terminated and methacrylated) were evaluated by the AlamarBlue test which
is based on the reduction of resazurin to resofurin in the cytosol of the living cells (O’Brien
et al. 2000). Unreacted methacrylated poly(ester anhydride) oligomers are the starting
material of the photocrosslinking and during in situ polymerization their leaching could
possible cause toxicity. Carboxyl acid terminated oligomers are degradation products of
crosslinked poly(ester anhydride) networks, and thus also their toxicity needs to be
assessed. These oligomers were compared with the hydroxyl terminated oligomer since it is
approved  by  the  US  Food  and  Drug  Administration  for  clinical  use  in  medical  and  drug
delivery devices (Nair and Laurencin 2007). Human gingival fibroblasts were chosen as the
model cell line since, in addition to the controlled drug release applications, poly(ester
anhydride) networks could be also used in tissue engineering applications (Rich et al.
2009).All of the studied oligomers were non-cytotoxic at the level of their solubility (Fig.
6.8). Cell activities with oligomer concentrations below 50 μg/ml were in the range of 85%–
100% (Fig. 6.8), and no statistically significant differences were found between the acetone-
treated control cells and oligomer-treated cells. At concentrations above 100 μg/ml, the
oligomers precipitated on the cells in aqueous solutions. These precipitates dose-
dependently decreased cell activities (data not shown), as they hindered the cellular
transport of gases and nutrients affecting viability. These results are in agreement with
earlier publications showing that the crosslinked networks formed from acrylated and
methacrylated oligomers are generally well tolerated (Davis et al. 2003; Poshusta et al. 2003)
even though there have been some reports of in vitro cytotoxicity of the methacrylated and
dimethacrylated oligomers (Bruining et al. 2000).
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Figure 6.8. Cell viability after incubating 50 g/ml either hydroxyl terminated, carboxyl acid
terminated, or methacrylated oligomers with human gingival fibroblasts for 24 h (mean ± SD, n
=  6).  No  statistical  differences  (p  <  0.05)  were  found  between  groups.  Acetone-treated  cells
were used as a control group.
The in vivo safety of poly(ester anhydride) networks was evaluated in rats by measuring
cytokine secretion after the subcutaneous implantation of poly(ester anhydride) discoids.
Cytokines are cell signaling proteins released in many pathological conditions e.g. infection
and inflammation and produced in response to microbes and other antigens. The
introduction of foreign materials, such as polymer implants, into the body evokes tissue
injury and subsequently inflammation and wound healing (Anderson 2001; Anderson et al.
2008). After the implantation of biomaterials, cytokines are secreted by many cells, such as
macrophages or neutrophils, promoting inflammation and wound healing processes
(Schutte et al. 2009). Thus, plasma concentrations of cytokines can be considered as markers
of immunogenic responses to the polymer materials (Anderson 2001; Baldwin and Hunt
2008; Bridges et al. 2008; Rodriguez et al. 2009; Schutte et al. 2009).
In this study, the rat plasma concentrations of nine cytokines were measured 12, 24, 36,
48 and 120 h after the subcutaneous implantation of drug-free poly(ester anhydride)
discoids (Table 6.2). TNF- levels were not included in the Table 6.2 since the majority of
the measurements were below the detection limit (1.95 pg/ml). The cytokine levels of the
control group (NaCl 0.9%, n = 5) were comparable to the poly(ester anhydride) group (n =
5). The only exceptions were the unexpectedly lower IL-1 levels at 120 h and the lower
IFN- levels at 24 h after the implantation of poly(ester anhydride) discoids. Based on the
present results, the studied photocrosslinked poly(ester anhydride) network did not
provoke any major immunogenic responses. These results are in concordance with
previously published safety studies of thermoplastic poly(ester anhydride) implants and
injectable pastes that have indicated no or only minor inflammatory reactions in mice and
rats (Jiang et al. 2001; Shikanov et al. 2004; Krasko et al. 2007).
6.4 CONCLUSION
In vivo functionality and biocompatibility of the photocrosslinked poly(ester anhydride)
network were demonstrated. The present results indicate that poly(ester anhydride)s
enable a high drug loading degree (up to 60% w/w), and are capable of surface erosion-
controlled drug release both in vitro and in vivo. In vitro cytotoxicity  and in vivo cytokine
secretion experiments indicated that the polymer is safe for use in drug delivery systems.
61
Table 6.2. Poly(ester anhydride) discoids (s.c., 200 mg/kg) did not induce plasma cytokine
levels in rats when compared with 0.9% NaCl administration.
Time (h) Cytokine Concentration in
plasma (pg/ml)
Time (h) Cytokine Concentration in
plasma (pg/ml)
NaCl Polymer NaCl Polymer
IL-	 IL-6
12 190±60 117±41 12 398±132 143±41
24 132±21 130±47 24 206±69 188±54
36 311±109 306±69 36 221±61 203±90
48 212±33 155±43 48 411±264 291±93
120 471±78*** 74±30*** 120 709±483 158±17
IL- IL-10
12 137±53 186±29 12 113±38 50±10
24 287±100 247±64 24 71±26 53±16
36 478±330 198±51 36 79±23 84±26
48 1469±483 869±420 48 103±35 101±22
120 225±58 102±27 120 138±48 59±13
IL-2 GM-CSF
12 256±130 74±27 12 52±21 21±8
24 166±64 96±33 24 44±14 18±6
36 174±56 153±73 36 43±14 33±13
48 358±251 185±82 48 65±38 37±15
120 807±551 116±23 120 123±68 27±7
IL-4 IFN-

12 58±23 23±10 12 381±131 116±42
24 46±14 22±10 24 678±246** 76±28**
36 49±14 38±17 36 490±270 81±8
48 81±49 46±21 48 279±137 88±34
120 152±88 33±10 120 573±190 142±68
***p<0.001, **p<0.01, Polymer vs. NaCl 0.9%,
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7 Characterization of internal structure, polymer erosion
and drug release mechanisms of biodegradable poly(ester
anhydride)s by X-ray microtomography4
Abstract:
Surface eroding biodegradable polymers can provide many advantages in drug delivery,
such as controllable and zero-order drug release. Photocrosslinkable poly(ester anhydride)s
are a recently developed family of surface-eroding polymers with readily modifiable
oligomer chemistry allowing tailoring of polymer properties. For example, in vivo release
rate of peptide from photocrosslinked poly(ester anhydride)s can be controlled by oligomer
hydrophobicity. In this study, X-ray microtomography (micro-CT) was used to gain a
deeper understanding on internal structure, polymer erosion and drug release mechanisms
of photocrosslinked poly(ester anhydride)s. Micro-CT is non-destructive and able to
provide quantitative and qualitative information on the 3D structure of the sample in
micrometer resolution. Photocrosslinked poly(ester anhydride) samples with varying drug
loading degrees (propranolol HCl 0, 10 and 60% w/w) and hydrophobicity (with and
without 12-carbon alkenyl chain) were prepared. The samples, both freshly prepared and
exposed to buffer solution for varying durations were characterized by micro-CT. The
results showed that drug release from photocrosslinked poly(ester anhydride)s was
primarily controlled by the surface erosion. However, drug diffusion had also a significant
role in drug release from less hydrophobic samples with very high (60% w/w) drug loading
degrees. In conclusion, micro-CT is a valuable tool in the characterization of surface-
eroding polymers.
4 Adapted from the submitted manuscript: Mönkäre J, Pajander J, Hakala RA, Savolainen P, Järveläinen M, Korhonen
H,  Seppälä  JV,  Järvinen  K.  Characterization  of  internal  structure,  polymer  erosion  and  drug  release  mechanisms  of
biodegradable poly(ester anhydride)s by X-ray microtomography. Submitted, 2012
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7.1 INTRODUCTION
Biodegradable  polymers  are  eroded  either  by  surface  or  bulk  erosion,  and  the  erosion
mechanism plays a significant impact on drug delivery properties of the polymer. In
surface erosion, material is lost solely from the exterior surface of the polymer matrix since
polymer degradation is faster than water penetration into the matrix (Tamada and Langer
1993; Siepmann and Göpferich 2001). In contrast, in bulk erosion, water penetration is faster
than polymer degradation, and the matrix is eroded throughout the entire volume
simultaneously. In general, surface erosion offers clear advantages over bulk erosion, such
as controllable and zero-order drug release rates irrespective of the physicochemical
properties of the drug. In addition, an intact matrix of surface-eroding polymer can protect
sensitive drugs from degradation catalyzed by polymer degradation products or the
surrounding medium.
Photocrosslinkable poly(ester anhydride)s are a recently developed family of surface-
eroding and biocompatible polymers suitable for drug delivery (Mönkäre et al. 2010, 2012)
and tissue engineering (Rich et al. 2009) applications. They have been developed with the
aim of combining the good mechanical strength of polyesters (Albertsson and Varma 2003)
with the surface erosion property of polyanhydrides (Göpferich and Tessmar 2002).
Molecular architecture, molecular size and hydrophobicity of the polyester oligomers can
be readily tailored during their synthesis (Hakala et al. 2009, 2011). Consequently,
photocrosslinkable precursors can be modified to be viscous liquids in room temperature,
allowing straightforward preparation of drug loaded devices by mixing the drug as
powder with precursors prior to photocrosslinking. Furthermore, polymer erosion and
drug release rates can be modified according to the principles of surface erosion in vitro and
in vivo by altering the oligomer hydrophobicity (Mönkäre et al. 2012).
Previously, polymer erosion and drug release mechanisms of photocrosslinked
poly(ester anhydride)s have been assessed by the mass loss and drug release profiles
(Mönkäre et al. 2010; Hakala et al. 2011). However, the typical analysis method of polymer
erosion,  measurement  of  changes  of  polymer  molecular  weight,  is  impractical  for
crosslinked polymers. Therefore, X-ray microtomography (micro-CT) was chosen to
provide a deeper understanding of the internal structure, polymer erosion and drug release
mechanisms of  photocrosslinked poly(ester  anhydride)s.  Micro-CT can provide a  detailed
3D-structure of the measured sample in micrometer resolution in a non-destructive
manner. It is based on transmission of X-rays and different ingredients in a pharmaceutical
formulation can be separated based on their density differences. Not only is it an excellent
tool for visualization, but micro-CT can also provide quantitative information about the
sample morphology. Previously, micro-CT has been applied in pharmaceutics to evaluate
internal structure, density variations and porosities of tablets and granules (Farber et al.
2003; Sinka et al. 2004; Busignies et al. 2006; Crean et al. 2010; Poutiainen et al. 2011). There
have  not  been  many  attempts  to  assess  structural  changes  of  formulation  during  drug
release by using micro-CT, instead it has mainly focused on investigating differences before
and after drug release (Traini et al. 2008; Wang et al. 2010b, 2010c).
In  this  study,  the  internal  structure,  erosion  mechanism  and  drug  release  behaviour  of
photocrosslinked poly(ester anhydride) discoids before and after the exposure to a buffer
solution for varying durations were characterized by micro-CT. The hydrophobicities of
photocrosslinked poly(ester anhydride)s were modified by functionalizing the oligomers
either  with  succinic  anhydrides  (SAH)  or  2-dodecen-1-ylsuccinic  anhydride  (12-ASA)
(Hakala et al. 2009, 2011). The 12-carbon alkenyl chain of the 12-ASA increases the
hydrophobicity of the polymer and subsequently reduces polymer erosion and drug release
rates (Mönkäre et al. 2012). In addition to the drug-free discoids, discoids with a model
drug, propranolol HCl, with two drug loading degrees (10 and 60% w/w) were
characterized. Propranolol HCl was chosen as a model drug since it is a small and highly
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soluble (Mw 296 g/mol, solubility 50 mg/ml) molecule, and thus it is suitable for testing
surface erosion-controlled drug release (Göpferich and Tessmar 2002).
7.2 MATERIALS AND METHODS
7.2.1 Materials
The oligomers were polymerized from -caprolactone (Solvay Interox Ltd., Warrington,
England) in the presence of stannous octoate and pentaerythritol. The -caprolactone was
redistilled  and  dried  over  molecular  sieves.  Stannous  octoate  as  an  initiator  and
pentaerythritol as a co-initiator were used in the ring-opening polymerization of the
oligomers. Succinic anhydride (SAH), 2-dodecen-1-ylsuccinic anhydride (12-ASA), and
methacrylic anhydride were used in the functionalizations, and camphorquinone was used
as an initiator for photo-curing. All reagents except -caprolactone were purchased from
Sigma-Aldrich Chemie, Germany and were used as received.
Propranolol HCl (Societa Italiana Medicinali Scandicci, Florence, Italy) was used as the
model drug in the study and the powder was sieved into the 53-149 μm fraction in order to
have  a  defined  particle  size  of  the  drug  phase.  pH  7.4  (0.2  M  NaOH-KH2PO4) buffer was
used  in  the  polymer  erosion  and  drug  release  studies.  NaOH  was  obtained  from  FF-
Chemicals (Yli-Ii, Finland) and KH2PO4 from Merck (Darmstadt, Germany).
7.2.2 Preparation drug-loaded polymer samples
The synthesis and properties of the poly(ester anhydride) based on poly(-caprolactone)
oligomers have been described earlier (Hakala et al. 2009, 2011). Briefly, -caprolactone
monomers were polymerized to star-shaped hydroxyl telechelic oligomers by ring-opening
polymerization. In the next step, the hydroxyl termination was changed to acid termination
with succinic anhydride (SAH) or 2-dodecen-1-ylsuccinic anhydride (12-ASA). In order to
obtain crosslinkable poly(ester anhydride) precursors with labile anhydride bonds, acid-
terminated oligomers were allowed to react with methacrylic anhydride.
In the photocrosslinking, the viscous liquid methacrylated precursors, camphorquinone
(1% w/w) with and without propranolol HCl powder (10 or 60 % w/w) were stirred until
homogeneity  was  achieved  and  the  mixture  was  then  placed  into  a  mold  in  order  to
produce  the  discoids  (2  mm  in  thickness,  5  mm  in  diameter  and  50  mg  in  weight).  Light
curing was done with visible light (11 W, 16 mW/cm2) at room temperature for 20 min. The
gel contents and double bond conversions were measured as described earlier and they
were >90% as in previous studies (Hakala et al. 2011; Mönkäre et al. 2012).
7.2.3 Characterization of density and particle size
The particle size of propranolol HCl sieved into 53-149 μm size fraction was characterized
by laser diffraction (Mastersizer 2000, Malvern Instruments Inc., Southborough, MA, USA)
using the dry measurement method (Scirocco2000). The densities were measured by a
pycnometer (MVP-1, Quantachrome, Syosset, NY, USA), using helium as the measuring
gas. The densities of propranolol HCl powder and photocrosslinked drug-free SAH and 12-
ASA-functionalized discoids were 1.205±0.005 (mean ± SD, n=6), 1.181±0.003 and 1.130
±0.009 g/cm3, respectively.
7.2.4 Micro-CT characterization
Poly(ester anhydride) discoids were characterized with micro-CT directly after preparation
and after the buffer exposure. In the latter case, samples were first exposed to 40 ml of pH
7.4 buffer (0.2 M NaOH-KH2PO4) with orbital shaking (120 r/min, +37C) in order to initiate
the polymer erosion and drug release. Samples (n=1) were removed from the buffer at 4, 12
and 24 h for the SAH-functionalized discoids and at 4, 12, 24, 36, 48 and 60 h for the 12-
ASA-functionalized discoids. After that samples were rinsed in water followed by removal
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of excess water before freezing samples at -85C. Next, all samples, whether they were
exposed to buffer or not, were dried in an ice condenser (ModulyoD, ThermoSavant, New
York, NY, USA) in freeze vacuum (-66C, 146 mbar). Between the drying and micro-CT
imaging, the samples were stored at -85C.
Samples were imaged with Skyscan 1172 instrument with software version 1.5 (Skyscan
N.V., Aartselaar, Belgium) in order to obtain projection images. X-ray source voltage and
current  were  60  kV  and  167  μA,  respectively.  The  rotation  step  was  set  at  0.7,  frame
averaging 5 and random movement 10. Imaging resolution was 1.6 μm for SAH-
functionalized samples without drug and with 10 %w/w drug loading degree and 3.3 μm
for other samples. Cross-section images were reconstructed with NRecon software (version
1.6.2.0, Skyscan N.V.) by setting the contrast to be between 0.0 and 0.15 and the post-
alignment setting suggested by the software was typically used. Ring artifact correction
was set at 10 and the beam hardening correction was 40%.
Structural analysis was performed with CTAnalyzer software (version 1.10.10.2, Skyscan
N.V.). The analysis was performed at a resolution of 3.3 μm for all samples and resizing by
factor of 2 was performed for samples imaged at resolution of 1.6 μm. Region and volume
of interest were set to encompass the whole sample volume as closely as possible. Binary
threshold  selection  was  done  based  on  the  histogram  of  brightness  distribution.  Three
different phases could be detected from the matrices, namely polymer and drug
(propranolol HCl), and the air, which depicted water penetrated into the polymer matrix
during  the  erosion.  A  number  of  different  quantitative  3D  and  2D  parameters  describing
structural characteristics of sample can be obtained in micro-CT analysis. Table 7.1
describes the parameters that were selected for closer analysis in this work.
The drug content of the freshly prepared drug-loaded poly(ester anhydride) discoids
were calculated as follows: mpro = Vpro / , in which mpro is weight of propranolol HCl in the
discoid, Vpro is the volume of propranolol phase (cm3) determined by CTAnalyzer, and  is
the density of propranolol HCl powder (g/cm3). Finally, mpro was divided by the weight of
the discoid to obtain the drug loading degree of the discoid that was compared to the
theoretical drug loading degree.
Table 7.1. Selected 3D structural  parameters Skyscan™ CT-analyzer software analyzed in this
study (Skyscan 2009)
Parameter Unit Definition
Percent object volume % A proportion of the certain phase (drug, polymer or air)
of the total object volume
Structural thickness μm Thickness of objects defined by the binarisation of the
volume of the interest (Hildebrand and Rüegsegger 1997)
Structure separation μm Thickness of spaces defined by the binarisation of the
volume of the interest
Fragmentation index μm-1 An inverse index of connectivity and the value is relative
(Hahn et al. 1992). The low and high values indicate
connected and disconnected structures, respectively.
Object surface volume ratio μm-1 Describing the thickness and complexity of the structures,
and the higher the value, the more evenly the phase is
distributed within the matrix
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7.3 RESULTS
7.3.1 Characterization of the internal structure
The freshly prepared photocrosslinked poly(ester anhydride) discoids with and without
drug were imaged, and propranolol HCl (when included), polymer and air phases could be
clearly separated in both SAH- and 12-ASA-functionalized discoids (Figs. 7.1-7.6). Drug-
free discoids displayed a uniform structure of cross-sections with black circles indicating air
entrapped during the preparation. In the case of drug loading degree of 10% w/w, light
grey  propranolol  HCl  particles  could  be  differentiated  easily  from  the  dark  grey  areas  of
polymer (Figs. 7.2 and 7.5). When the drug loading degree was increased to 60% w/w,
brighter  regions  of  light  grey  indicating  propranolol  HCl  and  regions  of  darker  grey
indicating polymer could be identified but the differences were not as clear as with the 10%
w/w drug loading degree. The hydrophobicity of poly(ester anhydride) oligomers (SAH- or
12-ASA-functionalized) had no effect on the separation of the phases.
Figure 7.1. Cross-section images of photocrosslinked drug-free SAH-functionalized discoids
before (0 h) and during the erosion at 4, 12 and 24 h. Diameter of the discoid at 0 h was 5 mm.
Figure 7.2. Cross-section images of photocrosslinked SAH-functionalized discoids with 10% w/w
propranolol HCl load before (0 h) and during the erosion at 4, 12 and 24 h. Diameter of the
discoid at 0 h was 5 mm.
Figure 7.3. Cross-section images of photocrosslinked SAH-functionalized discoids with 60% w/w
propranolol HCl load before (0 h) and during the erosion at 4, 12 and 24 h. Diameter of the
discoid at 0 h was 5 mm.
67
Figure 7.4. Cross-section images of photocrosslinked drug-free 12-ASA-functionalized discoids
before (0 h) and during the erosion at 4, 12, 24, 36, 48 and 60 h. Diameter of the discoid at 0 h
was 5 mm.
Figure 7.5. Cross-section images of  photocrosslinked 12-ASA-functionalized discoids with 10%
w/w propranolol  HCl  load before (0 h) and during the erosion at  4,  12,  24,  36,  48 and 60 h.
Diameter of the discoid at 0 h was 5 mm.
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Figure 7.6. Cross-section images of  photocrosslinked 12-ASA-functionalized discoids with 60%
w/w propranolol  HCl  load before (0 h) and during the erosion at  4,  12,  24,  36,  48 and 60 h.
Diameter of the discoid at 0 h was 5 mm.
As the micro-CT allows the non-destructive analysis of the whole sample volume, it was
utilized for the determination of the drug content of the discoids. The advantage of the
method is that drug does not need to be extracted from matrix, since this can cause loss or
degradation of the drug. The analysis was based on the measurement of the volume of
propranolol  HCl  phase  which  was  converted  into  the  weight  by  using  the  density  of
propranolol HCl powder. Drug loading degrees obtained with micro-CT analysis were
close to theoretical drug loading degrees except for the 12-ASA-functionalized discoid with
60% w/w drug loading degree that showed a lower value (Table 7.2). Thus, the results
indicate that micro-CT can be used to analyze the drug content of polymeric drug delivery
systems in a non-destructive manner without the need for the extraction of the drug.
Table 7.2. Drug  loading  degrees  (%w/w)  of  intact  photocrosslinked  poly(ester  anhydride)
discoids determined with micro-CT.
Method of drug
loading degree
SAH 10% SAH 60% 12-ASA 10% 12-ASA 60%
Theoretical 10 60 10 60
Micro-CT 10.5 54.1 9.6 46.7
Next, the capability of micro-CT was explored for non-destructive analysis of the particle
size distribution of propranolol HCl inside photocrosslinked poly(ester anhydride)
matrices. Before the preparation of the discoids, propranolol HCl was sieved into a 53-149
μm fraction in order to have a defined particle size of the drug, and the particle size
distribution was determined by the laser diffraction. The analysis of the size of the
propranolol HCl phase inside drug-loaded discoids was based on the distribution of
structure thickness values calculated by the CTAnalyzer software (Table 7.1), and the
calculated values were compared to the laser diffraction results. The results indicated that
structure thickness values of propranolol HCl in all samples were less than 50 μm while the
mean diameter (d0.5) of propranolol HCl in laser diffraction measurement was 60 μm (Fig.
7.7). It is postulated that the observed difference between the results of the size distribution
measured by micro-CT analysis and laser diffraction, can be attributed to technical
differences in these methods as postulated recently by Wang et al. (2010c) Laser diffraction
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measures the size of the propranolol HCl particle according to the largest external diameter
(Shekunov et al. 2007) while structure thickness is defined as the diameter of the largest
sphere fitting inside the propranolol HCl particle or the area of propranolol HCl
(Hildebrand and Rüegsegger 1997).
Figure 7.7. Size  distribution  of  propranolol  HCl  powder  by  laser  diffraction  and  structure
thickness distribution of propranolol HCl incorporated in SAH- and 12-ASA-functionalized
discoids. Inset shows the size distribution between 0 and 50 μm.
7.3.2 Polymer erosion
7.3.2.1 Drug-free discoids
Drug-free SAH- and 12-ASA-functionalized discoids had eroded completely in
approximately 36 h and 84 h, respectively. The relative volumes of polymer and air
remained constant until 12 h and 48 h for SAH- and 12-ASA-functionalized discoids,
respectively (Figs. 7.8A and 7.8B). There was some air inside the freshly prepared discoids
due to the entrapment of air during manufacturing but the increase in volume of air from
this baseline is corresponding to water penetrating into the matrix during the erosion. The
results  show  that  water  did  not  penetrate  into  the  matrix  which  is  in  agreement  with  the
principles of surface erosion. However, at the end of the erosion, the relative volume of the
air increased and correspondingly the volume of polymer decreased. In particular, in the
12-ASA-functionalized discoids, a sharp change was detected in the relative volume of air
at the end of the erosion. The cross-section images were in agreement with phase volumes
in that they displayed the large air voids in the matrix of SAH-functionalized discoid at 24
h and the distinguishable border area in the 12-ASA-functionalized discoids at 60 h (Figs.
7.1 and 7.4).
The structural parameters of the air phase parameters, which are presented in Table 7.3,
were used to provide more detailed information about the progression of the erosion. In
general, these values supported the findings obtained from the analysis of phase volumes
and cross-section images. Fragmentation index values of the air decreased from 0.18 of 12 h
to 0.12 of 24 h in the case of SAH-functionalized discoids and from 0.27 of 48 h to -0.11 of 60
h in the case of 12-ASA-functionalized discoids. In addition, object surface volume ratio
values also decreased both in SAH- and 12-ASA-functionalized discoids between 12 and 24
h, and 48 and 60 h, respectively. This indicated that the air phase had become more
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connected, probably due to the formation of the water channels during the final phase of
the erosion. In the case of SAH-functionalized discoids, structure thickness and separation
values increased as a function of time, further supporting the formation of larger and more
distant air voids. In contrast, in 12-ASA-functionalized discoids, structure thickness and
separation values did not change as a function of time.
Figure 7.8. Relative volumes (POV%) of polymer (), drug () and air () phases as defined by
percent  object  volume  (%)  as  a  function  of  time  for  different  photocrosslinked  poly(ester
anhydride)s with varying propranolol HCl loading degrees (% w/w) A) SAH 0%, B) 12-ASA 0%,
C) SAH 10%, D) 12-ASA 10%, E) SAH 60%, F) 12-ASA 60%.
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Table 7.3. Fragmentation index (μm-1), object surface volume ratio (μm-1), structure thickness
(μm)  and  structure  separation  (μm)  of  the  air  phase  for  SAH-  and  12-ASA  –functionalized
photocrosslinked  poly(ester  anhydride)  discoids  with  drug  loading  degrees  of  0,  10  and  60%
w/w.
Fragmentation index
Time (h) SAH-0% SAH-10% SAH-60% 12-ASA 0% 12-ASA 10% 12-ASA 60%
0 0.16 0.17 0.03 0.26 0.18 0.16
4 0.19 0.17 -0.01 0.27 0.20 0.16
12 0.18 0.18 -0.01 0.25 0.20 0.17
24 0.12 0.09 -0.02 0.27 0.13 0.14
36 0.22 0.18 0.17
48 0.27 0.14 0.20
60 -0.11 0.00 0.19
Object surface volume ratio
Time (h) SAH-0% SAH-10% SAH-60% 12-ASA 0% 12-ASA 10% 12-ASA 60%
0 0.30 0.34 0.15 0.54 0.31 0.31
4 0.35 0.30 0.12 0.50 0.30 0.24
12 0.12 0.33 0.12 0.47 0.30 0.25
24 0.05 0.12 0.09 0.44 0.25 0.20
36 0.48 0.24 0.24
48 0.42 0.23 0.27
60 0.09 0.13 0.29
Structure thickness
Time (h) SAH-0% SAH-10% SAH-60% 12-ASA 0% 12-ASA 10% 12-ASA 60%
0 22.38 25.24 24.73 16.80 28.01 19.77
4 25.21 31.88 29.06 29.63 30.92 24.64
12 67.04 24.57 28.82 27.00 30.77 24.77
24 117.02 40.87 40.21 36.77 24.94 25.82
36 16.11 29.29 22.65
48 23.00 24.27 22.62
60 29.72 30.61 23.18
Structure separation
Time (h) SAH-0% SAH-10% SAH-60% 12-ASA 0% 12-ASA 10% 12-ASA 60%
0 79.97 51.23 163.03 66.37 49.15 84.61
4 54.52 49.42 86.55 74.43 52.64 94.65
12 111.89 50.42 41.06 60.72 50.30 92.50
24 265.34 60.98 44.17 75.26 40.65 96.01
36 44.77 68.61 127.53
48 89.85 49.59 131.81
60 33.20 44.34 133.89
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7.3.2.2 Drug-loaded discoids
SAH- and 12-ASA-functionalized discoids were loaded either with 10% w/w or 60% w/w
propranolol HCl and the effect of the drug loading on the polymer erosion was evaluated.
The internal structure of the discoids during the erosion was not significantly affected by
the drug loading degree of 10% w/w. In the case of 60% w/w drug loading degree, clear
changes were detected in the internal structure of SAH-functionalized but not in 12-ASA-
functionalized discoids.
When the relative volumes of polymer, drug and air of the SAH- and 12-ASA-
functionalized discoids with 10% w/w drug loading degree were evaluated as a function of
time, the results indicated similar trends as those with drug-free discoids. At the end of the
erosion,  the  volume  of  the  air  increased  and,  in  particular,  the  volume  of  the  polymer
decreased correspondingly (Figs. 7.8C and 7.8D). In the 12-ASA-functionalized discoids
with 60% w/w drug loading degree, the relative volumes of drug, polymer and air were
also  practically  constant  during  the  erosion  (Fig.  7.8F).  In  contrast,  in  the  SAH-
functionalized discoids with 60% w/w drug loading degree, the volume of the air rapidly
increased and the volume of the drug was correspondingly decreasing (Fig. 7.8E). This
indicates that from the very beginning of the erosion, water was penetrating into the matrix
and replacing the drug phase. However, the volume of the polymer decreased only slightly,
suggesting that the actual rate of the polymer erosion had been unaffected and the erosion
mechanism remained as surface erosion.
The formation of the air voids was detected in the cross-section images of 10% w/w drug
loading degree discoids between the last time points: 12 and 24 h with SAH-functionalized,
and 48 and 60 h with 12-ASA-functionalized discoids (Figs. 7.2 and 7.5). In the SAH-
functionalized  discoids  the  voids  were  formed  inside  the  matrix,  similarly  to  drug-free
discoids, whereas in the 12-ASA-functionalized discoids, the increase of the volume of the
air was detected as the formation of the area with a high volume of air on the edges of the
discoid. When the drug loading degree was increased to 60% w/w, a clear difference was
seen between the cross-section images of the SAH- and 12-ASA-functionalized discoids. In
the SAH-functionalized discoids, the cross-section images confirmed that there had been
rapid water penetration and by 12 h no intact matrix could be detected (Fig. 7.3). In
contrast, in the 12-ASA-functionalized discoids, no apparent formation of the air voids or
the penetration of water was noted during the erosion (Fig. 7.6). Only visible changes in the
discoid structure were detected on the edges of the discoid.
Finally, structural parameters of the air phase of the drug-loaded discoids were
evaluated (Table 7.3). In the case of 10% w/w drug loading degree, the fragmentation index
and object surface volume ratio values decreased between 12 and 24 h, and 48 and 60 h in
SAH- and 12-ASA-functionalized discoids, respectively, which is in the agreement with the
results for drug-free discoids. This was evidence for the formation of the more closely
connected and coarsely distributed air phase. However, the structure thickness and
separation values of the air phase did not change as a function of time as was the case with
drug-free discoids. In the SAH-functionalized discoids with 60% w/w drug loading degree,
the changes in the structural parameters were relatively minimal despite dramatic changes
in cross-section images. Nevertheless, they supported cross-section images and analysis of
phase volumes since the fragmentation index, the object surface volume ratio and the
structure separation values of the air phase all decreased, particularly between 0 and 4 h.
These changes are evidence of an enlarged and more closely connected air phase. In the
more hydrophobic 12-ASA-functionalized discoids with the 60% w/w drug loading degree,
the changes of structural parameters were minimal,  which is in agreement with the phase
volume analysis and the cross-section images that also showed little changes.
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7.3.2 Drug release
As the polymer erosion mechanism could be analyzed by evaluating changes in the air
phase of the poly(ester anhydride) matrix, the drug release mechanism was examined by
exploring the changes of the drug phase.
The analysis of the relative volume of propranolol HCl as a function time (Figs. 7.8C-
7.8F) confirms that photocrosslinked poly(ester anhydride) matrices do not release the drug
before polymer erosion, except in the case of SAH-functionalized discoid with a 60% w/w
drug loading degree, and therefore it is believed that drug release was being mainly
controlled by the surface erosion. The volume of the drug remained relatively constant
(Figs. 7.8C, 7.8D and 7.8F), even though some slight decrease was seen towards the end of
the erosion, particularly in the case of 12-ASA-functionalized discoids with 10% w/w drug
loading degree (Fig. 7.8D). The only exception was with SAH-functionalized discoids with
60% w/w drug load, in which the relative volume of the drug decreased steadily during the
erosion (Figs. 7.8E). This demonstrates that drug was being released faster than the polymer
was being eroded, i.e. the polymer erosion was not solely controlling the drug release from
SAH-functionalized discoid with 60% w/w drug loading degree but also drug diffusion
was playing a role in the drug release.
Cross-section images of the discoids were used to evaluate the distribution of the drug
particles during the drug release process. In SAH-functionalized discoids with 10 % drug
loading degree, intact drug particles were visible at 12 h but later, at 24 h, the discoid had
relatively  few intact  drug particles  left  and they had been replaced by air  voids  (Fig.  7.2).
This is not fully in agreement with the phase volume analysis (Fig. 7.8C) but one can also
postulate that the drug partially diffuses out of the matrix at the end of drug release, when
the dimensions of the discoid had declined. The cross-section images of the SAH-
functionalized discoid with 60% w/w drug loading degree confirmed the fast release of the
drug, and only a polymer scaffold was left to erode after 12 h (Fig. 7.3). In the case of 12-
ASA-functionalized discoids, with 10% w/w drug load, it can be clearly seen that still at 60
h intact drug particles are remained wihin the polymer matrix, evidence of the ability of the
polymer to control the drug release (Fig. 7.5). In contrast to the SAH-functionalized
polymer, the more hydrophobic 12-ASA-functionalized polymer can also control the release
of the 60% w/w drug loading degree since cross-section images revealed the nearly intact
polymer matrix throughout the experiment (Figs. 7.6 and 7.8F).
Structural parameters were used further to analyze the drug release and the changes of
the drug phase during the release (Table 7.4). Essentially, no changes of these parameters
should be detected if the surface erosion is controlling the drug release i.e. drug phase
should remain intact within the matrix until the erosion front reaches the drug particles.
The fragmentation index values of the drug phase reveal only minor changes for 10%w/w
drug loading degree of SAH- and both of the 12-ASA-functionalized discoids supporting
the  belief  that  it  is  surface  erosion  which  is  controlling  drug  release.  In  contrast,  SAH-
functionalized discoid with 60% w/w drug loading degree is an exception since it showed
an increase in the fragmentation index value as a function of time. This indicates that
initially the high numbers of drug particles were in close contact and probably partially
aggregated but at the end of the erosion period, the remaining drug particles were in less
close contact after the majority of the drug has been released. In SAH-functionalized
discoids,  there  was some trend towards an increasing object  surface  volume ratio  and the
structure separation values, and a decrease in the structure thickness values. Taken
together, this indicates that the drug particles were smaller and more separated as the
erosion progressed, which can be related to the water penetration into the matrix inducing
dissolution of drug particles. In contrast, in 12-ASA-functionalized discoids, the values
depicting structure thickness and separation, and object surface volume ratio of the drug
phase remained unchanged, suggesting that the water penetration did not affect the drug
particles in the more hydrophobic matrices.
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Table 7.4. Fragmentation index (μm-1), object surface volume ratio (μm-1), structure thickness
(μm), structure separation (μm) of the drug phase for SAH- and 12-ASA –functionalized
photocrosslinked poly(ester anhydride) discoids with drug loading degrees of 10 and 60% w/w.
Fragmentation index
Time (h) SAH-10% SAH-60% 12-ASA 10% 12-ASA 60%
0 0.10 -0.09 0.12 -0.06
4 0.11 -0.04 0.12 -0.06
12 0.13 0.03 0.12 -0.07
24 0.12 0.05 0.13 -0.06
36 0.11 -0.09
48 0.14 -0.06
60 0.15 -0.09
Object surface volume ratio
Time (h) SAH-10% SAH-60% 12-ASA 10% 12-ASA 60%
0 0.26 0.14 0.19 0.17
4 0.22 0.18 0.18 0.16
12 0.31 0.22 0.19 0.16
24 0.34 0.22 0.25 0.16
36 0.16 0.14
48 0.21 0.15
60 0.26 0.14
Structure thickness
Time (h) SAH-10% SAH-60% 12-ASA 10% 12-ASA 60%
0 25.75 27.66 35.99 23.00
4 28.10 20.93 39.75 23.94
12 22.49 18.67 37.39 24.23
24 13.91 18.63 27.45 25.13
36 42.58 27.16
48 36.33 26.61
60 30.42 27.49
Structure separation
Time (h) SAH-10% SAH-60% 12-ASA 10% 12-ASA 60%
0 59.92 33.00 82.12 25.18
4 79.91 53.42 84.03 26.69
12 51.52 54.54 85.85 26.09
24 73.20 78.44 52.89 30.53
36 128.85 29.27
48 96.28 26.40
60 90.01 25.68
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7.4 DISCUSSION
Earlier we have proposed surface erosion-controlled drug and peptide release from the
present poly(ester anhydride)s, based on the strong correlation between the polymer
erosion and the linear drug release (Mönkäre et al. 2010, 2012). In the present study, the
erosion and drug release mechanisms of SAH- and 12-ASA –functionalized discoids were
further analyzed with a non-destructive micro-CT technique by assessing the changes in
the internal structure of the discoids as a function of time. Ideally, in the case of surface
erosion,  no  air  voids  due  to  water  penetration  into  the  matrix  should  be  formed  and  the
relative volume of the drug should remain constant as a function of time. The decrease in
the relative volume of the drug as a function of time indicates that the drug release is faster
than the polymer erosion. Overall, micro-CT analysis confirmed the surface erosion of
SAH- and 12-ASA-functionalized discoids and surface erosion-controlled drug release from
these matrices. The effects of polymer hydrophobicity and drug loading degree on polymer
erosion and drug release were clarified in the present study.
The oligomers used to prepare photocrosslinked poly(ester anhydride)s were modified
in order to alter their hydrophobicity. The SAH-functionalized oligomers were less
hydrophobic than the 12-ASA-functionalized counterparts that contained a 12-carbon
alkenyl chain. Thus, as expected, the 12-ASA-functionalized polymer prevented water
penetration into the discoids better than the SAH-functionalized polymer, regardless of the
drug loading degree (Figs. 7.2, 7.3, 7.5 and 7.6). The erosion mechanism of polymer matrix
is known to depend on two factors, namely the ratio of the reactivity of polymer bonds to
the diffusion coefficient of water inside a polymer, and matrix dimensions (Burkersroda et
al. 2002) Thus, the polymer matrix undergoes surface erosion when the polymer bonds
degrade faster than water diffuses into the matrix or when the size of the matrix is larger
than critical size defined for each polymer. When compared with SAH-functionalized
discoids, the diffusivity of water inside the matrix is smaller in the more hydrophobic 12-
ASA-functionalized discoid whereas the degradation rate of the functional groups of
polymer (anhydride bonds) and the matrix dimensions are similar. As a result, better
surface erosion characteristics were obtained with the 12-ASA-functionalized discoids.
Drug loading degree had an effect on the drug release mechanism but not on the erosion
mechanism  of  SAH-functionalized  discoids.  The  relative  volume  of  the  drug  remained
constant as a function of time in SAH-functionalized discoids containing 10% w/w of drug
(Fig. 7.8C) but it declined in SAH-functionalized discoids containing 60% w/w of drug (Fig.
7.8E),  indicating  faster  drug  release  than  polymer  erosion.  Thus,  drug  release  from  SAH-
functionalized discoids containing 60% w/w of drug was not solely surface erosion-
controlled  but  drug  was  released  also  by  diffusion.  This  could  be  explained  by  the
formation of the continuous drug phases in the polymer matrix. Once the drug was
dissolved from the discoid surface, the water readily diffused deeper into the matrix by
dissolving the continuous drug phases without significant restriction from the polymer
matrix. In contrast, it seems that 12-ASA-functionalized polymer was sufficiently
hydrophobic to prevent any excess water from penetrating into the edges of discoid, even
in the case with a drug loading degree of 60% w/w.
7.5 CONCLUSIONS
The polymer erosion and drug release mechanisms were evaluated by assessing the
internal structure of photocrosslinked poly(ester anhydride)s by micro-CT technique. Both
SAH- and 12-ASA-functionalized discoids exhibited surface erosion but the diffusion of
water into the more hydrophobic 12-ASA-functionalized discoids was slower. Drug release
from  both  poly(ester  anhydride)s  was  surface  erosion-controlled,  with  the  exception  of
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SAH-functionalized discoids with 60% w/w drug loading degree, from which drug release
was controlled by a combination of diffusion and erosion.
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8 Photocrosslinked poly(ester anhydride)s for peptide
delivery: Effect of oligomer hydrophobicity on PYY3-36
delivery5
Abstract:
The treatment for many diseases can be improved by developing more efficient peptide
delivery technologies, for example, biodegradable polymers. In this work, photocrosslinked
poly(ester anhydride)s based on functionalized poly(-caprolactone) oligomers were
investigated for their abilities to achieve controlled peptide delivery. The effect of oligomer
hydrophobicity on erosion and peptide release from poly(ester anhydride)s was evaluated
by developing a sustained subcutaneous delivery system for an antiobesity drug candidate,
peptide YY3-36 (PYY3-36). Oligomer hydrophobicity was modified with alkenylsuccinic
anhydrides containing a 12-carbon alkenyl chain. PYY3-36 was mixed as a solid powder
with methacrylated poly(ester anhydride) precursors, and this mixture was
photocrosslinked at room temperature to form an implant for subcutaneous administration
in rats. The oligomer hydrophobicity controlled the polymer erosion and PYY3-36 release
as the increased hydrophobicity via the alkenyl chain prolonged polymer erosion in vitro
and sustained in vivo release of PYY3-36. In addition, photocrosslinked poly(ester
anhydride)s increased the bioavailability of PYY3-36 by up to 20-fold in comparison with
subcutaneous administration of solution, evidence of remarkably improved delivery. In
conclusion, this work demonstrates the suitability of photocrosslinked poly(ester
anhydride)s for use in peptide delivery.
5 Adapted with permission of Elsevier from: Mönkäre J, Hakala RA, Kovalainen M, Korhonen H, Herzig KH, Seppälä
JV, Järvinen K. Photocrosslinked poly(ester anhydride)s for peptide delivery: Effect of oligomer hydrophobicity on
PYY3-36 delivery. European Journal of Pharmaceutics and Biopharmaceutics 80: 33-38, 2012.
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8.1 INTRODUCTION
Proteins  and  peptides  are  promising  candidates  for  drug  therapy  in  many  therapeutic
areas. However, they are still often formulated as suspensions or aqueous solutions that do
not always allow the most efficient delivery of macromolecules (Frokjaer and Otzen 2005).
Therefore, more sophisticated delivery systems need to be developed, i.e., to achieve
sustained and controlled release (Schwach et al. 2004; Park et al. 2010) or protection against
drug degradation at the site of administration (Katakam et al. 1997; Chen and Singh 2008).
Surface erosion-controlled delivery systems hold great potential for peptide
administration since the unreleased peptide remains intact inside the polymer matrix and
the peptide release rate is directly proportional to the polymer erosion rate (Göpferich
1996). Recently, we have investigated photocrosslinked poly(ester anhydride)s for their
potential in achieving surface erosion-controlled drug delivery (Korhonen et al. 2006;
Mönkäre et al. 2010). These biodegradable and biocompatible polymers combine favorably
the beneficial properties of the polyesters and polyanhydrides, such as good mechanical
strength of polyesters (Albertsson and Varma 2003) with the surface erosion property of
polyanhydrides (Göpferich and Tessmar 2002). One of the advantages of these poly(ester
anhydride)s is the flexibility offered by the possibility for the modification of oligomer
chemistry. As an example, changing the oligomer hydrophobicity (Hakala et al. 2009) can
alter the polymer erosion and drug release rates. If one wishes to fabricate photocrosslinked
poly(ester anhydride) devices, then the drug can be mixed as a solid powder with viscous
liquid precursors at room temperature without the need for solvents, and by using a low-
energy light source, one can avoid the unnecessary increase in the temperature. In addition,
the drug loading degree and device dimensions can be varied extensively, and also
injectable poly(ester anhydride) implants can be prepared.
Weight management is an example of a therapeutic application that could significantly
benefit from more efficient peptide delivery technologies. Obesity is a growing global
public  health  problem,  and  peptide  YY3-36  (PYY3-36)  is  one  of  the  most  promising  drug
candidates for its treatment (Neary and Batterham 2009). PYY3-36 is an endogenous gut
hormone, secreted from L-cells in the gastrointestinal tract, which regulates energy
metabolism in many ways, for example, by inducing satiety (Tatemoto and Mutt 1980;
Neary and Batterham 2009). Previously, intravenous (i.v.) administration of PYY3-36 has
been shown to reduce food intake in animals and humans (Batterham et al. 2002, 2003;
Degen et al. 2005) and to lower bodyweight in animals (Sileno et al. 2005; Chelikani et al.
2006). Due to its promising properties for the treatment of obesity, different delivery
systems have been explored for PYY3-36, e.g., the intranasal (Gantz et al. 2007) and peroral
(Steinert et al. 2010) routes. However, despite their many advantages, such as ease of
dosing, these delivery systems have also disadvantages, such as evoking adverse effects or
achieving inadequate therapeutic response. In a 12-week trial, intranasal administration
before meals did not induce weight loss and a higher dose evoked adverse effects, such as
nausea and vomiting (Gantz et al. 2007). The peroral route has been shown to be well
tolerated but PYY3-36 only appeared to be able to reduce the caloric intake when
administered with GLP-1 before a meal (Steinert et al. 2010). Interestingly, subcutaneous
(s.c.) injections of PYY3-36 solution have been shown to increase the feelings of satiety and
to decrease hunger in obese males with minimal adverse effects despite the presence of
higher plasma concentrations than obtained after intranasal administration (Gantz et al.
2007; Sloth et al. 2007). In addition, administration via the s.c. route produced an elevation
of  PYY  plasma  concentrations  for  more  than  4  h,  which  was  speculated  to  evoke  a  long-
lasting appetite-suppressive effect (Sloth et al. 2007).
In this work, the suitability of photocrosslinked poly(ester anhydride)s for controlled
peptide delivery was evaluated by developing a sustained s.c. delivery system for PYY3-36
(Mw 4050 g/mol). The poly(ester anhydride) oligomers were functionalized with succinic
anhydride (SAH) or with the more hydrophobic alkenylsuccinic anhydride (12-ASA)
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containing a 12-carbon alkenyl chain in order to clarify the effect of oligomer
hydrophobicity on peptide delivery.
8.2 MATERIALS AND METHODS
8.2.1 Materials
Oligomers were polymerized from -caprolactone (Solvay Interox Ltd., Warrington,
England) in the presence of stannous octoate and pentaerythritol. The -caprolactone was
redistilled  and  dried  over  molecular  sieves.  Stannous  octoate  as  an  initiator  and
pentaerythritol as a co-initiator were used in the ring-opening polymerization of the
oligomers. Succinic anhydride (SAH), 2-dodecen-1-ylsuccinic anhydride (12-ASA), and
methacrylic anhydride were used in the functionalizations, and camphorquinone was used
as an initiator for photocuring. All reagents except -caprolactone were purchased from
Sigma–Aldrich Chemie, Germany, and were used as received.
Human peptide YY3-36 (PYY3-36, Mw 4050 g/mol) was purchased from BCN Peptides
(Barcelona, Spain). In the in vitro drug release study, phosphate-buffered solution, pH 7.4
(0.2 M NaOH-KH2PO4) was prepared using NaOH from FF-Chemicals (Yli-Ii, Finland) and
KH2PO4 from Merck (Darmstadt, Germany). Bovine serum albumin (BSA, Sigma–Aldrich,
St.  Louis,  MO,  USA)  (0.1%  w/v)  was  dissolved  in  the  buffer  in  order  to  prevent  the
adsorption of PYY3-36 onto the laboratory materials during the in vitro experiment. Sodium
chloride solution (9 mg/ml, 0.9%) for injections was obtained from B. Braun Melsungen AG
(Melsungen, Germany) and Baxter Oy (Vantaa, Finland).
8.2.2 Animals
Male Wistar rats (age of 8–12 weeks, 293–398 g, mean 328 g) (Kuopio, Finland) were housed
in an environment-controlled room temperature +21 ± 1 °C, relative air humidity 55 ± 15%,
and 12/12 h light/dark cycle with lights on at 7 AM with food (Teklad 2016, Harlan Inc.) and
tap water available ad libitum. The National Animal Experiment Board of Finland approved
the experiments. Procedures were conducted in accordance with the guidelines set by the
Finnish Act on Animal Experimentation (62/2006) and European Community Council
Directives 86/609/EEC.
8.2.3 Preparation of poly(ester anhydride) implants
The synthesis and properties of the poly(ester anhydride) based on poly(-caprolactone)
oligomers have been described earlier (Helminen et al. 2003; Hakala et al. 2009), and the
main features are shown in Scheme 8.1. Briefly, -caprolactone monomers were
polymerized to star-shaped hydroxyl telechelic oligomers by ring-opening polymerization.
In the next step, the hydroxyl termination was changed to acid termination with succinic
anhydride (SAH) or 2-dodecen-1-ylsuccinic anhydride (12-ASA). In order to obtain
crosslinkable poly(ester anhydride) precursors with labile anhydride bonds, acid-
terminated oligomers were allowed to react with methacrylic anhydride.
In the photocrosslinking, the viscous liquid methacrylated precursors, camphorquinone
(1% w/w) with and without PYY3-36 powder (1% w/w) were stirred until homogeneity was
achieved and the mixture was then placed into a mold in order to produce the implants (2
mm  in  thickness,  5  mm  in  diameter,  and  50  mg  in  weight).  Photocrosslinking  was  done
using visible light (11 W, 16 mW/cm2) at room temperature for 20 min. The mean PYY3-36
doses were 525 and 483 μg/implant for SAH- and 12-ASA-functionalized implants,
respectively.
The gel contents of the photocured implants were measured by extracting the soluble
phase in dichloromethane at room temperature for 24 h, and it was found that gel contents
were >95%. Attenuated total reflectance infrared spectroscopy (ATR-FTIR, Nicolet Magna-
FTIR spectrometer 750 equipped with PIKE Technologies GladiATR with diamond crystal
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plate) was used to monitor the double bond conversion of the methacrylated precursors.
The double bond conversion in the implants was calculated based on the decrease in
absorbance near 1637 cm1, a characteristic absorbance of the methacrylate double bond
(Burdick et al. 2001; Helminen et al. 2003). The final double bond conversions were >93%.
Scheme 8.1. Preparation of photocrosslinked poly(ester anhydride)s from star-shaped hydroxyl-
terminated poly(-caprolactone) oligomers.
8.2.4 In vitro erosion of implants
The in vitro erosion (n = 3) of the poly(ester anhydride) implants was studied in 40 ml of pH
7.4 phosphate buffer in the water bath shaker with orbital shaking at a frequency of 120
strokes/min at +37 °C (Grant OLS200, Cambridge, UK). Samples were removed from the
buffer at predetermined time intervals and dried in a vacuum for 48 h prior to weighing.
The erosion (%) was calculated by dividing the dried mass of the sample by its initial mass.
8.2.5 In vitro release of PYY3-36
The in vitro PYY3-36 release (n = 3) from the SAH- and 12-ASA-functionalized poly(ester
anhydride) implants was studied by using USP Apparatus I (basket) under sink conditions.
The buffer (pH 7.4, +37 °C) volume was 400 ml, and the rotation speed of the basket was 50
rpm (Sotax AT6, Sotax AG, Basel, Switzerland). Samples (2 ml) were collected at
predetermined time intervals, and the sampling volume was replaced by fresh prewarmed
buffer. The released PYY3-36 in the buffer was analyzed using total human PYY ELISA kit
(Millipore Corp., Billerica, MA, USA) according to the manufacturer’s instructions.
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8.2.6 In vivo delivery of PYY3-36
One photocrosslinked poly(ester anhydride) implant was implanted subcutaneously in the
back of each rat. In addition to the PYY3-36-loaded SAH- and 12-ASA-functionalized
implants (n = 6), peptide-free SAH-functionalized (n = 4) and 12-ASA-functionalized (n = 3)
implants were implanted and three rats were sham-operated as controls. The implants were
purified with ethanol/water (70:30) solution before the insertion. Prior to the implantation,
the rats were anesthetized with a fentanyl citrate/fluanizone/midazolam mixture (0.158
mg/5 mg/2.5 mg/kg, s.c.). Blood samples were collected from the saphenous vein at
predetermined time intervals into heparinized capillaries (Drummond Microcaps,
Drummond Scientific Co. Broomall, Pa. USA). The plasma was separated by centrifugation
and frozen immediately. The implantation site was inspected visually at the end of the
experiment after sacrifice in order to visually detect any remainders of the implants. PYY3-
36 plasma concentrations were analyzed using total human PYY ELISA kit (Millipore
Corp.,  Billerica,  MA,  USA)  according  to  the  manufacturer’s  instructions.  By  using  this
ELISA kit, the administered human PYY3-36 in plasma was analyzed and endogenous rat
PYY3-36 did not interfere with the results.
In order to characterize the pharmacokinetics of PYY3-36, peptide solution (200 μl, 0.9%
NaCl) was administered both i.v. and s.c. with doses of 2 and 20 μg to the rats (n = 4). Blood
samples were collected and analyzed as described above. In order to avoid adverse effects
and the need for excessive dilution of plasma samples due to high plasma concentrations,
lower doses were used in i.v. and s.c. administration of solutions than were present in
implants.
8.2.7 Pharmacokinetic analysis
Pharmacokinetic parameters for PYY3-36 were determined from plasma concentration–
time data by using WinNonlin software (WinNonlin Professional, 5.3, Pharsight Corp,
USA)  and  non-compartmental  model  for  extravascular  and  bolus  intravenous  injection  in
the cases of s.c. and i.v. administration, respectively, and with uniform weighing. All data
are presented as mean ± SEM.
Maximum plasma concentration (Cmax) and time to reach Cmax values (tmax) were obtained
directly from the plasma concentration–time data. Terminal half-life (t½) was calculated as
0.693/Ke,  where  Ke is the terminal elimination rate constant. The area under the
concentration–time curve values (AUC0–last) until the last measured plasma concentration
(Clast) were determined by the linear trapezoidal rule, and AUC0– was determined as AUC0–
last +  Clast/Ke.  Clearance  (CL)  and  volume  of  distribution  (Vd) were calculated as D/AUC0–
and D/(Ke ·  AUC0–), where D is dose. Absolute bioavailability (F%) was calculated as
(AUCe.v./AUCi.v.) · (Di.v./De.v.) · 100%, where AUCe.v. and AUCi.v. are AUC0– values of
extravascular and i.v. administration, respectively, and De.v. and Di.v. are the corresponding
doses for extravascular and i.v. administration. Relative s.c. bioavailability (Frel%) was
calculated by using AUC0– values and doses of s.c. solution (s.c.) poly(ester anhydride)
(PEAH) administration as follows: (AUCPEAH/AUCs.c.) · (Ds.c./DPEAH) · 100%. In vivo release
and absorption profile based on percent AUC values (AUC%) were determined as (AUC0–
t/AUC0–) · 100% (Chu et al. 2006).
8.2.8 Statistical analysis
Mann–Whitney U test was used to compare the statistical differences of PYY3-36 between
pharmacokinetic parameters of two groups (i.v., s.c., or implant administration)
(GraphPadPrism 5.03 for Windows, GraphPad Software, San Diego, CA, USA). Kruskal–
Wallis (SPSS 14.0 for Windows, SPSS Inc.) with post hoc test (Siegel and Castellan 1988)
was used to compare statistical differences between multiple groups. The level of
significance was set at p < 0.05.
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8.3 RESULTS
8.3.1 In vitro erosion of implants and PYY3-36 release
The increase in oligomer hydrophobicity by the introduction of alkenylsuccinic anhydride
with 12-carbon alkenyl chain (12-ASA) slowed down the erosion of photocrosslinked
peptide-free poly(ester anhydride) implants (Fig. 8.1). 12-ASA-functionalized poly(ester
anhydride) implants eroded in 72 h and the erosion rate was 1.7 ± 0.01%/h with a 12 h lag
time. Peptide-free SAH-functionalized poly(ester anhydride) eroded in 48 h with the rate of
2.0 ± 0.04%/h without any lag time, as reported earlier (Mönkäre et al. 2010). Irrespective of
the degree of hydrophobicity, both poly(ester anhydride) implants exhibited surface-
eroding characteristics.
Figure 8.1. In vitro erosion  of  peptide-free  SAH-  () and 12-ASA-functionalized ()
photocrosslinked poly(ester anhydride) implants in pH 7.4 buffer (+37 °C) (mean ± SEM, n =
3).
Figure 8.2. PYY3-36 in vitro release  from  SAH-  () and 12-ASA-functionalized ()
photocrosslinked poly(ester anhydride) implants in pH 7.4 buffer (+37 °C) analyzed using total
human PYY ELISA kit (mean ± SEM, n = 3).
The in vitro release of PYY3-36 was also affected by the oligomer hydrophobicity. PYY3-
36-loaded SAH-functionalized implants released PYY3-36 completely in vitro in  24  h
showing a linear release rate of 4.5 ± 0.33%/h without any lag time (Fig. 8.2 and Table 8.1).
However, the fraction of PYY3-36 released from 12-ASA functionalized in vitro was less
than 20% in 60 h, although implants were completely eroded within that time (Fig. 8.2).
One explanation for this result could be that poorly soluble degradation products of 12-
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ASA-functionalized poly(ester anhydride) had been deposited on the implant surface and
PYY3-36 was interacting with this film-like layer (Göpferich et al. 1996; Kipper and
Narasimhan 2005).
Table 8.1. In vitro release and in vivo release by using percent AUC method of  PYY3-36 from
SAH- and 12-ASA-functionalized implants (Mean ± SEM, n=3 (in vitro) or n=6 (in vivo)).
Release rate
(%/h)
R2-value of
release
Duration of linear
release (h)
Lag time of linear
release (h)
SAH-functionalized
(in vitro) 4.5 ± 0.33 0.885 ± 0.029 24 0
SAH-functionalized
(in vivo) 2.0 ± 0.10 0.984 ± 0.002 46 ± 2.0 22 ± 2.0
12-ASA-functionalized
(in vivo) 1.0 ± 0.07 0.975 ± 0.006 102 ± 7.4 38 ± 4.8
8.3.2 In vivo delivery of PYY3-36
I.v. administration of 2 and 20 μg of PYY3-36 exhibited linear pharmacokinetics of PYY3-36,
based on first-order elimination kinetics as presented in Table 8.2 and 8.3. The terminal
elimination half-lives (t½) of PYY3-36 were approximately 40 min, which is slightly longer
than earlier reported values for mice (13 min) (Nonaka et al. 2003) or rabbits (13–19 min)
(Sileno et al. 2005). The AUC values achieved with 2 μg and 20 μg i.v. doses of PYY3-36
were compared, and the difference in values was only 6-fold instead of the expected 10-fold
increase, based on the assumption of linear pharmacokinetics. A comparison of primary
pharmacokinetic parameters between doses showed that values for volume of distribution
(Vd, p < 0.05) and clearance (CL) were smaller after 2 than after 20 μg dose. However, the
ratio of Vd to CL remained constant, and therefore, changes did not affect the terminal half-
lives.
Figure 8.3. PYY3-36 concentration in plasma after i.v. (solid line) or s.c. (dashed line) of 2 μg
() or 20 μg () dose of PYY3-36 in 200μl 0.9 % NaCl (Mean ± SEM, n=4).
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Table 8.2. Pharmacokinetic parameters of PYY3-36 after i.v. and s.c. solution and SAH- and 12-
ASA-functionalized photocrosslinked poly(ester anhydride) implant administration to rats (Mean
± SEM, n=4 for solutions and n=6 for implants).
Pharmacokinetic
parameter 2 μg i.v. 20 μg i.v. 2 μg s.c. 20 μg s.c.
SAH-
functionalized
(525 μg)
12-ASA-
functionalized
(483 μg)
Cmax (ng/ml) 26.8 ± 1.8
a 187 ± 26.1a 0.98 ± 0.26b 3.5 ± 0.44 b 72.0 ± 13.2c 29.2 ± 10.3 c
tmax (h) 0.017 0.017 0.63 ± 0.13 0.25 ± 0.09 42.0 ± 4.0
d 92.0 ± 4.0 d
t½ (min) 38.8 ± 2.3 39.8 ± 4.1 42.3 ± 4.2 78.0 ± 24.0
CL (ml/h/kg) 771 ± 97.1 1240 ± 110
Vd (ml/kg) 713 ± 81.6
a 1160 ± 74.4a
AUC0-last (h
ng/ml/kg) 27.0 ± 3.8
 a 167 ± 15.1 a 5.8 ± 1.7 8.7 ± 1.1 5750 ± 972 4760 ± 1390
AUC0- (h
ng/ml/kg)
27.6 ± 3.7 a 170 ± 15.8 a 6.0 ± 1.7 10.7 ± 1.9 5830 ± 958 4790 ± 1400
F% (2 μg i.v.) 17.9 ± 6.2 3.9 ± 0.7e 80.5 ± 13.2 e 71.2 ± 20.4 e
F% (20 μg i.v.) 29.1 ± 10.0 6.3 ± 1.1 e 131 ± 21.5 e 116 ± 33.1 e
F%rel (2 μg s.c.) 373 ± 61.2 330 ± 94.5
F%rel (20 μg s.c.) 2070 ± 340 1830 ± 524
Statistical differences: a) p < 0.052 μg i.v. vs. 20 μg i.v., b) p < 0.052 μg s.c. vs. 20 μg s.c., c) p <
0.05SAH vs. 12-ASA, d) p<0.01 SAH vs. 12-ASA, e) p<0.01 20 μg s.c. vs. SAH and 12-ASA
S.c. administration of PYY3-36 solution displayed evidence of limited s.c. absorption of
PYY3-36. The absolute bioavailability (F%) values were low and dose-dependent, being 17.9
± 6.2% and 6.3 ± 1.1% for 2 and 20 μg doses, respectively (Table 8.2). Furthermore, the
difference between AUC0– values  of  2  and 20  μg doses  was only  1.8-fold,  indicating that
the extent of s.c. absorption of PYY3-36 declined as the dose increased. In contrast, the dose
did not affect significantly the absorption rate, i.e.,  tmax and the shape of plasma
concentration–time profile (Table 8.2, Fig. 8.3). Elimination half-lives after s.c.
administration were 42 ± 4.2 min and 78 ± 24.0 min for 2 and 20 μg doses, respectively, that
are comparable to the literature values for non-parenteral administration in humans (per
oral 24–50 min) (Beglinger et al. 2008) or rabbits (intranasal 34–40 min) (Constantino et al.
2007).
In contrast to s.c. administration of PYY3-36 solution, PYY3-36 was absorbed nearly
completely into the systemic circulation from the photocrosslinked poly(ester anhydride)
implants (Table 8.2). The bioavailabilities of PYY3-36 administered in SAH-functionalized
or 12-ASA-functionalized poly(ester anhydride) implants were 81 ± 13.2% (131 ± 21.5%) and
71 ± 20.4% (116 ± 33.1%) when compared with 2 μg (or 20 μg) i.v. doses, respectively (Table
8.2). Significant differences (p < 0.05) between absolute bioavailabilities of 20 μg s.c.
solution  and  poly(ester  anhydride)  implants  were  found.  Furthermore,  the  relative  s.c.
bioavailabilities (Frel%) of PYY3-36 from the photocrosslinked poly(ester anhydride)
implants ranged from 330% to 2070%, which indicates that there was 3- to 20-fold higher
absorption from implants than from s.c. solution injection (Table 8.2). These results
demonstrate that photocrosslinked poly(ester anhydride)s can significantly improve PYY3-
36 delivery in comparison with the solution administration.
PYY3-36 administration via s.c. implanted photocrosslinked poly(ester anhydride)s
significantly sustained the release of the peptide. After administration in solution, PYY3-36
was detected in plasma for only 4 h, whereas peptide administration via poly(ester
anhydride)implants prolonged the detection period up to 9 days (Fig. 8.4). The duration of
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the in vivo release was analyzed by the percent AUC method (Chu et al. 2006), which
describes the drug input into systemic circulation by combining release and absorption
phases. The comparison of SAH-functionalized and 12-ASA-functionalized implants
indicated that hydrophobic modification with 12-carbon alkenyl chain sustained PYY3-36
release from 3 to 7 days (Fig. 8.4). In addition, the linear in vivo release rate halved from 2.0
± 0.10%/h of SAH-functionalized to 1.0 ± 0.07%/h with the 12-ASA-functionalized implants.
Similarly, oligomer modification with 12-ASA more than doubled the duration of the linear
release phase from 46 to 102 h and prolonged the lag time from 22 ± 2.0 to 38 ± 4.8 h (Table
8.1). In addition, pharmacokinetic parameters describing the rate of absorption were
affected by the oligomer modification, so that tmax was delayed from 42 ± 4.0 to 92 ± 4.0 h
and  Cmax decreased from 72 ± 13.2 to 29 ± 10.3 ng/ml (Table 8.2). At the end of the
experiments, rats were sacrificed and the implantation site was visually inspected. No
traces of polymer could be detected in the tissue around the site, indicating that there had
been complete erosion of the photocrosslinked poly(ester anhydride) implants.
Figure 8.4. In vivo cumulative release, by using percent AUC method, of PYY3-36 from SAH- ()
and 12-ASA-functionalized () photocrosslinked poly(ester anhydride) implants (mean ± SEM, n
= 6). The profile indicates the percent of PYY3-36 released and absorbed into plasma.
8.4 DISCUSSION
This work clearly demonstrates the suitability of photocrosslinked poly(ester anhydride)s
for achieving peptide delivery such that the release rate of the peptide can be tailored by
modifying the oligomer hydrophobicity of the poly(ester anhydride). These materials have
potential for use in applications requiring controlled short-term release of macromolecular
compounds.
The incorporation of a hydrophobic 12-carbon alkenyl chain into the oligomers
decreased the erosion rate of the photocrosslinked poly(ester anhydride) implant in
comparison with the implant without the alkenyl chain. This is in agreement with an earlier
study done with thermoplastic poly(ester anhydride)s (Korhonen et al. 2006). Since the
drug release from photocrosslinked poly(ester anhydride)s is surface erosion-controlled as
discussed below, the change in the erosion rate had a direct effect on the release rate of
PYY3-36. The 12-ASA-functionalization affected PYY3-36 in vitro release, which was
incomplete even though the implant had been totally eroded. When degradation products
of SAH- and 12-ASA-functionalized implants are compared, the only difference is their
hydrophobicity due to 12-carbon alkenyl chain of 12-ASA-functionalized polymer (Scheme
8.1). Therefore, it is postulated that incomplete in vitro release  is  due  to  a  hydrophobic
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interaction between PYY3-36 and hydrophobic moieties of degradation products of 12-
ASA-functionalized polymer rather than an interaction between PYY3-36 and anhydride
bonds. An earlier study demonstrated that in vitro degradation products of polyanhydride
microspheres, i.e., fatty acid dimers, formed an interaction with protein (Tabata et al. 1993).
However, in vivo release of PYY3-36 was nearly complete from 12-ASA-functionalized
poly(ester anhydride) implants, which leads to the conclusion that PYY3-36 and
degradation products of 12-ASA-functionalized polymer are not interacting in the
subcutaneous space.
In surface erosion-controlled drug release, the physicochemical properties of the drug
should not affect the release rate; this should be entirely controlled by polymer erosion.
Earlier, propranolol HCl (Mw 296 g/mol) release from photocrosslinked poly(ester
anhydride)s has been shown to be surface erosion-controlled in vitro and in vivo (s.c. rats)
(Mönkäre et al. 2010). In that work, in vitro release rates of propranolol HCl varied from
2.1% to 3.3%/h, depending on the drug loading degree (10–60%w/w), while in vivo release
rate was 1.7%/h from the implant with a loading degree of 40% w/w. These values
correspond closely to the PYY3-36 release rates in vitro (4.5%/h) and in vivo (2.0%/h) from
SAH-functionalized implants. Thus, although the physicochemical properties, particularly
the molecular weights of PYY3-36 (4050 g/mol) and propranolol HCl (296 g/mol), differ
considerably, their release rates from SAH-functionalized implants were similar, indicating
that the physicochemical properties of drugs did not influence the drug release. The
tendency of in vitro release rates to be slightly higher than those measured in vivo can be
explained by differences in water exposure, which is more limited in the subcutaneous
space than in in vitro settings (Mäder et al. 1997; Changez et al. 2004; Pulkkinen et al. 2009).
This  can  limit  the  polymer  erosion  based  on  the  hydrolysis  of  anhydride  bonds  and
consequently decrease the drug release rate.
Although earlier PYY3-36 has been administered subcutaneously to rodents and humans
(Pittner et al. 2004; Sloth et al. 2007; Moriya et al. 2009), its s.c. bioavailability has not been
reported. In this study, the s.c. bioavailability of PYY3-36 was low (3.9–29.1%) and dose-
dependent after administration as a solution, when compared with the s.c. bioavailabilities
of other peptides and proteins (Rowland and Tozer 1995; Porter and Charman 2000).
However, the s.c. bioavailability of the peptide was practically 100% when it was
administered in photocrosslinked poly(ester anhydride) implants. It must be noted that the
administered dose of PYY3-36 was not identical in the implants (500 μg) and solutions (2–
20 μg) and PYY3-36 showed dose-dependent s.c. absorption based on the comparison of s.c.
bioavailability and AUC0– values of 2 and 20 μg doses. However, the dose-dependent
absorption indicated that the higher the dose, the lower was the fraction absorbed, which is
opposite to the difference in bioavailability when the comparison was between solution and
implant administration. The fundamental difference between solution and implant
administration is the availability of peptide for absorption. After the administration of
solution, PYY3-36 was immediately available for absorption but with the implant, the
release rate is controlled, such that the release rate is constantly 5–10 μg/h during the linear
release phase. Based on differences in bioavailability between 2 and 20 μg doses in solution,
and between implant and solution administration, it is postulated that this low and steady
release rate would be beneficial for the absorption of PYY3-36. In addition, the unreleased
peptide was located in the polymer matrix where it would be protected from degradation
in the subcutaneous space (Katakam et al. 1997; Chen and Singh 2008). Thus, it is proposed
that s.c. administration via a biodegradable polymer represents an efficient route for
sustained and controlled PYY3-36 delivery.
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8.5 CONCLUSION
This work demonstrates the suitability of photocrosslinked poly(ester anhydride)s for
peptide delivery since by tailoring, the hydrophobicity of poly(ester anhydride) oligomers,
peptide delivery, and polymer erosion rates could be modified. PYY3-36 bioavailability was
increased clearly by using photocrosslinked poly(ester anhydride)s for s.c. administration
of PYY3-36 when compared with its administration in solution. Therefore, s.c.
administration via a biodegradable polymer is proposed to be an efficient route for PYY3-36
delivery.
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9 General Discussion and Future Prospects
The importance of peptides as drugs has increased in recent years since they offer major
advantages, such as good efficacy and selectivity (Vlieghe et al. 2010). However, the clinical
use of peptides is often severely hampered by their physicochemical and pharmacokinetic
properties, including rapid elimination and poor permeability across biological
membranes. In order to improve the clinical use of peptides, many approaches such as
chemical modifications of peptides and development of various peptide delivery systems
have been investigated to provide sustained release and to enhance the permeation.
In this work, two novel materials, PSi and photocrosslinked poly(ester anhydride)s, were
demonstrated to be suitable for controlled peptide delivery by using PYY3-36 as a model
peptide. PSi represent an emerging class of drug delivery systems, mesoporous materials
whereas photocrosslinked poly(ester anhydride)s are a recently developed surface-eroding
material that combines advantageous properties of polyanhydrides and polyesters.
Properties of PSi microparticles and photocrosslinked poly(ester anhydride) implants for
controlled peptide delivery are compared in Table 9.1. These materials have some common
features, such as peptide loading can be performed under mild conditions but they also
display distinct features, such as different peptide release mechanisms.
Table 9.1. Comparison  of  PSi  microparticles  and  photocrosslinked  poly(ester  anhydride)
implants as peptide delivery systems
PSi microparticles Photocrosslinked poly(ester
anhydride) implants
Synthesis Top-down fabrication from silicon
wafers
Chemical synthesis of crosslinkable
precursors
Tailorable properties E.g. surface chemistry, pore
diameter, pore volume and particle
size
E.g. molecular weight, hydrophobicity
and molecular architecture of
oligomers
Preparation of
delivery systems
Immersion of microparticles to
peptide solution followed by filtration
and drying
Mixing of viscous liquid polymer
precursors with peptide powder,
followed by photocrosslinking
Peptide release
mechanism
Several mechanisms, including
diffusion and competitive adsorption
Surface erosion-controlled
Peptide release
kinetics
Burst release followed by declining
drug release, in vivo PYY3-36
release up to 4 days
Lag time, followed by linear, zero-
order drug release, in vivo PYY3-36
release up to 7 days
Biocompatibility Preliminary studies show
biocompatibility
Preliminary studies show
biocompatibility
One common advantage of PSi microparticles and photocrosslinked poly(ester
anhydride)s is their feasibly tailorable properties during the fabrication (Salonen et al.
2008a; Hakala et al. 2011). As an example, surface chemistry of PSi and hydrophobicity of
poly(ester anhydride) oligomers were modified in this work, and these modifications had
significant effects on peptide release in vivo. Another common advantage of these materials
is that the peptide loading can be performed under mild loading conditions, reducing the
risk of potential peptide inactivation during the preparation of delivery system. In vivo
studies of this work demonstrated that peptide had been released in its active form from
PSi and photocrosslinked poly(ester anhydride)s since analysis of PYY3-36 concentrations
in plasma was based on specific antibody binding in an ELISA assay.
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The size  of  the  drug delivery system is  critical  with  regard to  the  administration route.
Nanoparticles can be administered via parenteral and peroral routes, and they can be given
intravenously which is typically needed when targeted drug delivery or rapid onset of
action are wanted. Microparticles can be administered via parenteral and peroral routes but
not intravenously. In general, administration of microparticles is easier than that of
nanoparticles, mainly due to the smaller aggregation tendency of microparticles. PSi can be
prepared as nano- or microparticles, and microparticles can also be formulated as tablets
(Bimbo et al. 2010; Tahvanainen et al. 2012). In the case of photocrosslinked poly(ester
anhydride)s, a macroscopic sized delivery system will be needed in practice, in order to
exploit  the  surface  erosion  property  of  photocrosslinked  poly(ester  anhydride)s.  In  the
future, photocrosslinked poly(ester anhydride)s could be administered as injectable
peptide-polymer mixtures that are photocrosslinked in situ after local or s.c. administration.
In addition, photocrosslinked poly(ester anhydride)s can be administered as implants
either inserted through a needle or after a minor surgical procedure.
In this work, PSi microparticles were injected s.c. to mice and photocrosslinked
poly(ester anhydride) implants were administered s.c. to rats after a minor surgical
procedure, in order to examine the potential benefits of these materials for controlled
peptide delivery. The gut hormone, PYY3-36, a promising candidate for the treatment of
obesity, was used as the model peptide. When PYY3-36 solution was administered by s.c.
injection, it was eliminated from circulation within 4-12 hours. In vivo release of PYY3-36
was significantly sustained when administered from PSi microparticles (up to 4 days) and
photocrosslinked poly(ester anhydride)s (up to 7 days). The release mechanisms and
kinetics of PYY3-36 from PSi and photocrosslinked poly(ester anhydride)s were different.
PYY3-36 release from PSi microparticles showed a high burst release followed by a
declining release. In contrast, PYY3-36 release from photocrosslinked poly(ester
anhydride)s followed zero-order kinetics after a lag time. These results can be explained by
the different release mechanisms. Based on the present studies, peptide release from PSi can
be controlled by several mechanisms such as diffusion and competitive adsorption whereas
poly(ester anhydride)s shows surface erosion-controlled peptide release allowing both
more controlled and more predictable peptide release.
In  this  study,  the  surface  chemistry  of  PSi  was  found to  affect  the  peptide  release  from
PSi microparticles in vitro and in vivo, demonstrating the importance of surface chemistry
on peptide release. The extent and rate of peptide release were affected by the surface
chemistry; TOPSi microparticles released PYY3-36 more efficiently than THCPSi and
UnTHCPSi microparticles. This can be explained to some extent by the minor alterations in
the interactions between PYY3-36 and different PSi surface chemistries, and partially by the
better  wettability  of  the  hydrophilic  TOPSi  surface  in  comparison  with  the  more
hydrophobic THCPSi and UnTHCPSi. When the in vitro release properties of three
peptides: PYY3-36, GhA and melanotan II (Kilpeläinen et al. 2011) from THCPSi
microparticles were compared, it was found that the release of all the peptides was
incomplete and that the release declined as a function of time. The durations of in vitro
release varied significantly between peptides from a few hours with GhA (Mw 930 g/mol) to
a few weeks with PYY3-36 (Mw 4050 g/mol) and melanotan II (Mw 1024 g/mol), indicating
that the physicochemical properties of peptides affected their in vitro release from PSi.
However, based on plasma concentrations of PYY3-36 and the pharmacological effects of
GhA (Kilpeläinen et al. 2009) and melanotan II (Kilpeläinen et al. 2011), a substantial
fraction of peptide was released in vivo within 24 h after administration without there being
any significant differences between peptides, Thus, in this work and related studies
(Kilpeläinen et al. 2009, 2011), in vitro peptide  release  experiments  did  not  predict  the
duration of in vivo peptide release from PSi microparticles. However, in the case of PYY3-
36, the surface chemistries had same order in vitro and in vivo with regard to the extent of
released peptide.
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Several mechanisms can control peptide release from PSi microparticles and based on
this study, no single release mechanism can be stated to solely control the peptide release.
Furthermore, the release can be controlled by different mechanisms simultaneously or
sequentially. However, peptide diffusion out of pores and competitive adsorption are
believed to have the most significant role in the peptide release. In all cases, the peptide
needs  to  diffuse  out  of  pores  in  order  to  be  released.  In  addition,  diffusion-controlled
release is further supported by time-square-root kinetics of in vitro peptide release
(Kilpeläinen et al. 2011) that is typical for diffusion-controlled release. The role of
competitive adsorption mechanism is indicated by the difference in the extent of peptide
release in vivo and in vitro due to the varying composition of soluble compounds between
these two environments. Thirdly, PSi is a biodegradable material and drug release from
oxidized PSi nanoparticles has been shown to be controlled by PSi degradation (Park et al.
2009). Therefore, PSi degradation might also have a role in the peptide release, particularly
after the peptide release has gone on for several days. Finally, the poor wettability of
hydrophobic PSi microparticles can control the peptide release if this limits significantly the
solvent penetration into pores, preventing peptide dissolution. In the future, interactions
between different small and macromolecular drugs and PSi surfaces as well as the effects of
various release mediums on drug release and PSi degradation should be investigated
systematically in order to gain a deeper understanding of the drug release mechanisms
from PSi.
This  work  provided  clear  evidence  that  the  release  of  peptides  and  small-molecular
drugs from photocrosslinked poly(ester anhydride) implants is primarily controlled by
surface erosion. Thus, peptide and drug release can be altered by modifying polymer
erosion by changing the hydrophobicity of poly(ester anhydride) oligomers. Polymer
erosion and drug release mechanisms of photocrosslinked poly(ester anhydride)s were first
characterized by using propranolol HCl as a model compound. This was chosen as a model
drug since its physicochemical properties, i.e. small size (Mw 296 g/mol) and high aqueous
solubility (50 mg/ml), can truly test the surface erosion-controlled drug release mechanism,
as a drug with these properties could readily diffuse out of the polymer matrix (Göpferich
and Tessmar 2002). Non-destructive micro-CT imaging showed that increased
hydrophobicity of 12-ASA-functionalized poly(ester anhydride) oligomers limited the
water penetration into the polymer matrix. Thus polymer erosion based on hydrolytic
degradation of anhydride bonds, was retarded which was consequently translated into a
decreased in vivo peptide release. In general, the relationship between polymer erosion and
peptide and drug release rates between in vitro and in vivo was good. The in vitro release of
PYY3-36 from both SAH- and 12-ASA-functionalized implants was slightly more rapid in
vitro than in vivo. This can be explained by the more limited water exposure in vivo than in
vitro, which can limit the polymer erosion and consequently decrease the peptide release
rate. In vitro release of PYY3-36 from 12-ASA-functionalized poly(ester anhydride)s was
incomplete, suggesting an interaction between peptide and polymer degradation products.
However, based on the plasma concentrations, in vivo release of PYY3-36 from 12-ASA
functionalized poly(ester anhydride)s was complete, indicating that the interaction
observed in vitro did not occur in vivo. The studied poly(ester anhydride)s have potential
for use in applications requiring controlled short-term release of peptides and other drugs.
However, in order to have long-term release, the erosion rate of photocrosslinked
poly(ester anhydride)s should be further slowed down without losing their surface erosion
behavior.
One of the most interesting findings of this study was that PYY3-36 administration via
TOPSi microparticles and photocrosslinked poly(ester anhydride) implants increased the
low absolute bioavailability (4-38%) of PYY3-36 solution after s.c. administration to
practically to 100%. Typically, higher bioavailability is obtained when the drug is
administered in solution instead of other dosage forms. These results suggest that
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controlled release systems can protect PYY3-36 from degradation in the s.c. space and/or
sustained release rate is more favorable for s.c. absorption of PYY3-36.
Both PSi and photocrosslinked poly(ester anhydride)s are biodegradable, and the
present and earlier preliminary safety evaluations (Hakala et al. 2011) have suggested that
PSi and photocrosslinked poly(ester anhydride)s should be non-toxic materials, and
suitable for drug delivery. However, before proceeding to clinical studies, more extensive
safety studies will be required.
This work demonstrates that incorporation of peptide into PSi and photocrosslinked
poly(ester anhydride)s results in sustained release of an active peptide and enhanced
bioavailability. Hence, both PSi and photocrosslinked poly(ester anhydride)s are promising
materials for peptide delivery. In the future, peptide delivery from these materials can be
further improved by tailoring their properties.
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10 Summary and Conclusions
Peptides are attractive drug candidates but their physicochemical and pharmacokinetic
properties such as rapid elimination and poor permeability limit their clinical use.
Therefore,  in  this  study,  two novel  materials,  namely PSi  and photocrosslinked poly(ester
anhydride)s, were developed and characterized for controlled peptide delivery. The
following conclusions can be drawn from this study:
1. Based on the comparison of the centrifuge, well-plate and USP Apparatus 1
methods, it was found that the centrifuge method was most suited for evaluation of
in vitro peptide release from PSi microparticles. The advantages of the centrifuge
method include the small sample amounts required and the good suspendability of
both hydrophilic and hydrophobic PSi microparticles.
2. The PSi microparticles provided sustained peptide release of model peptide PYY3-36
over several days in vitro and in vivo (mice, s.c.). The surface chemistry of PSi
microparticles affected the fraction of released peptide in the order TOPSi > THCPSi
> UnTHCPSi, and the order of the surfaces was the same in vitro and in vivo. In
addition, TOPSi microparticles improved low s.c. bioavailability of PYY3-36 (38%)
practically to 100%.
3. Drug release from photocrosslinked poly(ester anhydride) implants was found to be
controlled primarily by the surface erosion of polymer when a small and highly
soluble drug, propranolol HCl, was used as a model compound. Micro-CT imaging
revealed that increased hydrophobicity of poly(ester anhydride) oligomers retarded
water penetration into the matrix which decreased the rates of polymer erosion and
drug release in accordance with the principles of surface erosion-controlled release.
In addition, high drug loading degrees (60% w/w) were shown to affect the drug
release.
4. Photocrosslinked poly(ester anhydride)s provided sustained, surface erosion-
controlled release of model peptide PYY3-36 in vivo (rats, s.c.). Peptide release could
be  tailored  by  modifying  the  chemistry  of  poly(ester  anhydride)  oligomers  since
increased hydrophobicity of oligomers decreased the release rate of the peptide.
Furthermore, photocrosslinked poly(ester anhydride)s improved low s.c.
bioavailability of PYY3-36 (4-29%) to approximately 100%. Preliminary safety studies
indicated that photocrosslinked poly(ester anhydride)s seem to be safe materials for
peptide delivery.
5. Peptides can be incorporated into PSi microparticles and photocrosslinked poly(ester
anhydride)s implants under mild conditions and the peptide release can be tailored
based on highly modifiable properties of both of these materials. PSi microparticles
allowed easier administration by s.c. injections whereas poly(ester anhydride)
implants provided more predictable and controlled peptide release due to their
surface erosion-controlled peptide release.
In summary, PSi and photocrosslinked poly(ester anhydride)s are promising materials for
controlled peptide delivery. The knowledge gained in this work can also be applied in the
development of PSi and photocrosslinked poly(ester anhydride) based drug delivery
systems beyond the peptide delivery.
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The importance of peptides as drugs 
is increasing but the clinical use of 
peptides is often severely hampered 
by their physicochemical and phar-
macokinetic properties. However, 
it may be possible to expand the 
clinical use of peptides by develop-
ing improved delivery systems. In 
this thesis, two novel materials, 
porous silicon and photocrosslinked 
poly(ester anhydride)s were demon-
strated to be suitable materials for 
achieving controlled peptide delivery 
in both in vitro and in vivo experi-
ments. 
